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ABSTRACT
Human polyomaviruses (HPyVs) are known to cause benign initial infection at an early
age. They have a high prevalence in the population with frequent incidences of
reactivation, and pathologic consequences in those who are elderly or immunosuppressed.
Thus far 12 HPyV species have been known. The first two HPyVs, JC virus (JCPyV) and
BK virus (BKPyV) were described in 1971. They are associated with specific diseases,
progressive multifocal leukoencephalopathy (PML) and polyomavirus-associated
nephropathy (PVAN), respectively. Since 2007, 10 additional HPyVs have been identified
by molecular genetic techniques. Study of the role of these new viruses in human disease
is a new challenge in the HPyV area. The Karolinska Institute (KIPyV) and Washington
University (WUPyV) viruses were discovered in respiratory secretions of patients with
unidentified causes of pneumonia. Other examples of newly found HPyVs are the Merkel
cell polyomavirus (MCPyV) in Merkel cell carcinoma (MCC), and trichodysplasia
spinulosa-associated polyomavirus (TSPyV) in Trichodysplasia spinulosa (TS), both skin
diseases in immunocompromised patients. The potential pathogenicity of the remaining
HPyVs awaits assessment. Seroprevalence studies indicate that HPyVs infect 30 to 90% of
the general population and are transmitted apparently independently of one another. Thus
far, although their modes of transmission have yet to be resolved, HPyVs are frequently
detectable at different body sites and in bodily fluids of healthy immunocompetent
individuals, including the skin, hair follicles, saliva, urine, feces, and respiratory
secretions, and they can also be found in the environment.
To investigate their tropism, persistence site, reactivation, transmission route, and
contribution  to  disease,  we  have  developed  for  KI,  WU,  MC,  and  TS  polyomaviruses
comprehensive diagnostic methods. We studied the occurrence of their DNAs and
antibodies to these viruses from birth to death.
In our study, using recombinant fusion protein antigens, IgG antibodies were detectable
for KIPyV in 55% and for WUPyV in 69%. Rapidly increasing and high IgG
seroprevalences showed that KIPyV and WUPyV are acquired early in childhood and
supported the notion that these polyomaviruses are widespread. Our results not only
suggested the significance of protein conformation in immunoreactivity of VP1, the major
capsid protein, but also pointed to the antigenic importance of the minor proteins VP2 and
VP3.
 Among aging individuals, by employment of recombinant virus-like particles (VLPs)
as antigens in ELISA, MCPyV and TSPyV IgG seroprevalences were 59.6% and 67.3%.
Among 462 pregnant women, MCPyV IgG seroprevalence was 46% and in
constitutionally healthy individuals, TSPyV IgG seroprevalence among children was 39%
and among adults 70%.
In  addition,  our  DNA  PCR  studies  of  respiratory  specimens  indicated  exposure  to
KIPyV  and  WUPyV,  as  well  as  to  MCPyV.  We  observed  MCPyV  and  TSPyV  DNAs
particularly often in tonsillitis or hypertrophic tonsillar tissues, unlike for KIPyV or
WUPyV.  MCPyV  and  TSPyV  DNA  in  the  tonsillar  biopsies  suggested  lifelong
persistence in lymphoid tissue or mucosa. MCPyV DNA occurred in tonsils more
frequently in adults than in children. By contrast, WUPyV DNA was found preferentially
in children. MCPyV occurred also in nasal swabs and NPAs, at a frequency similar to that
of KIPyV and WUPyV. The tonsil may be an initial site of WUPyV infection and a site of
MCPyV  persistence.  On  the  other  hand,  TSPyV  PCR  positivity  of  tonsillar  samples  of
individuals with long-term immunity provided evidence of TSPyV persistence in tonsils
and suggests lymphoid tissue as a latency site also for this emerging human pathogen.
Our  results  indicated  that  MCPyV  DNA,  unlike  TSPyV  DNA,  occurs  in  low  copy
numbers in serum in a notable proportion of aging individuals. Whether the enhanced viral
replication in our elderly participants is a reflection of waning immune surveillance and is
correlated with increased MCC risk deserves further exploration.
Furthermore, to investigate the frequency of fetal infections by these new viruses, we
sought the KIPyV, WUPyV, and MCPyV DNAs by PCR, from 535 fetal autopsy samples
(heart, liver, placenta) from intrauterine fetal deaths (IUFDs), miscarriages, or induced
abortions. Examining by PCR 535 fetal autopsy samples and the corresponding pregnant
women  by  serology,  we  obtained  data  to  rule  out  vertical  transmission  of  the  new
polyomaviruses  KI,  WU,  and  MC.  Our  data  suggest  that  none  of  the  three  often  cause
miscarriages or IUFDs, nor are they transmitted to fetuses.
By means of new molecular methods several emerging polyomaviruses have been
discovered.  Although  it  is  still  too  early  to  reach  a  conclusion  on  this  point,  it  seems
apparent that these novel viruses follow the pattern established for the JC and BK
polyomaviruses: a mild initial infection at an early age, high prevalence in the general
population, lymphoid tissue as a latency site, and pathologic consequences among the
immunosuppressed and/or the elderly.
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aa amino acids
BLAST Basic Local Alignment Search Tool
BKPyV BK polyomavirus
BKV BK virus
bp base pair
BMT bone marrow transplant
CNS central nervous system
CPE cytopathic effect
CSF cerebrospinal fluid
DTS digital transcriptome subtraction
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
HPV human papillomavirus
HPyV6 human polyomavirus 6
HPyV7 human polyomavirus 7
HPyV9 human polyomavirus 9
HPyV10 human polyomavirus 10
HPyV12 human polyomavirus 12
HSCT hematopoietic stem cell transplantation
ICTV International Committee on Taxonomy of Viruses
JCPyV JC polyomavirus
JCV JC virus
KIPyV KI polyomavirus
LTag large tumor antigen
LPyV lymphotropic polyomavirus
MCC Merkel cell carcinoma
MCPyV Merkel cell polyomavirus
MPyV mouse polyomavirus
MWPyV Malawi polyomavirus
MXPyV Mexico polyomavirus
MDA multiple displacement amplification
MS multiple sclerosis
MK monkey kidney
NP nasopharyngeal
NPA nasopharyngeal aspirate
NCCR non-coding control region
PCR polymerase chain reaction
PML progressive multifocal leukoencephalopathy
PyV polyomavirus
PyVAN polyomavirus-associated nephropathy
PyVHC polyomavirus hemorrhagic cystitis
qPCR quantitative real-time PCR
9RT renal transplant
RDA representational difference analysis
Rb retinoblastoma
RCA rolling circle amplification
sTag small tumor antigen
SA12 simian agent 12
SDS-page                      sodium dodecyl sulfate–polyacrylamide gel electrophoresis
SCC squamous cell carcinoma
STLPyV St Louis polyomavirus
SV40 simian vacuolating virus 40
TS trichodysplasia spinulosa
TSPyV trichodysplasia spinulosa polyomavirus
VP1 viral capsid protein 1
VLP virus-like particle
WUPyV WU polyomavirus
WHIM                       warts, hypogammaglobulinaemia, infections, myelokathexis
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INTRODUCTION
Polyomaviruses (PyVs) are ubiquitous; they infect many different mammalian species
including humans. For about 35 years (1971-2007) the Polyomaviridae family was
thought to include only two viruses in humans; the BK polyomavirus (BKPyV or BKV)
and the JC polyomavirus (JCPyV or JCV). These two human viruses are associated with
serious diseases, respectively including polyomavirus-associated nephropathy (PVAN)
and progressive multifocal leukoencephalopathy (PML).
Since 2007, with the aid of new molecular techniques, particularly deep sequencing,
subtractive hybridization, rolling circle amplification (RCA), degenerate polymerase chain
reaction (PCR), pyrosequencing, multiple displacement amplification (MDA), and
complementary DNA library screening, the number of known human members of the
Polyomaviridae family has grown six-fold, by the discovery of 10 new species infecting
humans.
In 2007, the first two novel human polyomaviruses (HPyVs), Karolinska Institute
polyomavirus (KIPyV) and Washington University polyomavirus (WUPyV) were
identified in children suffering from acute respiratory tract infections. A year later, the
carcinogenic  Merkel  cell  polyomavirus  (MCPyV)  was  discovered,  and  shown  to  be
mutated and chromosomally integrated in Merkel cell carcinoma (MCC).
In  2010,  human  polyomaviruses  6  (HPyV6)  and  7  (HPyV7)  were  discovered  on  the
forehead skin of healthy volunteers. In that same year, another skin-associated
polyomavirus, trichodysplasia spinulosa-associated polyomavirus (TSPyV), was isolated
from the face of an immunocompromised patient suffering from trichodysplasia spinulosa
(TS).  In 2011, human polyomavirus 9 (HPyV9) was amplified from the blood of a renal
transplant patient.
 HPyV10 and its two isolates Malawi polyomavirus (MWPyV) and Mexico
polyomavirus (MXPyV) were identified in 2012, and their whole-genome identity criteria
proved  them  to  be  belong  to  a  single  species.  MXPyV-like  MWPyV  was  identified  in
stool  samples  of  children;  analysis  of  condyloma  specimens  from  a  patient  with  warts,
hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome demonstrated
the presence of HPyV10.
In December 2012, the 11th novel polyomavirus was isolated from stool specimens
obtained  from both  the  Gambia  and  the  United  States.  This  was  provisionally  called  St.
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Louis polyomavirus (STLPyV); finally in March, 2013, the last novel polyomavirus thus
far was initially identified in resected human liver tissue and provisionally called human
polyomavirus 12 (HPyV12).
With the discovery of 10 new viruses, the nomenclature of polyomaviruses has
continued to evolve. The Polyomaviridae Study Group of the International Committee on
Taxonomy of Viruses (ICTV) proposed several criteria for polyomavirus classification,
including dividing the polyomaviruses into three genera, with Orthopolyomavirus and
Wukipolyomavirus containing all the mammalian species and Avipolyomavirus restricted
to bird polyomaviruses. In addition, the committee proposed that for a polyomavirus to be
designated a unique species within the family; the whole-genome nucleotide sequence
must have less than 81% nucleotide identity to the sequence of known polyomavirus
species.
During the past four decades, much effort has been focused on previously discovered
JCPyV and BKPyV. Basic questions about the viruses themselves and their interactions
with the host still remain unanswered. The recent discoveries of new HPyVs certainly
raise several fundamental questions. The involvement of these novel HPyVs in a disease
and their prevalences remain to be determined. Furthermore, the routes of transmission,
latency sites, host cells, and epidemiology of these emerging viruses will need to be
determined. We therefore developed for four of the newly found HPyVs (KIPyV,
WUPyV, MCPyV, and TSPyV) comprehensive diagnostics, and examined their
occurrence from life to death and possible association with other diseases and disorders.
It  is  impossible  to  tell  how  meny  new  HPyVs  are  yet  to  be  found;  thus  far  10  new
viruses have been reported since 2007. This literature review focuses almost entirely on
the 12 HPyVs discovered thus far in two chapters. The first section, however, discusses
the biology of polyomaviruses in general including the history, classification and
phylogeny, genome and capsid structure, pathogenicity, associated diseases, cancer and
clinical aspects. The second section of the literature review deals specifically with the 12
HPyVs and focuses on the discovery methods, molecular and serological occurrence and
their clinical significance.
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REVIEW OF THE LITERATURE
1. BIOLOGY OF POLYOMAVIRUSES
1.1. Brief history, classification, and phylogeny
Polyomaviruses are viruses known since 1953 which have the ability to cause multiple
tumors in rodents. These small DNA tumor viruses have been subjects of intensive study
since their discovery (Gross, 1953). The derivation of the family name Polyomaviridae
originates from the observation that the first-discovered member of this family could
induce multiple (poly) tumors (oma) in mice (Eddy et al., 1958). The first polyomavirus
was  the  mouse  polyomavirus  (MPyV),  found  over  50  years  ago.  When  scientists
independently sought to isolate a leukemogenic viral agent by injecting cell-free extracts
from leukemic AKR mice into newborn mice, they by chance discovered this
polyomavirus (Gross, 1953, Stewart, 1953). MPyV is a ubiquitous and persistent pathogen
in wild mice. Its natural transmission most likely occurs through a respiratory route.
MPyV is shed from infected carriers via their urine and also occurs in saliva and feces. We
do, however, lack understanding of the mechanism by which these lytic viruses maintain
life-long persistent infections in their natural host reservoirs (Teunissen et al., 2013).
The taxonomy of polyomaviruses grouped them originally together with the
papillomaviruses under the designation of papovaviruses until their separation into two
separate and distinct families in 2000 (http://ICTVonline.org). The Papovaviridae family
comprised papillomaviruses, polyomaviruses, and simian virus 40 (SV40). The family
name came from three abbreviations: Pa for (rabbit) papillomavirus, Po for (mouse)
polyomavirus, and Va for (simian) vacuolating agent 40, later named SV40.
These two first members of the polyomavirus family, MPyV and SV40, were identified
as filterable agents that could cause tumors in newborn mice and hamsters (Gross, 1953,
Eddy et al., 1958, Sweet and Hilleman, 1960). SV40 was first isolated in 1960 from
cultures of Rhesus monkey kidney cells which were being used to produce poliovirus
vaccines (Sweet and Hilleman, 1960). Thus far, however, no evidence implicating SV40
as a human pathogen has been convincing (Atkin et al., 2009). Although many people may
have been exposed to SV40 by a contaminated polio vaccination, evidence of widespread
SV40 infection in the human population, of increased tumor incidence in those receiving
contaminated vaccine, or any direct role for SV40 in human cancer remains insufficient
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(Poulin and DeCaprio, 2006). Historically, polyomaviruses, especially SV40, have
improved our understanding of basic eukaryotic cellular processes, but they needs to be
studied as human pathogens as well.
Polyomaviruses  are  ubiquitous,  and  in  addition  to  MPyV  and  SV40,  other  PyVs  are
detectable in many vertebrate hosts including human beings, other nonhuman primates,
mice, cattle, birds, bats, rabbits, and rodents (Krumbholz et al., 2009, Johne et al., 2011).
At least 32 different polyomaviruses hitherto known infect both mammalian and avian
species (Figure 1) (Feltkamp et al., 2013); among them are 12 PyVs detected in humans
(Gardner et al., 1971, Padgett et al., 1971, Allander et al., 2007a, Gaynor et al., 2007, Feng
et al., 2008, Schowalter et al., 2010, van der Meijden et al., 2010, Scuda et al., 2011, Buck
et al., 2012, Siebrasse et al., 2012b, Yu et al., 2012b, Korup et al., 2013, Lim et al., 2013).
The  explosion  of  discovery  of  new  viruses  has  led  to  a  steady  evolution  in  the
classification of polyomaviruses. First divided into three major clades (genetically-related
groups), the family of Polyomaviridae included the SV40 clade, the avian clade, and the
murine polyomavirus clade (Perez-Losada et al., 2006). In October 2010, the
polyomaviridae study group of the ICTV recommended the naming of all polyomaviruses
to be standardized (Figure 2) (Johne et al., 2011).  Taxonomical revisions meant that the
family Polyomaviridae now contains two mammalian genera designated
Orthopolyomavirus and Wukipolyomavirus (Figure  2).  The Orthopolyomavirus genus
includes not only BKPyV and JCPyV, but also the recently discovered human Merkel cell
polyomavirus (MCPyV) and the trichodysplasia spinulosa-associated polyomavirus
(TSPyV). The Wukipolyomavirus genus  comprises  the  KI  polyomavirus  (KIPyV),  WU
polyomavirus (WUPyV), and Human polyomaviruses 6, 7, and 9 (Johne et al., 2011).
Three further polyomaviruses isolated from humans MW polyomavirus, STL
polyomavirus, and HPyV12, have not been fully classified or officially thus far accepted;
hence, the taxonomy of this family is ongoing. However, the current official ICTV report
regarding the family of Polyomaviridae still holds only one Polyomavirus genus and 13
species, of which 3 are human viruses (http://ICTVonline.org).
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Figure 1.  Time-line indicating 32 (putative) polyomavirus species discovered up to June 2014.
Human Monkey Ape
Rodent Mammal Bird
1950
1963
1967
1971
1976
1979
1981
2000
2006
2011
2012
2013
1953
1954
1960
BK	polyomavirus	(BKPyV)	
KI	polyomavirus	(KIPyV)	 WU	polyomavirus	(WUPyV)	
Bornean	orangutan	polyomavirus	(OraPyV1)
Sumatran	orangutan	polyomavirus	(OraPyV2)
JC	polyomavirus	(JCPyV)	
Trichodysplasia	spinulosa	polyomavirus	(TSPyV)
Human	polyomavirus	6	(HPyV6)	
Human	polyomavirus	7	(HPyV7)	
Human	polyomavirus	9	(HPyV9)
Mastomys	polyomavirus	(MasPyV)		
Malawi	polyomavirus	(MWPyV)	
STL	polyomavirus	(STLPyV)	Human	polyomavirus	12	(HPyV12)	
Murine	pneumotropic	virus	(MptV)	
Murine	polyomavirus	(MPyV)	
Simian	virus	40	(SV40)	
Baboon	polyomavirus	1	(SA12)	
Hamster	polyomavirus	(HaPyV)	
Bovine	polyomavirus	(BPyV)	
B-lymphotropic	polyomavirus	(LPyV)	
Avian	polyomavirus	(APyV)	
Goose	hemorrhagic	polyomavirus	(GHPyV)	
Crow	polyomavirus	(CPyV)	 Finch	polyomavirus	(FPyV)	
California	sea	lion	polyomavirus	(SLPyV)	
Canary	polyomavirus	isolate	(CaPyV)	
Chimpanzee	polyomavirus	(ChPyV)	
Equine	polyomavirus	(EPyV)	
Squirrel	monkey	polyomavirus	(SqPyV)
Gorilla	gorilla	gorilla	polyomavirus	(GggPyV1)
Pan	troglodytes	verus	polyomavirus	(PtvPyV)
Bat	polyomavirus	(BatPyV)	
2007
2008
2009
2010
2014
Merkel	cell	polyomavirus	(MCPyV)	
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Figure 2. Unrooted phylogenetic tree of 32 (putative) polyomavirus species based on LT, VP1, and VP2
protein comparisons. Reproduced with permission from Feltkamp, M.C., Kazem, S., van der Meijden, E.,
Lauber, C., Gorbalenya, A.E., 2013. From Stockholm to Malawi: recent developments in studying human
polyomaviruses. The Journal of General Virology 94, 482-496.
1.2. Discovery of human polyomaviruses
Many viruses cannot be cultivated in the laboratory and can be characterized only by
molecular methods. Recent advances in molecular methods have revolutionized the
discovery of new viruses. These methods have, now also for polyomaviruses, gained
increasing use (Figure 3).
  The  gap  between  the  two  initially  discovered  HPyVs  and  the  first  new  ones
discovered in 2007 is over 35 years (Table 1). Reports on the first two, JCPyV and
BKPyV, appeared concurrently in 1971 in The Lancet (Gardner et al., 1971, Padgett et al.,
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1971). JCPyV was cultured from PML brain tissue in a patient with Hodgkin's lymphoma;
BKPyV was isolated from the urine of a nephropathic kidney-transplant patient. These
two viruses were first identified by traditional methods of cell culture in 1971. Evolution
of methods of nucleic acid amplification and detection bypassed the need for cytopathic
changes observed in cell culture in order to detect the presence of a virus. Recent versions
of these molecular techniques allow sensitive and high throughput analysis of large
numbers of clinical samples, revolutionizing the means of virus discovery. Because
nucleic acids isolated from both diseased and healthy persons' tissues can serve as a
template for such techniques, the identified viruses are therefore not necessarily
pathogenic. Reduction in the content of their hosts' genomic DNA makes possible this and
other strategies to enrich the original sample for viral DNA or RNA (Delwart, 2007).
One such large-scale molecular virus-screening system led, in 2007, to the discovery of
two new HPyVs: KIPyV and WUPyV. These were named after the institutions in
Stockholm, Sweden, and in St. Louis, Missouri, USA, where the identifications took place
(Allander et al., 2007a, Gaynor et al., 2007). Both viruses came from children with
respiratory tract infections, though whether these viruses are responsible for symptomatic
infection is yet unknown (Norja et al., 2007).
MCC is a rare but aggressive human skin cancer usually affecting those who are elderly
or immunosuppressed. Studying MCC samples by digital transcriptome subtraction
(DTS), detected a fusion transcript between a previously undescribed virus T antigen and a
human-receptor tyrosine phosphatase (Feng et al., 2008). Their further work led to the
identification  and  sequence  analysis  of  an  about  5  kilobase  (kb)  genome of  a  previously
unknown MCPyV.
 One of the new molecular techniques allowing the discovery of several new
polyomaviruses is RCA (Schowalter et al., 2010, van der Meijden et al., 2010, Buck et al.,
2012, Siebrasse et al., 2012b). Development and improvement of the RCA technique
allowed the  isolation  from healthy  human skin  swabs  of  circular  DNA viral  genomes  of
HPyV6 and HPyV7 (Schowalter et al., 2010). RCA also allowed the discovery of the new
HPyV associated with trichodysplasia spinulosa (TS),  TSPyV,  and  identified  it  as  the
possible cause of TS in an immunocompromised patient (van der Meijden et al., 2010).
RCA analysis also introduced two almost identical previously unknown polyomaviruses
called Malawi polyomavirus (MWPyV) in stool from a 1-year-old healthy child and
human  HPyV10  from  an  anal  wart  of  an  immunocompromised  patient  with  warts,
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hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome  (Siebrasse et
al., 2012b, Buck et al., 2012).
Other sequence-independent approaches like random PCR, degenerate oligonucleotide-
primed PCR, and multiple displacement amplification (MDA) also can detect totally novel
HPyVs (Scuda et al., 2011, Yu et al., 2012b, Korup et al., 2013, Lim et al., 2013). Random
PCR and an unbiased deep sequencing approach led to the identification, in stool samples
from  children,  of  the  Mexico  polyomavirus  (MXPyV),  a  closely  related  variant  of  the
MWPyV and HPyV10 (Yu et al., 2012b).
 Shotgun 454 pyrosequencing of DNA amplified by multiple displacement
amplification techniques (MDA) applied to the stool of a healthy 15-month-old child in
Malawi  led  to  the  identification  of  HPyV11 or  STLPyV.  STLPyV also  were  detected  in
clinical stool specimens from the USA and the Gambia at up to 1% frequency (Lim et al.,
2013).
A generic PCR assay using degenerate and deoxyinosine-substituted primers identified
two novel viruses; the HPyV9 from a kidney transplant patient receiving
immunosuppressive treatment (Scuda et al., 2011) and the HPyV12 from resected human
liver tissue (Korup et al., 2013).
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Figure 3. Methods used for discovery of 12 human polyomaviruses.
BKPyV,JCPyV
cell culture
MCPyV
  DTS
KIPyV,WUPyV
Deep sequencing
HPyv9,HPyV12
Generic PCR
MXPyV,STLPyV
Random PCR
HPyV6,7,TSPyV,HPyV10
               RCA
~5 kb
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Table 1. Twelve human polyomaviruses thus far discovered.
Nomenclature Discovery Method	of	identification Prevalence	(%) Disease	associations
BK	polyomavirus,	
BKPyV,	BKV
(Gardner et al.,
1971)
Culture isolation from urine of
renal transplant recipient 82-99
PVAN,
haemorrhagic
cystitis,
ureteral stenosis
JC	polyomavirus,	
JCPyV,	JCV
(Padgett et al.,
1971)
Culture isolation from brain tissue
with progressive multifocal
Leukoencephalopathy(PML)
30-81 PML
Karolinska	Institute	
polyomavirus,
KIPyV,	KI
(Allander et al.,
2007a)
Deep sequencing of
DNAase-treated respiratory fluids 55-90 Not defined
Washington	
University	
polyomavirus,
WUPyV,WU
(Gaynor et al.,
2007)
Deep sequencing of
DNAase-treated respiratory fluids 69-98 Not defined
Merkel	cell	
polyomavirus,
MCPyV,	MCV
(Feng et al., 2008) Digital transcriptome subtractionof  Merkel cell carcinoma tissue 60-81
Merkel cell
carcinoma (MCC)
Human	
polyomavirus	6,	
HPyV6
(Schowalter et al.,
2010)
Rolling-circle amplification of
skin and hair samples 69 Not defined
Human	
polyomavirus	7,	
HPyV7
(Schowalter et al.,
2010)
Rolling-circle amplification of
skin and hair samples 35 Not defined
Trichodysplasia	
spinulosa-
associated	
polyomavirus,
TSPyV,TSV
(van der Meijden
et al., 2010)
Rolling-circle amplification of
trichodysplasia spinulosum lesion
in transplant recipient
70-80 Trichodysplasia
spinulosum (TS)
Human	
polyomavirus	9,	
HPyV9
(Scuda et al.,
2011)
Consensus PCR and deep
sequencing  of  blood sample of a
renal transplant patient
21-53 Not defined
Malawi	or	Mexico	
polyomavirus,
MWPyV,MXPyV,
HPyV10
(Yu et al., 2012b,
Siebrasse et al.,
2012b, Buck et
al., 2012)
Rolling-circle amplification,
Multiple displacement
amplification, random PCR of
stool and wart
26-68 Not defined
St	Louis	
polyomavirus,	
STLPyV,	HPyV11
(Lim et al., 2013)
Pyrosequencing and multiple
displacement amplification of
stool
Not defined Not defined
Human	
polyomavirus	12,	
HPyV12
(Korup et al.,
2013)
Generic polyomavirus PCR of
liver tissue 12-33 Not defined
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1.3. Genome and capsid structure of the polyomaviruses
Polyomavirus particles are non-enveloped and approximately 40 to 45 nm in diameter
icosahedral particles with 72 capsomers in a skewed (T=7) arrangement (Fields et al.,
2013). The virion consists of 72 pentamers of the capsid protein VP1 with a single copy of
VP2 and VP3 associated with each pentamer (Stehle et al., 1994). The capsids enclose a
single molecule of circular double-stranded DNA of fairly uniform size within the family,
ranging in size from 4754 (STLPyV) to 5387 (MCPyV) base pair (bp) and able to be
divided by transcriptional criteria into three regions (Van Ghelue et al., 2012). In mature
particles, the viral DNA is associated with the host-cell histone proteins H2a, H2b, H3,
and H4 in a supercoiled, chromatin-like complex. No evidence shows virus particles to
contain any carbohydrates or lipids (Fields et al., 2013).
All polyomaviruses have a similar genomic organization; the genome is almost evenly
divided into an early and a late region encoded on opposite strands (Figure 4). Between
these two regions is a non-coding control region (NCCR).  This region contains the origin
of replication, the TATA box, the T-antigen-binding sites, the cellular transcription factor-
binding  sites,  and  a  bidirectional  promoter.  It  also  contains  the  promoter  elements  that
control transcription of both the early and late transcripts. NCCR is thought to be the main
determinant of the viral tropism. Importantly in JCPyV, modifications in the NCCR region
are associated with an increase in viral transcription and replication in patients with PML
(Tan et al., 2010, Reid et al., 2011).
The early region, transcribed soon after the initial infection of the host cell, encodes at
least  two proteins:  the large tumor antigen (LTag) and the small  T antigen (sTag);  these
share the amino-terminal 75–80 amino acids (aa). This shared part is encoded by exon 1 of
the LTAg gene. The LTag is a non-structural, multifunctional protein that regulates the
switch from early to late viral protein transcription and the replication of the viral genome.
This protein interacts with a number of cellular proteins (such as retinoblastoma protein
and p53), and its role in cancerogenesis is being investigated (Gjoerup and Chang, 2010).
The sTag and other T antigen variants are produced by cellular splicing of the LTag RNA;
these proteins perform multiple functions.
Late transcripts generally encode three structural proteins (VP1, VP2, and VP3), as
well  as  additional  proteins  in  some of  the  polyomavirus  species  (Fields  et  al.,  2013).  Of
the three structural proteins, VP1 makes up more than 70% of the total protein content of
virus particles and is also called the major structural protein. Five VP1 molecules surround
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either a VP2 or VP3 molecule to form stable assembly units, or capsomers; 72 capsomers
link together in icosahedral symmetry to form the capsid of each virion. The VP2 and VP3
molecules may be necessary to ensure specific encapsidation of the replicated
polyomavirus genome. All of these proteins originate from the same mRNA transcript, but
they are produced upon differential splicing and internal translation (Good et al., 1988).
VP4, which also originates from the late transcript, thus far has been detectable only in
SV40, where it functions as a viroporin, promoting the release of the virus from the cell
(Giorda et al., 2012). The human polyomaviruses JCPyV and BKPyV, the monkey
polyomaviruses SV40, SV40-Ri257, baboon polyomavirus 1 (isolate SA12), chimpanzee
polyomavirus, squirrel monkey polyomavirus and bovine polyomavirus also encode the
agnoprotein in the leader region of the late transcript (Gerits and Moens, 2012). No other
polyomaviruses are, however, known to encode this agnoprotein. Murine and hamster
polyomaviruses encode a middle T antigen which functions as a transforming protein
(Cheng et al., 2009). MCPyV encodes a protein phylogenetically related to this middle T
antigen, one called ALTO (Carter et al., 2013). Alternative splicing of the STLPyV early
region yields, in addition to the expected LTag and sTag, a unique form of T antigen,
which is called 229T (Lim et al., 2013).
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Figure 4 .The prototypical circular double-stranded DNA genome has three main regions: a non-coding
control region, an early region, and a late region. Agnoprotein (Agno) is encoded by a late transcript from
JC polyomavirus and BK polyomavirus, but has yet to be confirmed in the new human polyomaviruses.
Reproduced with permission from Moens, U., Ludvigsen, M., Van Ghelue, M., 2011. Human polyomaviruses
in skin diseases. Pathology research international 2011, 123491.
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1.4. Human polyomavirus pathogenicity, associated diseases, and
clinical aspects
Among the 12 polyomavirus species identified in humans thus far, only four have been
consistently linked to human pathologies (Table 1) (White et al., 2013). BKPyV to PyV-
associated nephropathy (PyVAN) and PyV-associated hemorrhagic cystitis (PyVHC),
JCPyV  to  PML  and  rarely  PyVAN,  MCPyV  to  MCC,  and  TSPyV  to trichodysplasia
spinulosa (TS) of the skin (Dalianis and Hirsch, 2013).
     The host cells and tissues that support infection by the new HPyVs in vivo are
unknown, and their identification is among the most essential task in research. Some of
the new HPyVs may transmit horizontally by direct contact, or transmit by aerosol or
fecal–oral routes (Babakir-Mina et al., 2011, Csoma et al., 2012, Babakir-Mina et al.,
2013, Coursaget et al., 2013, Dalianis and Hirsch, 2013, DeCaprio and Garcea, 2013,
Ehlers and Wieland, 2013, Feltkamp et al., 2013). Infection site, the original site of the
polyomavirus’s identification, and the distant organs in which the virus is detectable may,
however, be distinct and be hard to relate to any pathophysiology (Dalianis et al., 2009).
     Although several of the new HPyVs have been isolated from nasopharyngeal or
stool samples, correlations between infection and respiratory symptoms or diarrheal illness
remain circumstantial (Bialasiewicz et al., 2007a, Bialasiewicz et al., 2007b, Wattier et al.,
2008, Babakir-Mina et al., 2009b, Bialasiewicz et al., 2009a, Bialasiewicz et al., 2009b,
Babakir-Mina et al., 2011). The data remain confounded by the presence of numerous
viral agents in the samples studied, such that no single entity has been singled out as the
causative agent.
     Because the clinical symptoms of primary infection with BKPyV and JCPyV still
lack conclusive identification, it is perhaps not surprising that the new HPyVs in this
context have not been associated with any clinical symptoms, either (Chen et al., 2011a,
Chen  et  al.,  2011b).  Attempts  to  link  the  new  polyomaviruses  to  clinical  disease  have
focused mostly on immunosuppressed or older individuals, in whom immunity is already
waning. In particular, opportunistic diseases in immunocompromised individuals have
been studied, but with no specific correlations with HPyVs yet identified (Tables 2-10).
     JCPyV and BKPyV can cause a lytic infection resulting in tissue destruction. JCPyV
infection  of  oligodendrocytes  in  the  central  nervous  system  (CNS)  (that  is,  PML)  and
BKPyV infection of renal tubule cells (that is, PVAN) result in loss of these cells, similar
to the well-described cytopathic effect (CPE) of SV40. However, except for MCPyV and
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TSPyV, the new HPyVs have shown no clear association with any clinical syndrome.
Whereas some of the HPyVs (JCPyV, BKPyV, TSPyV, and MCPyV) are associated with
disease, the respiratory diseases associated with KI and WU polyomaviruses have been
questionable, and no disease association has been established for HPyV6, 7, 9, 10, 12, and
STLPyV thus  far  (Figure  5).  On the  basis  of  the  sites  from whence  polyomavirus  DNA
has been isolated, suspected sites of infection include the nasopharynx and lung for
KIPyV and WUPyV, the skin for HPyV6, HPyV7, HPyV9, and MWPyV, and the
gastrointestinal tract for MWPyV, STLPyV, and HPyV12 (Allander et al., 2007a, Gaynor
et al., 2007, Schowalter et al., 2010, Scuda et al., 2011, Buck et al., 2012, Korup et al.,
2013, Lim et al., 2013). HPyV6 and HPyV7 in contract with HPyV9 seem to be a regular
part of the human skin microbiome. Therefore, their association with different skin tumors
and some non-tumorous skin lesions has been under investigation in some studies (Table
6, 7,  and 9).  MWPyV and STLPyV are the first  two polyomaviruses to be discovered in
human  stool  samples,  and  we  still  are  not  clear  as  to  whether  they  have  primary
gastrointestinal tropisms; many outstanding questions relate to the potential role of
HPyV12 and other emerging polyomaviruses in human infections. In addition, one study
investigated whether reactivation of the newly discovered KIPyV, WUPyV, MCPyV,
HPyV6, HPyV7, TSPyV, HPyV9, and HPyV10 is associated with neurological
complications after allogeneic hematopoietic stem cell transplantation (HSCT) and found
no  HPyV  DNA  in  any  of  the  32  cerebrospinal  fluid  (CSF)  samples  (Gustafsson  et  al.,
2012).
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Figure 5. Human polyomaviruses and associated diseases. Reproduced with permission from White,
M.K., Gordon, J., Khalili, K., 2013. The rapidly expanding family of human polyomaviruses: recent
developments in understanding their life cycle and role in human pathology. PLoS pathogens 9, e1003206.
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1.5. Human polyomavirus cancer association
About a fifth of all human cancers worldwide are caused by infectious agents. In 12%
of cancers, seven different viruses have been causally linked to human oncogenesis:
Epstein-Barr virus, hepatitis B virus, human papillomavirus (HPV), human T-cell
lymphotropic virus, hepatitis C virus, Kaposi’s sarcoma herpesvirus, and Merkel cell
polyomavirus. Many molecular mechanisms of oncogenesis have been discovered over the
decades of study of these viruses (White et al., 2014).
   The role of animal polyomaviruses in tumorigenesis has long been known (Gross,
1953, Stewart, 1953, Sweet and Hilleman, 1960). More recently, ten new HPyVs have
been discovered, and one of these, MCPyV, was identified in patients with MCC, which is
a rare but highly aggressive malignancy (White et al., 2013, White et al., 2014). No
evidence exists thus far for any correlation between malignant transformation and the
newly discovered HPyV6 and 7, TSPyV, HPyV9, MWPyV, or HPyV11 and 12, but
obviously additional investigations are necessary.
    A role in malignant transformation for BKPyV and JCPyV was proposed soon after
their initial isolation in 1971 (Gardner et al., 1971, Padgett et al., 1971, Walker et al.,
1973). In vitro studies supported the oncogenic contribution of their LTag and sTag with
the potential to cooperate with other oncogenic alterations. There exist several reports on
detection  of  BKPyV  DNA  in  tumors  such  as  urothelial  malignancies  and  renal  tubular
malignancies, colorectal tumors, lymphomas, pancreatic cancer, brain tumors, prostate
cancer, and a range of sarcomas, and for non-UV light- associated melanomas (Emerson et
al., 2008, Giraud et al., 2008, Abend et al., 2009). Interpretation of these reports has been
varied and controversial, but based on inadequate evidence in humans and sufficient
evidence in experimental animals, a WHO International Agency for Cancer Research
Monograph Working Group recently classified BKPyV and JCPyV as possibly
carcinogenic to humans (Group 2B), (Bouvard et al., 2012).
    Several studies have investigated whether KIPyV or WUPyV is involved in tumor
development. Thus far, results for childhood brain tumors and non-UV-exposed
melanomas have been negative (Giraud et al., 2009). In one study, KIPyV VP1 DNA was
detectable in 9 of 20 lung cancer cases of undefined origin and in both of 2 transplant
patients  (Babakir-Mina  et  al.,  2009b).  In  two  of  the  lung-tissue  samples,  only  the  C-
terminal  domain  of  the  early  region  of  KIPyV  was  successfully  identified;  analysis  of
possible integration did not take place. Thus, there is no compelling evidence to date
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supporting any role for KIPyV in oncogenesis, although the data may indicate the lung as
a site of viral persistence.
    The most recent human oncogenic virus to be discovered was MCPyV (Feng et al.,
2008). Cell culture and small animal models for MCPyV replication are not yet available,
but there is strong mechanistic evidence that it directly contributes to the development of a
large proportion of MCCs (Chang and Moore, 2012). First of all, MCPyV sequences were
identified in 8 of 10, and integrated in 5 of 8 MCCs as mentioned above, thus immediately
linking MCPyV to the pathogenesis of MCC (Feng et al., 2008). This study was followed
by others, again detecting MCPyV in around 80% of the MCC samples, revealing that the
LTag is frequently truncated before the helicase domain (Duncavage et al., 2009b). In
addition, reports have also presented deletions of the VP1 region (Sharp et al., 2009). On
the  other  hand,  the  role  of  MCPyV  in  MCC  is  further  supported  by  the  fact  that  MCC
patients frequently have very high antibody titers to MCPyV as compared to titers of the
population in general, indicating that MCPyV infection indeed is associated with MCC
(Pastrana et al., 2009). It is therefore possible that cell-mediated immunity (CMI) may be
involved in protection against MCPyV-induced malignancy (Kumar et al., 2011a).
     Patients with MCC have an increased risk of developing chronic lymphocytic
leukemia (CLL) (Koljonen et al., 2009a, Koljonen et al., 2010). An investigation has
reported MCPyV sequences in 27.1% of purified malignant cells from CLL samples
(Pantulu  et  al.,  2010),  yet  the  causal  association  remains  to  be  proven.  Presence  of
MCPyV has been sought for numerous other tumors, particularly those of the skin (Table
2).  Thus  far,  evidence  is  limited  that  MCPyV plays  a  role  in  the  oncogenesis  of  tumors
other than MCC.
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Diagnosis No.	Samples
No.	Positive	
Lesions/total	(%) Reference
Lung	small	cell	carcinoma	 30 2/30 (7.5) (Andres et al., 2009)
Seborrheic	keratosis 12 2/12 (16.7) (Andres et al., 2010)
Basal	cell	carcinoma		 50 11/50(18.0) (Imajoh et al., 2013)
Basal	cell	carcinoma 147 47/147 (32) (Kassem et al., 2009)
Bowen’s	disease 23 4/23 (17.4) (Kassem et al., 2009)
Squamous	cell	carcinoma 6 1/6 (16.7) (Wieland et al., 2009)
Squamous	cell	carcinomas		 63 16/63(22.2) (Imajoh et al., 2013)
Kaposi’s	sarcoma 49 3/49 (6.1) (Katano et al., 2009)
Malignant	melanoma 12 2/12 (16.7) (Wieland et al., 2009)
B-cell	associated	lymphomas 161 5/161 (3.1) (Shuda et al., 2009)
T-cell	associated	lymphomas 104 1/104 (1) (Shuda et al., 2009)
Malignant	melanoma	 47 10/47(19.1) (Imajoh et al., 2013)
Langerhans	cell	sarcoma		 7 3/7 (43) (Murakami et al., 2014)
Lung	small	cell	carcinoma	 10 Absent (Wetzels et al., 2009)
Basal	cell	carcinoma 11 Absent (Andres et al., 2010)
Basal	cell	carcinoma	 20 Absent (Reisinger et al., 2010)
Lentigo	malignant	melanoma 10 Absent (Andres et al., 2010)
Squamous	cell	carcinoma 20 Absent (Reisinger et al., 2010)
pulmonary	neuroendocrine	
carcinomas 26 Absent (Busam et al., 2009)
Mesotheliomas 45 Absent (Bhatia et al., 2010)
Table 2.  Presence and absence of MCPyV DNA in some entities.
TSPyV was reported as the eighth HPyV in follicular papules and keratin spines
(spicules) of a heart transplant patient with ts (van der Meijden et al., 2010). Thereafter, it
attempts have been made to find TSPyV in other immunosuppressed patients not suffering
from ts (Kanitakis et  al.,  2011, Fischer et  al.,  2012, Kazem et al.,  2012, Siebrasse et  al.,
2012a, Wieland et al., 2014). There is no evidence for a correlation between TSPyV in
other disease or malignant transformation so far, but obviously additional investigations
are necessary.
In addition, by use of a bead-based multiplex assay, the presence of HPyVs: BKPyV,
JCPyV,  KIPyV,  WUPyV,  MCPyV,  HPyV6,  7,  9,  TSPyV,  and  MWPyV  as  well  as  the
primate PyVs, SV40, and lymphotropic polyomavirus (LPyV) have been analyzed in 37
mucosal melanomas; none of the samples analyzed were positive for any of the examined
viruses (Ramqvist et al., 2014).
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2. TWELVE SPECIES OF HUMAN POLYOMAVIRUSES
2.1. John Cunningham polyomavirus (JCPyV or JCV)
JC virus, as the first of 12 polyomavirus (PyV) members identified in humans thus far,
was identified in 1964 by electron microscopy (EM), when the neuroscientists Zu Rhein
and Sam Chou were investigating formalin-fixed brain tissue sections from patients with
PML (Zurhein and Chou, 1965). Numerous non-enveloped viral particles of icosahedral
symmetry were visible in the nuclei of oligodendrocytes, either dispersed or arranged in
filamentous or crystal-like arrays. Six years later, the virus was isolated by cell culture
from post-mortem PML tissue from the brain of a Hodgkin's lymphoma patient with the
initials J.C. This allowed further studies on the biology and pathogenesis of JCPyV
(Padgett et al., 1971, Padgett and Walker, 1973, Padgett et al., 1976, Padgett et al., 1977a,
Padgett et al., 1977b).
JC virus is implicated as a causal agent in a rare but often fatal infection known as PML
(Tyler, 2008). JCPyV, a highly human-specific virus, has only one major serotype (Hirsch
et al., 2013). It infects approximately half of the general population, but its transmission
route is still unresolved (Hirsch et al., 2013). This virus persists in the reno-urinary tract,
and viral replication is detectable as asymptomatic viruria in about one-third of all infected
immunocompetent individuals. The key JCPyV diseases are associated with
immunological failure at parenchymal sites of the body like the CNS and the kidney, but
possibly also at other sites, including the colon. Moreover, kidney transplant patients may
have PyVAN, as well as other JCPyV-associated pathologies including possibly some
forms of cancer (Ferenczy et al., 2012). Thus, JCPyV still remains challenging. Its biology
and the clinical implications of JCPyV infection, replication, and disease warrant study.
JCPyV genome and structure
Taxonomically, JCPyV is proposed to be a member of the Orthopolyomavirus genus
(Figure 2) (Johne et al., 2011). Characterization of the JCPyV species reveals that only
one major VP1 serotype exists, but at least seven major genotypes. These genotypes,
initially distinguished by their restriction-site pattern and by sequences from the intergenic
region located between the distal early viral gene region and the late viral gene region,
were preferentially detected in different geographic areas of the world (Yogo et al., 1990,
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Sugimoto et al., 1997). Initially, eight major genotypes were distinguished, based on
coding region polymorphisms from 100 full-length JCPyV sequences (Cubitt et al., 2001).
JCPyV virions, like all polyomaviruses, are nonenveloped particles of approximately
42 nm in diameter of T = 7 icosahedral symmetry and hence are morphologically
indistinguishable from other PyV particles. The capsid consists of 360 VP1 molecules
spontaneously assembled from 72 VP1 pentamers and mediates host cell receptor binding
for uptake. Inside the VP1 shell are found the minor capsid proteins, the myristoylated
VP2, and the VP3; these probably play a role not only in packaging, but also in uncoating
and delivery of the JCPyV genome to the host cell nucleus (Shishido-Hara et al., 2004,
Gasparovic et al., 2006, Neu et al., 2009).
The genome size is approximately 5130 bp, although single isolates can differ in length,
due to alteration in their noncoding regions. The JCPyV genome is wrapped around
histones in a nucleosomal core-like organization (Sugimoto et al., 2002). The NCCR lies
between the early and late coding regions. The early coding region spans 2.4  kb and
encodes five proteins: the LTag, the sTag, and three different splice variants (Hirsch et al.,
2013). The late viral gene region of ∼2300 bp contains the ORFs of the capsid proteins
VP1, VP2, and VP3, which are also derived by splicing of one major transcript, but going
in  the  other  direction  from  the  NCCR.  In  addition,  the  JCPyV  late  viral  gene  region
encodes a small leader protein starting directly adjacent to the NCCR; this is called an
agnoprotein, and it has, as thus far determined, a counterpart  in several polyomaviruses
including BKPyV and SV40 but not in all known PyVs (Suzuki et al., 2010).
JCPyV epidemiological aspects
JC virus is one of the most prevalent viruses worldwide (Knowles et al., 2003, Tan and
Koralnik, 2010); aerosol inhalation and ingestion of contaminated water or food may be
major modes of its human transmission (Cinque et al., 2009). JCPyV infection is
widespread in the general population, and several seroprevalence studies of human
populations have detected JCPyV-specific antibodies in 30 to 70% of healthy individuals
(Stolt et al., 2003, Kean et al., 2009, Ferenczy et al., 2012). Many reports show that most
of their study populations appear to be infected, either transiently or latently, with JCPyV
(Hirsch  et  al.,  2013).  Based  on  different  detection  methods,  the  epidemiology  of  JCPyV
varies  somewhat  from study to  study,  with  10  to  30% of  adults  excreting  JCPyV in  the
urine. PCR detection of viral DNA allows for accurate and sensitive detection of
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individuals with actively replicating virus. Nevertheless, its transmission route is not yet
well  defined,  although  the  presence  of  JCPyV  DNA  in  B  cells  and  stromal  cells  of  the
tonsils indicates that tonsils may serve as the initial site of viral infection (Monaco et al.,
1998). The virus may enter the upper respiratory tract via close interpersonal contact or
via fomites, and then presumably spread by a hematogenous route from the primary site of
infection to secondary sites such as the kidneys, bone marrow, lymphoid tissues, and the
brain to establish focal areas of infection or remain persistent (Figure 6) (Chapagain and
Nerurkar, 2010, Aksamit, 2012). Potential alternative modes of transmission include by
urino-oral and transplacental routes, via blood transfusion, in semen and by organ
transplantation (Jiang et al., 2009).
     The archetypal virus is also isolated from sewage samples from various geographic
areas, suggesting possible transmission by contaminated food, water, or fomites (White
and Khalili, 2011). Transplacental transmission is unlikely (Boldorini et al., 2008), but
transmission from parent to child can occur (Zheng et al., 2004, Boldorini et al., 2011).
JCPyV infection in immunocompetent hosts is usually subclinical and remains localized in
the kidney. It is unclear whether JCPyV reactivation causes viral spread to the CNS or if a
latent infection in the CNS becomes locally reactivated. However, JCPyV is permissive in
B-lymphocytes of the bone marrow and peripheral blood (Dorries et al., 2003), suggesting
that viral spread after primary replication may occur via a hematogenous route. In the
CNS, JCPyV infects glial cells, including astrocytes, and myelin-producing cells known as
oligodendrocytes (Zurhein and Chou, 1965). Studies suggest that the virus can remain
latent in the brains of healthy people (Tan et al., 2010). In cases of immunosuppression,
JCPyV can become reactivated, leading to enhanced viral replication and a lytic infection
of the CNS causing cytolytic destruction of oligodendroglia, resulting in the fatal disease
PML (Khalili and White, 2006). The exact mechanism of oligodendroglia cell death in
PML is unknown (Khalili and White, 2006).
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Figure 6. Pathogenesis of JC virus infection causing progressive multifocal leukoencephalopathy.
Reproduced with permission from Aksamit, A.J., Jr., 2012. Progressive multifocal leukoencephalopathy.
Continuum 18, 1374-1391.
JCPyV disease associations
After asymptomatic primary infection with JCPyV, which occurs in childhood, in
addition to the kidney, bone marrow, lymphoid tissues, and tonsils (Tan and Koralnik,
2010, White and Khalili, 2011), may remain latent in the brains of healthy people (Tan
and Koralnik, 2010). Asymptomatic reactivation of latent JC virus is common in
individuals who are immunocompetent, and the virus can be detected in the urine of about
30% of individuals who are healthy (Tyler, 2010)
Attributed to JC virus are also some new neurological disorders including granule cell
neuropathy, encephalopathy, and meningitis (Tan and Koralnik, 2010). Discovery of new
neurological syndromes that result from neuronal infection with JC virus, and the presence
of this virus in the gray matter are under debate (Tan and Koralnik, 2010). It has been
suggested that the JC virus is associated with cognitive decline, dementia, strokes, and
brain- and some other tumors (Katona, 2009, Rollison, 2010).
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PML and MS
PML was originally described in 1958 as a demyelinating disease of the CNS (Astrom
et al., 1958), and later, viral particles were detected by EM in the brains of patients with
PML (Silverman and Rubinstein, 1965, Zurhein and Chou, 1965). JC virus from the brain
tissue of a patient with Hodgkin's lymphoma who developed PML was described in
Lancet article in 1971 (Padgett et al., 1971). PML results from lytic JC virus infection of
glial cells in immunosuppressed patients (Tan and Koralnik, 2010). It was first described
as a complication of immune suppression 50 years ago and emerged as a major
complication  of  HIV  infection  in  the  1980s  (Focosi  et  al.,  2010).  PML  has  recently
become topical because it is a side-effect of some newly developed immunomodulatory
drugs for autoimmune diseases, including natalizumab for multiple sclerosis and Crohn’s
disease, rituximab for systemic lupus erythematosus, and efalizumab for psoriasis (Focosi
et al., 2010, Tan and Koralnik, 2010, White and Khalili, 2011). PML has had a dramatic
effect  on  the  use  of  these  drugs.  Efalizumab  was  withdrawn  from  the  market  in  April
2009, and natalizumab was temporarily withdrawn in February 2005 after three confirmed
cases of PML (Tyler, 2010).
Multiple sclerosis (MS) is another primarily inflammatory disorder of the brain and
spinal cord in which focal lymphocytic infiltration leads to damage of myelin and axons.
MS and PML are both diseases resulting in demyelinated brain lesions; they are
distinguished by morphologically distinct bizarre astrocytes, inclusion bodies within the
nuclei of oligodendrocytes, and also by the lack of the inflammatory inflitrates which are
characteristic of PML (Khalili et al., 2007). Because these diseases are so similar,
researchers have studied the association of MS with JCPyV reactivation and PML.
Reports of JCPyV DNA and viremia in patients with MS conflict: several report a lack of
evidence for JCPyV infection in MS patients (Buckle et al., 1992, Bogdanovic et al.,
1998), while others have found JCPyV DNA sequences in CSF of some MS patients but
not in healthy controls (Ferrante et al., 1998, Koralnik et al., 1999).
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2.2. Thea Brennan-Krohn polyomavirus (BKPyV or BKV)
BKPyV was one of the first two HPyVs identified. It was isolated from both urine and
ureteral epithelial cells of a Sudanese renal transplant (RT) recipient presenting with renal
failure  and  ureteral  stenosis  (Gardner  et  al.,  1971).  A  urine  sample  from  a  patient  who
underwent kidney transplantation 3.5 months earlier contained many inclusion-bearing
epithelial cells. Dr. Anne Field examined the sample by EM and found a large number of
viral  particles  that  were  similar  to  the  common  wart  virus  (Knowles,  2006).  Post-
inoculation of urine to cell culture, a CPE occurred in the secondary Rhesus monkey
kidney and African monkey kidney (Vero) cell culture; the cell culture supernatant
contained viral particles. The virus was called BK after the initials of the patient, and the
original isolate was called the Gardner strain (Gardner et al., 1971).
BK virus is a very common polyomavirus globally, similar to the JC virus. BKPyV
infects most people subclinically during childhood and establishes a lifelong infection in
the reno-urinary tract. In most immunocompetent individuals, infection is completely
asymptomatic, but in frequent episodes of viral reactivation, virus is shed into the urine. In
immunocompromised patients, reactivation is followed by high-level viral replication, and
this  can  lead  to  severe  disease:  1  to  10% of  kidney-transplant  patients  develop  PyVAN,
and 5 to 15% of allogenic HSCT patients develop polyomavirus-associated haemorrhagic
cystitis (PyVHC) (Rinaldo et al., 2013).
BKPyV genome and structure
Comparative analysis of the BKPyV genome shows its considerable homology to
JCPyV (Frisque et al., 1984), and more distantly to other human PyVs. This is evident by
their phylogenetic tree (Figure 2).
The non-enveloped, ichosahedral virion of BKPyV is about 45 nm in diameter
(Takemoto and Mullarkey, 1973). Its capsid is composed of 72 capsomers, each consisting
of five copies of the major structural protein VP1 and one internal minor structural
protein, either VP2 or VP3, linking the viral genome to the capsid (Li et al., 2003). The
BKPyV genome is a circular, double-stranded DNA molecule of 5135 bp (Dunlop strain)
packed around the cellular histones H2A, H2B, H3, and H4, thereby forming a
minichromosome (Hirsch, 2005). The late coding region of BKPyV codes the viral capsid
proteins (VP1, VP2, and VP3) as well as the agnoprotein (Abend et al., 2009).
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The two forms of the virus, the archetype virus and rearranged variants, are based on
the DNA sequence structure of the NCCR. The archetype virus can often be isolated by
transient reactivation events from the urine both of healthy individuals and from diseased
patients (Doerries, 2006). In contrast, rearranged variants most often occur in the serum of
patients with BKPyV-associated diseases.
There are four sub-types of BKPyV (defined by antigenic variations of some viral
capsid proteins) distributed according to the various populations (age, HIV co-infection,
etc.); genotype 1 is the most frequent (Ahsan and Shah, 2006).
BKPyV epidemiological aspects
 Its high prevalence of infection, low morbidity, asymptomatic reactivation, and host
specificity suggest the co-evolutionary adaptation of BKPyV to its human host (Hirsch
and Steiger, 2003). Primary infection typically occurs during early childhood, after the
waning of maternal antibodies. Before the child reaches the age of 10 years, the
seroprevalence increases to 91%, and the overall rate of seropositivity for BKPyV is 81%
(Knowles et al., 2003). The natural route of BKPyV transmission has not been resolved
and may be respiratory or oral. BKPyV, like JCPyV, is fairly resistant to environmental
inactivation, and both are detectable in human sewage. Latency is established in renal
tubular epithelial and urothelial cells. Reactivation and low-level replication with
asymptomatic viruria occurs in 5% of healthy individuals (Hirsch and Steiger, 2003). The
prevalence may increase with pregnancy, older age, or immune dysfunction to rates of >
60% (Rinaldo et al., 2013). In addition, the level of replication may increase to a BKPyV
DNA load from <105 to >107 copies/mL of urine. However, that BKPyV disease is rare
suggests that additional factors are required.
Additionally, BKPyV viruria can be detected in up to 25% of pregnant women (Jin et
al., 1993). Moreover, BKPyV is a significant human pathogen that causes disease in
immunocompromised individuals. BKPyV is able to reactivate in renal transplant- and
bone marrow-transplant (BMT) patients in whom a lytic infection results, respectively, in
polyomavirus-associated nephropathy (PyVAN) and hemorrhagic cystitis (HC). Rarely,
BKPyV reactivation and disease are observable in other immunocompromised conditions
such as systemic lupus erythematosus, in addition to solid organ-transplant recipients, and
in patients with HIV/AIDS (Jiang et al., 2009).
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BKPyV disease associations
High prevalence, latent infection, and asymptomatic reactivation of BKPyV complicate
our understanding and evaluation of its pathogenic role. Various disease processes have
been linked to BKPyV infection, but the two most important diseases are PyVAN
affecting kidney transplant patients and PyVHC affecting allogenic HSCT patients. In
immunocompromised individuals, other associated conditions include ureteric stenosis,
encephalitis, meningoencephalitis, pneumonia, and vasculopathy. Although BKPyV has
been associated with cancer development, especially in the bladder, definitive evidence of
its role in human malignancy is lacking.
PyVAN and PyVHC diseases
PyVAN, the most frequent BKPyV-associated disease occurring after renal
transplantation, is a form of acute interstitial nephritis (Nickeleit and Mihatsch, 2006).
BKPyV viruria and viremia due to reactivation appear in up to 80% of renal transplant
patients; 10% of such patients progress to PyVAN, resulting in allograft loss 90% of the
time (Hirsch et al., 2002, Bressollette-Bodin et al., 2005, Egli et al., 2007, Huang et al.,
2010).  Lytic  infection  in  kidney  epithelial  cells  as  a  result  of  BKPyV  leads  to  PyVAN,
which is characterized by necrosis of proximal tubules and denudation of the basement
membrane (Nickeleit et al., 2003). Recently, PyVAN incidence has been rising because of
new and more potent immunosuppressive regimens (Nickeleit et al., 2000, Mengel et al.,
2003); this finding indicates a relationship between BKPyV reactivation and disruption of
the immune system.
Among  allogenic  HSCT  patients,  5  to  15%  are  affected  by  PyVHC,  a  late-onset
hemorrhagic cystitis usually starting about 50 days post-transplantation. The pathogenesis
of PyVHC is not fully understood, but is suggested to result from the following sequence
of  events  (Azzi  et  al.,  1999).  First  the  bladder  mucosa  is  subclinically  damaged  by  the
toxic metabolite of cyclophosphamide, a drug used as a conditioning protocol prior to
stem-cell transplant. Next, during the aplastic phase, immunologically uncontrolled high-
level BKPyV replication causes denudation of the damaged bladder mucosa. Finally, upon
engraftment of the allogeneic stem cell graft inflammation occurs. Though PyVHC usually
affects allogenic HSCT patients, some case reports describe PyVHC also in other
immunocompromised patients (Hirsch and Steiger, 2003, Kinnaird and Anstead, 2010).
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2.3. Karolinska Institute polyomavirus (KIPyV)
In 2007 the Karolinska Institute polyomavirus (KIPyV) was identified in Stockholm,
Sweden (Allander et al., 2007a). It was discovered in respiratory-tract samples from
individuals with acute respiratory tract infections, but by totally new methods. The
Allander group developed a system for large-scale molecular virus screening of clinical
samples based on host DNA depletion, random PCR amplification, large-scale
sequencing, and bioinformatics (Allander et al., 2005, Allander et al., 2007a). In this
technology for virus screening, the nasopharyngeal aspirates were randomly selected,
centrifuged, and the cells were collected. Before DNA and RNA were extracted, the
resulting pellet was recovered, resuspended, and treated with DNase (Allander et al.,
2001). Extracted DNA and RNA were amplified separately by random PCR (Froussard,
1992, Allander et al., 2001, Allander et al., 2005, Allander et al., 2007a). The nucleic acids
served as a template for random PCR, and the products were separated by gel
electrophoresis, cloned, and sequenced. This resulted in several sequence reads that were
subsequently trimmed, clustered, and sorted by use of dedicated software. Finally, BLAST
(Basic Local Alignment Search Tool) searches were performed in search of similarities
with known viral sequences listed in GenBank (Allander et al., 2005, Allander et al.,
2007a). Following these findings, various biological specimens and body compartments
were screened in an attempt to establish a pathogenetic role for KIPyV in the respiratory
tract or in other human diseases (Table 3).
KIPyV genome and structure
The genomic organization of KIPyV is typical for a member of the family
Polyomaviridae, with an early region encoding regulatory proteins (LTag and sTag) and a
late region coding for structural proteins, separated by a noncoding regulatory region
(Figure 7) (Allander et al., 2007a). The genome size falls within the range of the
polyomaviruses. The KIPyV genome is circular and 5,040 nucleotides in length (Allander
et al., 2007a). Whereas the nonstructural proteins have substantial sequence similarity to
those of the other primate polyomaviruses, the structural proteins have a very low degree
of similarity to those of other known polyomaviruses (Allander et al., 2007a).
The early proteins show similarities to other members of the polyomavirus family,
primarily BKPyV, JCPyV, SV40, and simian agent 12 (SA12). Alignment with the LTag
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of other polyomaviruses shows that most regions characteristic of LTag are present also in
KIPyV (Allander et al., 2007a).
In the late region of the genome are putative ORFs for capsid proteins VP1, VP2, and
VP3 (Figure 7). As in all polyomaviruses, VP3 is encoded by the same ORF as VP2 by the
use of an internal start codon.  An overlap exists between the C terminus of VP2/3 and the
N terminus of VP1, as is the case in other polyomaviruses. It can be noted that both VP2
and VP3 of KIPyV are large in comparison with those of other members of the
polyomavirus family (400 and 257 aa, respectively) (Allander et al., 2007a).
The degree of aa identity between the VP1 proteins of the HPyVs has been reviewed
(Moens et al., 2013) and the highest degree of identity is found between BKPyV and
JCPyV (78%), HPyV6 and HPyV7 (69%), and KIPyV and WUPyV (66%). The degree of
similarity of KIPyV VP1 with other VP1 proteins is markedly low. VP1 has only 30%
identity with its closest counterparts (those of JCPyV and MPyV). In KIPyV VP1, the
only  region  that  shows  a  relatively  high  degree  of  similarity  to  those  of  other
polyomaviruses is the sequence that in MPyV VP1 binds calcium, corresponding to
approximately aa 237 to 248 in VP1 of KIPyV (Allander et al., 2007a).
The VP2/VP3 gene shows even lower similarity to its counterparts in other
polyomavirus species. In fact, neither a nucleotide nor a translated BLAST search with
this gene sequence generated any significant matches in the public databases. Thus, the
identity of this ORF is indicated only by its position in the genome. VP2 and VP3 of all
other polyomaviruses contain a conserved VP1-binding domain. No corresponding
sequence is found in KIPyV. In KIPyV, the region between the start codons of VP2 and of
ST/LT is long (513 bp); this could possibly indicate the presence of an agno gene.
However, no corresponding ORF is present in this region (Allander et al., 2007a).
There is no evidence hinting at a virus structure for the KIPyV and other newly
discovered HPyVs differing from other polyomaviruses. However, because their virions
have not been displayed by EM, no evidence exists for the precise virion structure at this
stage.
KIPyV epidemiological aspects
Seroepidemiological studies show that the seroprevalence of KIPyV in the adult
population is high, suggesting that primary infection occurs early in childhood (Kean et
al., 2009, Nguyen et al., 2009, Moens et al., 2013). Indeed, Nguyen and colleagues, using
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an enzyme-linked immunosorbent assay (ELISA) test for human VP1 antibodies, reported
a seropositivity of about 70% for KIPyV in the age-group of 50 to 64 years (Nguyen et al.,
2009). The primary sequences of KIPyV and WUPyV VP1 are 66% identical with several
linear stretches that are completely identical. However, use of plasma samples of patients
and fixed Sf9 cells infected with recombinant baculovirus expressing either KIPyV or
WUPyV VP1 revealed no indication of antibody cross-reaction in an immunofluorescence
assay (Neske et al., 2010). In histidine-tagged VP1-based ELISA both IgG and IgM seem
to be specific for KIPyV or WUPyV (Miller et al., 2012). These findings were confirmed
by another group who failed to detect antibody cross-reactivity between BKPyV/JCPyV
and KIPyV/WUPyV in a VP1-based ELISA (Kean et al., 2009, Nguyen et al., 2009).
KIPyV has a worldwide distribution (Table 3). Detectable by PCR in the respiratory
samples of patients from all continents, detection rates range from 0.5 to 8% (Babakir-
Mina et al., 2008, Ren et al., 2008, Babakir-Mina et al., 2009b, Mourez et al., 2009).
Several real-time PCR methods allow detection of and often distinction between these
viruses (Bialasiewicz et al., 2007a, Bergallo et al., 2009, Lindau et al., 2009, Kuypers et
al., 2012). Almost all KIPyV-DNA detection has been done by PCR methods. The choice
of PCR and target region may affect the final result for KIPyV detection. Conventional
PCR has lower sensitivity than does real-time PCR (Lindau et al., 2009). The location of
primer and probe sequences in different genomic regions can affect KIPyV and WUPyV
detection rates (Bialasiewicz et al., 2007a, Bergallo et al., 2009) and therefore the
prevalence of these two viruses in different clinical syndromes. Indeed, primers/probes
located in the regulatory or sTag regions of KIPyV have yielded a lower detection rate
than have primers/probes located in the VP1 region of KIPyV, when researchers are
testing in the same specimen type (Bergallo et al., 2009).
Measuring high KIPyV viral loads (geometric mean of 6.6 × 106 copies/cell; 6.4 × 1013
copies/mL) in respiratory samples of immunocompromised patients compared to a control
group (geometric mean of 3.1 × 104 copies/cell; 6.9 × 1010 copies/mL, P = 0.019), led to
the hypothesis of an increased pathogenic potential for this virus in immunocompromised
patients, particularly in HSCT patients (Rao et al., 2011). However, frequent co-detection
with other respiratory viruses makes it difficult to correlate these viral load determinations
with disease severity.  High viral  loads also measured in lymphoid tissue of patients with
AIDS (Sharp et al., 2009) imply that diseases associated with KIPyV are more likely to
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occur in immunocompromised patients. No correlation between the presence of KIPyV
and CD4+ cell counts was, however, observable (Babakir-Mina et al., 2010a).
In a large prospective study, carried out on 2,732 nasal wash samples collected from
222 patients during the first year after allogeneic hematopoietic cell transplantation, the
cumulative incidence of KIPyV was 26% (Kuypers et al., 2012). Sputum production and
wheezing were associated with KIPyV detection. No association existed, however,
between polyomavirus detection and graft-vs-host disease, cytomegalovirus reactivation,
neutropenia, lymphopenia, hospitalization, or death.
KIPyV disease associations
KIPyV has been discovered in respiratory tract samples from individuals with acute
respiratory tract  infections (Allander et  al.,  2007a),  but without conclusive data as to the
role of KIPyV as a respiratory pathogen, determination of KIPyV viral loads in diagnostic
laboratories is not routine. A causal role for this virus in the respiratory tract is unlikely
(Norja  et  al.,  2007).  Seroepidemiological  surveys  show  that,  similarly  to  BKPyV  and
JCPyV, primary infection with KIPyV occurs early in life, probably through the
respiratory and oral-fecal routes. The virus remains latent in the body, to become
reactivated if immunosuppression occurs. However, differing respiratory tract specimen
types tested (nasopharyngeal aspirates, nasal washes, bronchoalveolar lavages,
broncoaspirates, throat swabs), non-standardized time-points of specimen collection, and a
lack of standardized PCR methods, of a clear clinical cutoff value, of prospective
quantitative studies including an asymptomatic control group, all interfere with the use of
viral load in management of patients with KIPyV reactivation.
     The presence of KIPyV and WUPyV has been described in the brains of patients
with and without PML (Barzon et  al.,  2009b).  These results contrast  with those reported
by other groups that did not detect KIPyV, WUPyV or MCPyV in the CNS (Bialasiewicz
et al., 2009b, Giraud et al., 2009). As mentioned, these conflicting results may be linked to
ethnic differences in patient populations, different laboratory methods, sequence variations
in the viral target, and sensitivity of the PCR methods. Standardization of the methods can
help to define the prevalences of the novel polyomaviruses in the CNS.
     No KIPyV or WUPyV DNA was detected in the neuroendocrine tumor (Duncavage
et al., 2009a), and in another study, all 36 melanoma biopsies examined were also negative
for these two viruses (Giraud et al., 2008). Moreover, using an improved RCA technique,
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found  no  KIPyV  or  WUPyV  (Schowalter  et  al.,  2010).  Although  a  small  number  of
individuals have been screened thus far, KIPyV and WUPyV do not seem to possess skin
tropism.
Sample	type	 No.	Positivesamples	/total	
(%)
Patients
Median	age
(age	range,	
years)
Country Reference
Respiratory tract sample 6/637 (1) 7 (<0.1–90) Sweden (Allander et al., 2007a)
Respiratory tract sample 14/983 (1.4) – (0.3–34) UK (Norja et al., 2007)
Respiratory tract sample 5/486 (1) 0.9 (0.1–5.9) South Korea (Han et al., 2007)
Respiratory tract sample 24/951 (2.5) 1.5 (0.1–95) Australia (Bialasiewicz et al., 2007b)
Respiratory tract sample 75/2866 (2.6) 1.38 (<0.1–95) Australia (Bialasiewicz et al., 2008)
Respiratory tract sample 11/406 (2.7) 0.8 (<0.1–9) China (Yuan et al., 2008)
Respiratory tract sample 6/302 (1.9) 1 (<0.1–14) Thailand (Payungporn et al., 2008)
Respiratory tract sample 2/415 (0.5) 8.2 (0.1–14) China (Ren et al., 2008)
Respiratory tract sample 1/222 (0.5) 27 (0.5–82) Italy (Babakir-Mina et al., 2008)
Respiratory tract sample 3/537 (0.6) 1.6 (0.10–2.6) France (Foulongne et al., 2008)
Respiratory tract sample 10/371 (2.7) 0.8 (<0.1–79) UK (Abedi Kiasari et al., 2008)
Respiratory tract sample 17/265 (6.5) 46 (3.6–85.3) France (Mourez et al., 2009)
Respiratory tract sample 7/232 (3) – (0.1–7.6) Japan (Teramoto et al., 2011)
Respiratory tract sample 9/161 (5.6) 4.9 (–) USA (Rao et al., 2011)
Respiratory tract sample 7/295 (2.3) 4.9 (–) USA (Rao et al., 2011)
Tonsil 11/91 (12) 42 (10–88) Italy (Babakir-Mina et al., 2009a)
Lymphoid tissue 3/42 (7.1) – (–) UK (Sharp et al., 2009)
Lymphoid tissue 1/55 (1.8) – (–) UK (Sharp et al., 2009)
Lung tissue 9/20 (45) 68 (40–85) Italy (Babakir-Mina et al., 2009b)
Lung tissue 1/30 (3.3) – (45–77) Japan (Teramoto et al., 2011)
Stool 1/192 (0.5) 1(<0.1–17) Sweden (Allander et al., 2007a)
Stool 1/193 (0.5) 1.3 (<0.1–11.8) Australia (Bialasiewicz et al., 2009b)
Stool 10/86 (11.6) 7.1 (1–27)54 (17–75) Italy (Babakir-Mina et al., 2009b)
Stool 1/9 (11.1) 46 (3.6–85.3) France (Mourez et al., 2009)
Plasma HIV-1 positive 2/62 (3.2) 45.5 (37–54) Italy (Babakir-Mina et al., 2009a)
Plasma HIV-1 positive 4/153 (2.6) 41.9 (33.8–47.3) Italy (Babakir-Mina et al., 2010a)
Plasma HIV-1 negative 4/130 (3.1) 41 (32–47.5) Italy (Babakir-Mina et al., 2010a)
Blood HIV-1 positive 1/100 (1) 46 (23–82) Italy (Barzon et al., 2009a)
Plasma	 3/640 ∼ (0.5) 40 (--) France (Touinssi et al., 2013)
Respiratory tract -HIV
infected and uninfected 91/1460 (6.2) -(<2) South African (Nunes et al., 2014)
Table 3. Detection of KI polyomavirus in various biological specimens.
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Figure 7. Genome map of KI, WU, MC, and TS polyomaviruses Indicated are the five identified ORFs
representing the putative “early” genes encoding small and large T antigen, and the putative “late” genes
encoding VP1, VP2, and VP3. The NCCR is placed on top and contains the putative ori. Nucleotide position
1 was chosen within the NCCR in the large T binding region. Each map reproduced with permission from its
source: (Allander et al., 2007a, Gaynor et al., 2007, Feng et al., 2008, van der Meijden et al., 2010).
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2.4. Washington University polyomavirus (WUPyV)
 Discovery of WUPyV resulted through a large-scale molecular virus screening system
in 2007 created by David Wang’s research group at Washington University, in the USA.
They reported the identification of a novel WU polyomavirus present in respiratory
secretions from human patients with symptoms of acute respiratory tract infection (Gaynor
et al., 2007). This virus was initially detectable in a nasopharyngeal aspirate from an
Australian 3-year-old child diagnosed with pneumonia. A random library was generated
from nucleic acids extracted from the nasopharyngeal aspirate and was analyzed by high-
throughput DNA sequencing. The multiple DNA fragments they cloned possessed limited
similarity to known polyomaviruses. They also used library construction and shotgun
sequencing techniques. For sample preparation, NPA was thawed and directly treated with
DNase. Total nucleic acid was extracted and randomly amplified. RNA in the total nucleic
acid preparation was converted to cDNA by reverse transcription with the first primer.
Two rounds of random priming with the first primer and extension with sequenase enabled
second-strand cDNA synthesis as well as random priming of the DNA originally present
in the total nucleic acid sample. Amplicons were then generated via PCR by use of a
second primer. The second primer-amplified material was TOPO cloned into pCR4.0 and
transformed into bacteria, and white colonies were placed into 384-well plates. DNA was
purified by magnetic bead isolation and sequenced. Product analysis of shotgun sequences
and complete genome amplification revealed limited homology to known polyomaviruses.
They subsequently sequenced the entire virus genome of 5,229 bp, referred to as ‘‘WU
virus’’. It had genomic features characteristic of the family Polyomaviridae (Gaynor et al.,
2007).
Thereafter, WUPyV have been detectable worldwide (Table 4) and provide serological
evidence of infection. Like KIPyV, the status of this virus as a human respiratory
pathogen is a topic of debate because of its detection in samples from healthy individuals
and its frequent co-detection with other respiratory viruses.
WUPyV genome and structure
WUPyV DNA sequence analysis has revealed genomic features characteristic of
polyomaviruses. The genome size of WUPyV, 5,229 bp, is quite comparable to those of
the other primate polyomaviruses (Figure 7) (Gaynor et al., 2007). The WUPyV genome
shows the highest sequence identity with that of KIPyV. Phylogenetic analysis
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demonstrates that WUPyV, along with its sibling KIPyV, defines a novel clade within the
family Polyomaviridae (Johne et al., 2011). The genome organization includes an early
region coding on one strand for sTAg and LTAg, and a late region coding on the opposite
strand for the capsid proteins VP1, VP2, and VP3 (Figure 7). These two regions are
separated by a regulatory region that contains typical polyomavirus features (Gaynor et al.,
2007). Unusual features in the WU regulatory region include two partially overlapping
LTAg binding sites and slightly variant spacing between the LTAg binding sites when
compared to that of SV40, BKPyV, and JCPyV (Gaynor et al., 2007).
WUPyV epidemiological aspects
The first prevalence data for WUPyV was based on PCR detection of virus DNA in
NPA  samples  (Gaynor  et  al.,  2007).  Now  it  is  obvious  that  this  virus  is  widespread
globally (Table 4). Its DNA prevalence in respiratory tract samples of healthy individuals
has  ranged  from 0.4  to  9%,  a  difference  no  higher  for  those  of  patients  with  respiratory
symptoms. Its prevalence has increased in immunosuppressed individuals in some, but not
in all reports (Ren et al., 2008, van der Zalm et al., 2008, Rao et al., 2011). In parallel with
this, other studies used similar methods to look at the prevalence of WUPyV at sites other
than the respiratory site, e.g. in urine, blood, and stool (Abedi Kiasari et al., 2008, Dalianis
et al., 2009, Ren et al., 2009). WUPyV genomic DNA monitored for by PCR is seldom
detectable in the urine of normal or immunosuppressed individuals, or in their blood, but
WUPyV  has  occurred  at  very  low  frequency  (<1%)  in  stool  samples  (Allander  et  al.,
2007a, Gaynor et al., 2007, Ren et al., 2009). Moreover, WUPyV has been absent from the
CSF of patients with or without PML (Dang et al., 2011).
No WUPyV DNA has been detected in plasma, urine or respiratory samples from
pregnant and non-pregnant women. KIPyV DNA appeared in two plasma samples from
non-pregnant women (2%) but was undetectable in other samples from pregnant or non-
pregnant women (Csoma et al., 2012). The epidemiology of KIPyV and WUPyV in
healthy populations in France, by examination of 640 plasma samples by a conserved real-
time PCR detection system, resulted in three KIPyV but no WUPyV sequences found
(Touinssi et al., 2013).
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Furthermore,  ELISA  tests  for  VP1  antibodies  show  that  exposure  to  WUPyV  is
common (55–98%), and suggests that the initial exposure occurs during childhood (Carter
et al., 2009, Dalianis et al., 2009, Kean et al., 2009, Nguyen et al., 2009).
WUPyV disease associations
 Since  the  time  that  WUPyV  were  first  identified  in  St.  Louis,  in  the  USA,  viral
sequences have been regularly detected in respiratory materials worldwide (Table 4),
suggesting that viruses are widespread among humans with respiratory tract diseases, but
none of these studies revealed a clear correlation between WUPyV and respiratory disease
(Babakir-Mina et al., 2011).
     Often KIPyV and WUPyV occur together with other known pathogens and not in
loads high enough to suggest any causal relationship. Nonetheless, the pathogenicity of
KIPyV and WUPyV remains speculative (Norja et al., 2007). Further, the link between
KIPyV and WUPyV infection and respiratory disease is complicated by their high rate of
co-infection with other respiratory viruses (Allander et al., 2007a, Bialasiewicz et al.,
2007a, Bialasiewicz et al., 2007b, Gaynor et al., 2007, Han et al., 2007, Abedi Kiasari et
al., 2008, Babakir-Mina et al., 2008, Neske et al., 2008). However, in some cases, KIPyV
or WUPyV were the only pathogens detected, despite wide screening including for
viruses, bacteria, and fungi (Han et al., 2007, Mourez et al., 2009). Nasopharyngeal
aspirate samples from 1,980 pediatric patients with suspected acute respiratory tract
infection, and 82 samples from healthy subject controls in South China were analyzed by
multiplex PCR and results showed 53 (2.7%) patients as being positive for WUPyV, while
none of the 82 healthy controls were positive. One of the most common pathogens in co-
infected samples was WUPyV (54.9%) (Cai et al., 2014).
     These preliminary studies led to the hypothesis that these new viruses do play an
etiological role in childhood respiratory disease. Although both viruses occur mainly in
respiratory-tract samples of immunocompromised patients, no clear causative link yet
exists with respiratory disease (Allander et al., 2007a, Gaynor et al., 2007). Indeed,
absence of specific clinical or radiological findings, frequent co-detection with other
respiratory pathogens, detection in subjects without signs or symptoms of respiratory
disease, and variability in viral loads have prevented any definitive conclusions.
Prospective studies with large sample sizes including both immunocompromised and
immunocompetent patients with and without respiratory symptoms will be vital.
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Standardized quantitative real-time PCR (qPCR) methods, definition of a clear clinical
cut-off value, and the identical timing in the collection of respiratory samples are also
crucial to understand the pathogenic role, if any, of KIPyV and WUPyV in human
pathology.
Sample type
No. Positive
samples /total
(%)
Patients Median
age (age range,
years)
Country Reference
Respiratory tract sample 37/1245 (3) 2 (0.3–53) Australia (Gaynor et al., 2007)
Respiratory tract sample 6/890 (0.7) 3 (0.3–51) USA (Gaynor et al., 2007)
Respiratory tract sample 34/486 (7) 0.9 (0.1–5.9) South Korea (Han et al., 2007)
Respiratory tract sample 3/72 (4.2) 1.2 (0.1–6.5) South Korea (Han et al., 2007)
Respiratory tract sample 2/79 (2.5) 1.1 (1.1) Canada (Abed et al., 2007)
Respiratorytract sample 5/78 (6.4) 1.8 (1.1–2.0) Canada (Abed et al., 2007)
Respiratory tract sample 10/983 (1.0) – (0.3–34) UK (Norja et al., 2007)
Respiratory tract sample 17/406 (4.2) 2.2 (<0.1–8) China (Yuan et al., 2008)
Respiratory tract sample 62/1277 (4.9) 1.6 (<0.1–22) Germany (Neske et al., 2008)
Respiratory tract sample 19/302 (6.3) 1 (<0.1–14) Thailand (Payungporn et al., 2008)
Respiratory tract sample 10/415 (2.4) 0.8 (0.1–14) China (Ren et al., 2008)
Respiratory tract sample 128/2866(4.5) 1.38 (<0.1–95) Australia (Bialasiewicz et al., 2008)
Respiratory tract sample 13/537 (2.4) 0.11 (0.2–4) France (Foulongne et al., 2008)
Respiratory tract sample 4/371 (1) 0.8 (<0.1–79) UK (Abedi Kiasari et al., 2008)
Respiratory tract sample 1/278 (0.35) 3 (<0.1–5) China (Lin et al., 2008)
Respiratory tract sample 2/265 (0.75) 46 (3.6–85.3) France (Mourez et al., 2009)
Respiratory tract sample 3/98 (3) – (<3) Germany (Kleines et al., 2008)
Respiratory tract sample 38/232 (16.4) – (0.1–7.6) Japan (Teramoto et al., 2011)
Respiratory tract sample 5/161 (3) 4.9 (–) USA (Rao et al., 2011)
Respiratory tract sample 14/295 (5) 4.9 (–) USA (Rao et al., 2011)
Tonsils 4/91 (4.4) 42 (10–88) Italy (Babakir-Mina et al., 2009a)
Lymphoid tissue 3/42 (7.1) – (–) UK (Sharp et al., 2009)
Stool 2/ 377 (0.5) 0.9 (0.1–13) China (Ren et al., 2009)
Stool 7/193 (3.6) 1.3(<0.111.8) Australia (Bialasiewicz et al., 2009b)
Stool 2/221 (0.9) 41.8(0.197.6) Australia (Bialasiewicz et al., 2009b)
Stool 7/86 (8.1) 7.1 (1–27)54 (17–75) Italy (Babakir-Mina et al., 2009b)
Cerebral spinal fluid 1/60 (1.6) 44 (4–88) Italy (Barzon et al., 2009b)
Plasma HIV-1 positive 1/62 (1.6) 45.5 (37–54) Italy (Babakir-Mina et al., 2009a)
Serum HCV positive 2/79 (2.5) – (–) USA (Miller et al., 2009)
Plasma HIV-1 positive 7/153 (4.6) 41.9(33.8–47.3) Italy (Babakir-Mina et al., 2010a)
Plasma HIV-1 negative 1/130 (0.8) 41 (32–47.5) Italy (Babakir-Mina et al., 2010a)
Blood HIV-1 positive 1/100 (1) 46 (23–82) Italy (Barzon et al., 2009a)
Plasma	 0/640 (0) 40(--) France (Touinssi et al., 2013)
Respiratory tract -HIV
infected and uninfected 156/1460(10.7) -(<2)
South African (Nunes et al., 2014)
Table 4. Detection of WU polyomavirus in various biological specimens.
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2.5. Merkel cell polyomavirus (MCPyV)
MCPyV is the first polyomavirus linked to human cancer. Its recent discovery helps
explain many of the ambiguous features of MCC (Feng et al., 2008). MCPyV is clonally
integrated into MCC tumor cells, which, to survive, require continued MCPyV
oncoprotein expression. The integrated viral genomes have a tumor-specific pattern of
tumor antigen gene mutation that incapacitates viral DNA replication (Feng et al., 2008).
MCPyV is the first human cancer virus that is mostly harmless viral flora in human skin
(Foulongne et al., 2010, Schowalter et al., 2010), but is believed to initiate cancer in a host
with specific susceptibility factors, such as age and immune suppression if it acquires a
precise set of mutations. Identification of this tumor virus has led to new opportunities for
early diagnosis and targeted treatment of MCC (Chang and Moore, 2012).
Digital transcriptome subtraction (DTS) is the new molecular technique developed by
Feng et al. to discover MCPyV associated with human cancers (Feng et al., 2007, Feng et
al., 2008). MCC was known as a rare but aggressive skin cancer common in the elderly
and the immunocompromised, and it also occurred among organ transplant recipients
(Koljonen et al., 2009b). Based mainly on the link between MCC and immunesuppression,
they attempted to determine whether MCC has an infectious origin (Feng et al., 2008).
Representational difference analysis (RDA) was used to create representations of the DNA
genome of normal or diseased tissue. RDA is a technique used to find sequence
differences between two genomic or cDNA samples. Genomes or cDNA sequences from a
cancer sample and a normal sample are PCR amplified, and differences are analyzed using
subtractive DNA hybridization.
To  search  for  viral  genomes  in  MCC,  they  built  on  the  principles  of  RDA  and
modernized the technique by combining it with the availability of sequences from the
entire human genome. The product was a related but distinct method known as DTS (Feng
et al., 2008). They generated two cDNA libraries from a total of four anonymized MCC
tumors, an approach requiring precise discrimination between human and nonhuman
cDNA sequences. Database comparisons show a high likelihood that small viral sequences
can be successfully distinguished from human sequences. The work on this approach
began over a decade ago, prior to the release of the full human genome. It has become a
practical approach to new-virus discovery only with the generation of highly-verified
human genomic sequence databases and the development of low-cost, high-throughput
sequencing  (Feng  et  al.,  2007).  After  cDNA  is  created  from  RNA  extracted  from  fresh
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tumor tissues through reverse transcription, this library is then exhaustively sequenced to
generate a high-fidelity transcriptome database of the tumor. Precise discrimination
between human and non-human cDNA sequences then occurs, and known human
sequences that align to GenBank human reference sequences are then computationally
subtracted. Careful screening and selection of high-quality sequences prior to
computational subtraction is necessary to increase chances of discovering a true candidate.
The non-matching non-human sequences remaining are candidate pathogen cDNAs. This
smaller candidate database can then be explored using low-stringency alignment to virus
databases or by experimental extension to identify novel viral sequences (Feng et al.,
2008).
MCPyV genome and structure
Similar to other polyomaviruses, MCPyV has a 5,387 bp genome that is divided into
early and late coding regions by a noncoding regulatory region (NCRR) (Figure 7). The
MCPyV NCRR contains a 71-bp core sequence that constitutes the viral replication origin,
which efficiently sustains T antigen-directed DNA replication (Chang and Moore, 2012).
NCRR contains regulatory elements and transcriptional promoters for early and late viral
gene expression that are bidirectionally coordinated with viral DNA replication (Feng et
al., 2011). The MCPyV early region encodes an LT, an sT, and a 57 kT, all of which share
a 78-aa N terminus (Figure 7). MCC-derived MCPyVs have tumor-associated missense
mutations or deletions in the portion of the T antigen gene encoding LT. These mutations
eliminate the C-terminal replication functions of this protein but do not interfere with N-
terminal LT domains, including the LXCXE motif that targets cellular retinoblastoma and
related pocket proteins, or with expression of the MCPyV sT protein, which plays a more
critical role in cell transformation than does SV40 sT (Feng et al., 2008).
     The late region encoding VP1, VP2, and VP3 is expressed after the start of viral
DNA replication to self-assemble into ∼55-nm-diameter viral particles that demonstrate
the icosahedral symmetry characteristic of polyomaviruses (Tolstov et al., 2009). MCPyV
structural  proteins are relatively dissimilar to those of BKPyV and JCPyV, so antibodies
against MCPyV VP generally do not cross-react with those of these viruses (Pastrana et
al., 2009).
     A study based on analysis of a 1284 bp-long fragment of MCPyV generating three
distinct  MCPyV  genomic  fragments  of  LTag,  VP1,  VP2,  and  NCCR  demonstrated  the
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existence of five major geographically related MCPyV genotypes, which are
European/North American/Caucasian, African (Sub-Saharan), Oceanian, South
American/Amerindian, and Asian/Japanese (Martel-Jantin et al., 2014). In addition,
complete and partial sequences of sTag and LTag from 32 Japanese MCPyV-infected
MCC revealed that each Japanese patient harbored a specific MCPyV strain with some
synonymous or silent mutations and stop codons or deletions, but functional domains of T
antigen had no aa changes. All stop codons were localized after the retinoblastoma
protein-binding domain. These Japanese MCPyV strains were very closely interrelated.
Phylogenetic analysis of nine Japanese sequences and 70 other sequences for the sT and
LT genes registered in GenBank indicated that Japanese or Asian MCPyV strains formed
distinct clades from the Caucasian clade, and a phylogenetic tree only of the sT gene
formed a characteristic three clades and showed that all Japanese or Asian strains were
included in the dominant clade (Matsushita et al., 2014).
MCPyV epidemiological aspects
Early studies identified low copy numbers of the MCPyV genome in various tissues
from healthy individuals and from non-MCC patients. Although most MCC tumors have
high copy numbers of the viral genome, MCPyV DNA appears at trace levels in other
tissues, particularly in skin, which is consistent with MCPyV’s being part of the healthy
human flora (Foulongne et al., 2010, Schowalter et al., 2010, Foulongne et al., 2012).
Detection of MCPyV has been reported on environmental surfaces as well (Bofill-Mas et
al., 2010, Foulongne et al., 2011). Serologic studies have confirmed this finding and have
revealed that MCPyV causes a common if not ubiquitous human infection. Polyomavirus
serology has been based largely on antibodies reacting with the late structural proteins
VP1  and,  to  a  lesser  extent,  VP2.  Serum  reactivity  to  isolated  MCPyV  VP1  was  first
reported as a 25 to 42% prevalence in MCPyV antibody positivity (Kean et al., 2009). An
improved multiplex antibody-binding assay has been used to detect levels of MCPyV VP1
in sera and it is found in control subjects from the general population, at a prevalence of
59% (Carter et al., 2009). Immunoblotting of VP1 reveals, however, that conformational
epitopes present in assembled viral particles provide higher sensitivity and specificity for
measuring  past  MCPyV exposure  (Chen et  al.,  2011a).  Expression  of  MCPyV VP1 and
VP2 in cells generates self-assembling virus-like particles (VLPs) that can serve as
antigens for immunoassays. Use of this approach revealed an age-related increase in
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MCPyV seroprevalence up to age 50, at which age, 80% of healthy North American blood
donors showed evidence of past MCPyV exposure (Tolstov et al., 2009). Use of MCPyV
VLPs provided similar results (Touze et al., 2010). Antibody responses to MCPyV VLPs
are not diminished by cross competition with other polyomavirus antigens, which
indicates that they are highly specific for MCPyV infection (Pastrana et al., 2009).
Thus, similar to other HPyVs, MCPyV appears to be a common infection of childhood,
and primary infection may be asymptomatic. The rate of seroprevalance in children
younger than age 4 is 9%, which by 4 to 13 years of age increases to 35% (Chen et  al.,
2011a). In a longitudinal study of healthy adult gay and bisexual men aged 18 and up,
recruited  and  followed  for  signs  and  symptoms  related  to  HIV  and  AIDS,  79%  had
antibodies to MCPyV at study entry, and subsequently, over a 4-year follow-up period, 31
(5.5%) of the men seroconverted to MCPyV positivity (Tolstov et al., 2011). No apparent
signs,  symptoms,  or  common  laboratory  test  results  were  significantly  associated  with
primary MCPyV infection among these men.
MCPyV DNA has been detectable among non-tumor samples at a variable frequency
(Table 5), such as in nasopharyngeal aspirates (NPAs) (Goh et al., 2009) and respiratory
tract samples from Australian patients with upper respiratory symptoms (Bialasiewicz et
al., 2009a). MCPyV DNA has been amplified in lower-respiratory-tract samples from
hospitalized Italian patients with lower-respiratory-tract symptoms (Babakir-Mina et al.,
2010b).
Studies have shown T-cells to be important mediators of MCPyV-specific immune
surveillance  (Iyer  et  al.,  2011,  Kumar  et  al.,  2011a,  Kumar  et  al.,  2011b,  Kumar  et  al.,
2012). A study of the associations between immune cell counts, MCPyV DNA, patient
and tumor characteristics, and patient outcome, showed the numbers of T cells to be
generally higher in MCPyV-positive than in MCPyV-negative MCC (Sihto et al., 2012).
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Sample No.	Samples DNA-Positive	% Reference
Respiratory	tract	samples 526 1.3 (Bialasiewicz et al., 2009a)
Respiratory	tract	samples 635 4.2 (Goh et al., 2009)
Respiratory	tract	samples	 305 3.27 (Abedi Kiasari et al., 2011)
Lymph	nodes 29 10.3 (Toracchio et al., 2010)
Lymphoid	Tissue 55 1.8 (Sharp et al., 2009)
Sera 23 39 (Fukumoto et al., 2013)
PBMC 21 14 (Shuda et al., 2009)
Buffy	coat 60 22 (Pancaldi et al., 2011)
Lung 43 26 (Loyo et al., 2010)
Saliva 10 100 (Loyo et al., 2010)
Saliva	 135 30 (Baez et al., 2013)
Bladder 10 60 (Loyo et al., 2010)
Liver 37 54 (Loyo et al., 2010)
Colon 50 18 (Loyo et al., 2010)
Table 5. Detection of MCPyV DNA among non-tumor materials at a variable frequency.
MCPyV disease associations
MCPyV is linked to a human cancer, Merkel cell carcinoma. Merkel cells are large,
clear, oval cells in touch-sensitive areas, such as palmar aspects of the hands and plantar
aspects of the feet, lips, and buccal mucosa of vertebrates. The vast majority of Merkel
cells are intimately associated with a nerve terminal. They were first described by
Friedrich Sigmund Merkel (1845 – 1919), a German anatomist and histopathologist, in
1875 and were referred to as “Tastzellen” or “touch cells” (Halata et al., 2003, Koljonen,
2006). Merkel cells are localized in the basal layer of the skin and mucosa either as single
cells or in clusters. In 1972, Toker first described a trabecular carcinoma of the skin
(Toker, 1972). However, whether the Merkel cell carcinoma truly derives from the Merkel
cell  is  still  to  date  strongly  debated.  Without  any  doubt,  more  studies  are  needed  to
elucidate the origin of Merkel cell carcinoma, because systemic therapy in patients with
disseminated disease would probably have a significantly higher impact on survival and
on disease-free rates, due to modifications based on the origin of the cancer cells.
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Figure 8. Merkel cell carcinoma on the right eyebrow of a 82-year old patient. Reproduced with
permission from Bachmann, J., et al., 2005. Pancreatic metastasis of Merkel cell carcinoma and
concomitant insulinoma: case report and literature review. World Journal of Surgical Oncology 3, 58.
Since the discovery of polyomaviruses, they have been implicated as causative agents
of human cancer. In vitro studies and experimental animal models have shown that the
early viral proteins LTag and sTag of SV40, BKPyV, and JCPyV possess oncogenic
potential (Barbanti-Brodano et al., 2006). The novel viral sequences have been found in
four Merkel cell carcinoma tumor tissues (Feng et al., 2008). Similar to SV40 and murine
polyomaviruses, MCPyV encodes a multiply spliced tumor antigen protein complex that
targets several tumor-suppressor proteins (Shuda et al., 2008). Within infected tumors, the
T antigen is expressed only in tumor cells, as is predicted for a direct viral carcinogen
(Shuda et al., 2009). The LT antigen acts mainly by blocking the function of the cellular
tumor-suppressor proteins pRb and p53 and by inducing chromosomal aberration and
instability in the host-cell genome. The sTag binds the regulatory and catalytic subunits of
the protein phosphatase PP2A, thereby constitutively activating the ?-catenin pathway
which drives the cells into proliferation (Moore and Chang, 2010).
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Further  studies  show  a  prevalence  of  40  to  100%  of  the  MCPyV  in  Merkel  cell
carcinoma specimens (Agelli et al., 2010). The Chang-Moore Laboratory observed
monoclonal viral integration in five of ten (50%) patient samples and, interestingly,
primary and metastatic MCC tissues from the same patient showed an identical viral
integration pattern, indicating that the integration of MCPyV preceded the metastatic
spreading of the cancer (Feng et al., 2008).
Given these features, the strongest evidence to support MCPyV as causing MCC comes
from its random clonal integration into Merkel cell tumors and from knockdown studies
showing that T antigen expression is required for the survival of virus-positive Merkel cell
lines (Feng et al., 2008, Sastre-Garau et al., 2009, Houben et al., 2010). Although skin
carriage of the virus is common, no other tumors except MCC have yet been convincingly
linked to MCPyV infection (Schowalter et al., 2010, Moens et al., 2011).
MCPyV, which has tumor-specific truncation mutations, illustrates common features
among the human tumor viruses involving immunity, virus replication, and tumor-
suppressor targeting (Figure 9). Although MCPyV is a common infection, loss of immune
surveillance through aging, AIDS, or transplantation (Koljonen et al., 2009b), and
subsequent treatment with immunosuppressive drugs may lead to resurgent MCPyV
replication in skin cells (Pastrana et al., 2009). If a rare integration mutation into the host
cell genome occurs (Feng et al., 2008), the MCPyV T antigen can activate independent
DNA replication from the integrated viral origin that will cause DNA strand breaks in the
proto-tumor cell (Shuda et al., 2008). A second mutation that truncates the T antigen,
eliminating its viral replication functions but sparing its RB1 tumor suppressor targeting
domains, is required for the survival of the nascent Merkel tumor cell. Exposure to
sunlight (ultraviolet, UV, radiation) and other environmental mutagens may enhance the
sequential mutation events that turn this asymptomatic viral infection into a cancer virus
(Mogha et al., 2010).
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Figure 9. Merkel cell polyomavirus (MCPyV), which has tumor-specific truncation mutations, illustrates
common features among the human tumor viruses involving immunity, virus replication and tumor
suppressor targeting. Reproduced with permission from Moore, P.S., Chang, Y.A., 2010. Why do viruses
cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 10, 878-889.
     Thus, strong evidence exists that MCPyV is the etiological agent responsible for
most cases of MCPyV. Based on the evidence accumulated to date, the WHO
International Agency for Cancer Research recently classified MCPyV as ‘‘probably
carcinogenic to humans’’ (Group 2A) (Bouvard et al., 2012).
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2.6. Human polyomavirus 6 (HPyV6)
Rolling-circle amplification (RCA) was performed on forehead swab-samples of
healthy individuals to explore the possibility that non-integrated MCPyV genomes and
other polyomaviruses commonly inhabit healthy human skin (Schowalter et al., 2010).
They applied some adjustments to increase RCA sensitivity, such as DNA exonuclease
treatment to digest cellular DNA (Schowalter et al., 2010).
Among the newly available techniques for whole-genome amplification, the RCA
technique has been involved in the discovery of several new members of the polyomavirus
family (Schowalter et al., 2010, van der Meijden et al., 2010, Buck et al., 2012, Siebrasse
et al., 2012b, Yu et al., 2012b). RCA using the DNA polymerase of bacteriophage phi29 is
showing  great  value  for  the  analysis  of  viral  DNA genomes.  This  polymerase  possesses
several features such as strand-displacement activity, proof-reading activity and generation
of very long synthesis products, which make it most suitable for the efficient amplification
of circular DNA molecules from complex biological samples (Johne et al., 2009).
Therefore, phi29 polymerase-dependent RCA has been applied to the study of several
virus families possessing circular DNA genomes.
As specific primer sequences are not required for this technique, many novel viruses
have been discovered. Moreover, one-step whole genome amplification by RCA has
enabled rapid sequencing of viral genomes and generation of infectious genomic clones.
This approach has revealed the identity of a new polyomavirus, HPyV6, on the skin of a
healthy individual (Schowalter et al., 2010). DNA from the skin swab specimens extracted
and then subjecting these to random hexamer-primed RCA (Schowalter et al., 2010). Their
initial study goal was to isolate full-length wild-type MCPyV genomic DNA from swabs
drawn across the surface of the human skin. RCA reactions performed on DNA extracted
from skin swabs were analyzed by digesting the finished reaction with restriction enzymes
that would be expected to cut known MCPyV isolates to unit length. Agarose gel analysis
of an initial  set  of samples showed a smoothly distributed smear of products,  suggesting
that the majority of RCA products were derived from random fragments of linear cellular
DNA, as opposed to discrete circular DNA templates. Therefore, to overcome this
problem, the authors incorporated a pre-processing step in which the extracted DNA was
digested with exodeoxyribonuclease V, an enzyme that digests linear DNA molecules but
spares double-stranded circular DNA molecules. This pre-processing step was augmented
by the inclusion of a restriction enzyme that they reasoned would be unlikely to digest
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MCPyV  DNA.  The  full  genomic  sequence  of  the  previously  unknown  polyomavirus
species of human origin was amplified by PCR and cloned, and named in the order of its
appearance, HPyV6.
HPyV6 genome and structure
The novel HPyV6 shares a genome organization that is typical among polyomaviruses
(Figure 4). Phylogenetic comparison of the complete genomes of HPyV6 to other
polyomavirus species shows that these occupy a distinct clade (Schowalter et al., 2010). It
also occupies a longer common branch with WUPyV and KIPyV (Figure 2), an apparent
affiliation attributable primarily to the extreme divergence of the late regions (VP1 or VP2
capsid genes) of this virus from all other polyomaviruses. In contrast to the late regions,
the  early  regions  of  HPyV6  are  quite  distinct  from  those  of  WUPyV  and  KIPyV
(Schowalter et al., 2010).
HPyV6 epidemiological aspects
Since  the  first  reports  on  this  novel  PyV,  a  number  of  studies  have  evaluated  its
occurrence in healthy subjects and in immunocompetent and immunosuppressed patients
suffering from a variety of diseases (Table 6). By high-throughput metagenomic
sequencing, HPyV6 was evident in skin swabs of normal-appearing forehead skin from
three of six individuals (Foulongne et al., 2012).
One study analyzed over 300 skin swabs from different groups of healthy volunteers
who were free of skin diseases; it used type-specific qPCRs and detected HPyV6 DNA in
28.7% of the swabs. The same authors consecutively collected swabs from over 100
healthy individuals, and in these volunteers, persistent cutaneous infections were evident
in 24% (Ehlers and Wieland, 2013).
The presence of some known HPyVs was investigated with qPCR in 716 clinical
specimens  of  32  children  receiving  a  transplant  (11  bone  marrow,  11  liver,  5  heart,  2
kidney, 2 lung, and 1 liver/lung transplants). HPyV6 was detectable in the feces of a lung
and a BMT recipient and in the nasopharyngeal swab of a heart transplant patient
(Siebrasse et al., 2012a).
Another study investigated detection rates and DNA loads by qPCR in various skin
cancers from Japanese patients. MCPyV, HPyV6, and HPyV7 were detectable at low copy
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numbers in 22.2%, 3.2%, and 1.6% of squamous cell carcinomas, 18.0%, 2.0%, and 4.0%
of basal cell carcinomas, and 19.1%, 4.3%, and 4.3% of melanomas, (Imajoh et al., 2013).
Schowalter and colleagues found antibodies against VP1 of HPyV6 in 69% of blood
donors, identical to that of MCPyV (Schowalter et al., 2010).  A very recent study on the
seroprevalence of HPyV6, HPyV7, HPyV9, TSPyV, and MCPyV detected HPyV6
antibodies in 37.5% of 1- to 4-year-old children.  Their  prevalence rose to 67% in 30- to
39-year-old adults, and to 98% in those 80 and older (Nicol et al., 2013b).
HPyV6 disease association
HPyV6 has not yet been clearly associated with any disease.
Sample type DNAprevalence (%) Patients, age (years) Country
Reference
Skin swabs 14 35 volunteers, ages not reported USA (Schowalter et al., 2010)
Forehead skin
swabs 50
5 healthy adults (32–63y), 1 patient
with previous MCC (75 y) France (Foulongne et al., 2012)
NP swabs 0.6 160 NP swabs, 32 childrenmean 5.8 y; median 3.1 y USA (Siebrasse et al., 2012a)
Urines 0 169 urines, 32 children mean 5.8 y;median 3.1 y USA (Siebrasse et al., 2012a)
Feces 1.6 122 feces , 32 children mean 5.8 y;median 3.1 y USA (Siebrasse et al., 2012a)
Plasma 0 265 plasma, 32 children mean5.8 y; median 3.1 y USA (Siebrasse et al., 2012a)
Forehead skin
swabs HIV-
infected
39.0 210 men, median age 43 y Germany (Wieland et al., 2014)
Forehead skin
swabs HIV-
uninfected
27.6 239 men, median age 48 y Germany (Wieland et al., 2014)
Squamous cell
carcinomas
(SCC)
3.2 63 SCC, median age84 y ( 62–100 y) Japan (Imajoh et al., 2013)
Basal	cell	
carcinoma	
(BCC)	
2.0 50 BCC, median age78 y ( 51–92 y) Japan (Imajoh et al., 2013)
Malignant	
melanoma	
(MM)	
4.3 47 MM, median age  70 y (25–92 y) Japan (Imajoh et al., 2013)
Table 6. Detection of HPyV6 in various biological specimens.
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2.7. Human polyomavirus 7 (HPyV7)
To detect HPyV6- and WUPyV-like sequences, an additional novel polyomavirus was
found in these healthy skin samples and was called HPyV7. Biochemical experiments
show that polyomavirus DNA is shed from the skin in the form of assembled virions.
Since it did not appear to be possible to design universal primers capable of binding a
broad range of polyomavirus species, they designed partially degenerate primers targeting
sequences conserved between specific pairs of polyomaviruses. A primer pair designed to
bind both HPyV6 and WUPyV successfully amplified a unique polyomavirus-like
sequence. The complete genome of HPyV7 identified was amplified by PCR and was
found to be 68% identical to HPyV6 at the nucleotide level (Schowalter et al., 2010).
HPyV7 genome and structure
Phylogenetic  studies  of  the  HPyV  genomes  indicate  that  KIPyV  and  WUPyV  are
closely  related,  as  are  HPyV6 and  HPyV7 (Van Ghelue  et  al.,  2012).  Whereas  VP1s  of
HPyV classified on different phylogenetic branches display ~26 to 55% aa identity, VP1s
of HPyV on the same phylogenetic branch possess high identity: KIPyV and WUPyV:
65.5%, HPyV6 and HPyV7: 68.5%, LPyV and HPyV9: 84.1%, BKPyV and JCPyV:
78.2%. However, the predicted overall structure of all HPyV VP1 proteins is similar in
containing exposed loops (Van Ghelue et al., 2012).
The novel HPyV7 shares a genome organization that is typical among polyomaviruses
(Figure 4). The early region encodes the regulatory proteins sTag and LTag, and the late
region encodes the structural proteins VP1, VP2, and VP3. These regions are separated by
a NCCR. An open reading frame encoding the agnoprotein present in the human BKPyV
and JCPyV was not identified in the HPyV7. In combined phylogenetic analysis of LTag,
VP1, and VP2 proteins, HPyV6 forms a clade with HPyV7, HPyV10 with MWPyV (and
MXPyV), and HPyV9 with the LPyV; a polyomavirus of African green monkeys) and
other non-human primate PyVs (Figure 2).
HPyV7 epidemiological aspects
HPyV7 was first identified in skin swabs of healthy individuals (Schowalter et al.,
2010). By high-throughput metagenomic sequencing, HPyV6 appeared in skin swabs from
three  of  six  individuals,  and  HPyV7 was  detectable  in  one  skin  swab (Foulongne  et  al.,
2012).
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Forehead swabs, 449 from 210 HIV-positive men and 239 healthy male controls, were
analyzed by five type-specific qPCR for the presence of HPyV7; HPyV7 DNA was
detectable in 21.0% of the forehead skin swabs of the HIV-positive men, compared to
13.4% of the healthy controls (Wieland et al., 2014).
The seroprevalence of HPyV6 and HPyV7 was investigated in two studies, Schowalter
and colleagues found antibodies against VP1 of HPyV6 in 69% and against HPyV7 in
35% of 95 blood donors, compared with 69% for MCPyV. Of the blood donors, 28% had
antibodies  against  both  HPyV6  and  HPyV7,  and  16%  against  all  three  cutaneous  PyVs
(Schowalter et al., 2010). In another study, seroprevalence for HPyV7 was lower than for
HPyV6. Only 10% of the 1- to 4-year-old children were seropositive. In adults aged 20 or
older, HPyV7 seroprevalence increased with age from 45 to 86% (Nicol et al., 2013b).
Van der Meijden et al. investigated the serological behavior of cutaneous HPyVs in a
general population. They analyzed 799 sera from immunocompetent Australian
individuals from newborns to adults of 87 with a Luminex xMAP technology-based
immunoassay for the presence of VP1-directed IgG antibodies against  MCPyV, HPyV6,
HPyV7,  TSPyV,  HPyV9,  and  used  BKPyV as  a  control.  Except  for  HPyV9,  the  overall
seropositivity was high for the cutaneous polyomaviruses (66-81% in adults), and
gradually increased with age. Children below 6 months displayed seropositivity rates
comparable to those of the adults, indicative of maternal antibodies. These profiles
indicated heterogeneity among cutaneous polyomaviruses and probably reflected
differences in exposure and in the pathogenic behavior of these viruses (van der Meijden
et al., 2013).
HPyV7 disease association
HPyV7, discovered at the same time as the skin-tropic HPyV6, has, similarly, not yet
been clearly associated with any disease.
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Sample type DNAprevalence (%) Patients, age (years) Country
Reference
Skin swabs 11 35 volunteers, age not reported USA (Schowalter et al., 2010)
Forehead skin
swabs 17
5 healthy adults (32–63y),
1 patient with previous MCC
(75 y)
France (Foulongne et al., 2012)
NP swabs 0.6 160 NP swabs, 32 childrenmean 5.8 y; median 3.1 y USA (Siebrasse et al., 2012a)
Urines 0.6 169 urines, 32 children mean5.8 y; median 3.1 y USA (Siebrasse et al., 2012a)
Feces 0 122 feces , 32 children mean5.8 y; median 3.1 y USA (Siebrasse et al., 2012a)
Plasma 0 265 plasma, 32 children mean5.8 y; median 3.1 y USA (Siebrasse et al., 2012a)
Forehead skin
swabs HIV-
infected
21 210 men, median age 43 y Germany (Wieland et al., 2014)
Forehead skin
swabs HIV-
uninfected
13.4 239 men, median age 48 y Germany (Wieland et al., 2014)
Squamous cell
carcinomas (SCC) 1.6
63 SCC, median age
84 y ( 62–100 y) Japan (Imajoh et al., 2013)
Basal cell
carcinoma (BCC) 4.0
50 BCC, median age
78 y ( 51–92 y) Japan (Imajoh et al., 2013)
Malignant
melanoma (MM) 4.3
47 MM, median age
70 y (25–92 y) Japan (Imajoh et al., 2013)
Table 7. Detection of HPyV7 in various biological specimens.
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2.8. TS-associated polyomavirus (TSPyV)
In  2010,  use  of  RCA  allowed  the  identification  and  reporting  of  a  new  HPyV  in
plucked facial spiny papules of a heart-transplant patient with trichodysplasia spinulosa
(TS), a rare skin disease exclusively seen in immunocompromised patients (van der
Meijden et al., 2010). TSPyV is a new species of the family Polyomaviridae that was
discovered from a skin lesion. Thereafter, EM, immunohistochemistry, and viral load
measurements have indicated an etiological role for active TSPyV infection in the
development of this disease.
The TSPyV genome was amplified through RCA in the following manner, described
herein  brief.  The  TempliPhi  100  RCA  Kit  (GE  Healthcare,  UK  Limited)  was  used
following the manufacturer’s instructions with some slight modifications. The isolated
total DNA was diluted in sample buffer, denatured at 95°C,  and  cooled  down slowly  to
4°C to allow primer annealing. Meanwhile a premix of 5 ml reaction buffer, 0.2 ml
TempliPhi enzyme (bacteriophage Q29 DNA polymerase), and an extra 450 mM of each
dNTP was prepared and added to the denatured DNA in sample buffer. The RCA reaction
was performed at 30°C for 16 hours followed by inactivation of the enzyme at 65°C for 10
minutes. The RCA product was stored at -20°C for genomic sequencing, assembly,
sequence alignments, and phylogenetic analysis (van der Meijden et al., 2010).
TSPyV genome and structure
TSPyV has  a  genomic  orientation  similar  to  that  of  the  other  polyomaviruses  (Figure
7).  It  consists  of  a  relatively  small  genome  of  5,232  bp  that  contains  five  open  reading
frames, transcription of which is regulated by the NCCR (van der Meijden et al., 2010).
Although TSPyV transcription patterns have not been described yet, analogous with other
polyomaviruses, upon infection probably the first (early) genes are expressed that encode
LTag and sTag. They initiate at the same start codon, but are subject to alternative
splicing. As a result, TSPyV sTag and LTag share an N-terminal region of approximately
80 aa which contains some highly conserved regions important for polyomavirus
replication and transformation. Furthermore, sTag contains a putative PP2A-binding
motif, whereas LTag contains motifs that putatively interact with the tumor suppressor-
and cell cycle-regulatory proteins pRb and p53 and may inhibit their function. (van der
Meijden et al., 2010).
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The opposing strand of the TSPyV genome encodes the structural proteins VP1, VP2,
and VP3 that form the viral capsid. VP1 is the major protein of the pentameric viral
capsomere that furthermore incorporates one copy of either VP2 or VP3 (Stehle et al.,
1996). The icosahedral capsid is constructed of 72 such capsomers. Serologically, VP1 is
considered the immunodominant polyomavirus protein, and therefore TSPyV VP1
represents an important antigen in measuring host antibody reactivity against TSPyV (van
der Meijden et al., 2011).
TSPyV epidemiological aspects
TSPyV DNA prevalence has been studied by several groups (Table 8). Studies that
have looked at TSPyV prevalence in various samples (skin swabs, skin biopsies, plucked
eyebrow hairs, serum/plasma, urine) have found less than 5% DNA-positivity in
asymptomatic individuals, regardless of their immune status (Kazem et al., 2013a). A high
TSPyV prevalence (100%) and high viral loads were reported only in TS patients (Kazem
et al., 2012), which suggests that TSPyV is the causative agent of the disease.
Hypothetically, at some stage TSPyV infecting the skin might cause disease there in a
small minority of immunocompromised hosts. Whether, however, the skin represents the
major organ of TSPyV persistence is far from clear, as the majority of infected
(seropositive) individuals are skin-TSPyV negative. What remains unknown at the
moment is whether TS is a manifestion of TSPyV reactivation from an as yet unidentified
transplanted organ reservoir, or an unfortunately timed primary infection in the midst of
immunosuppression.
A study both of healthy control children and of children and adults undergoing
diagnostic testing showed HPyV6, 7, 9, and TSPyV also to be detectable in respiratory
specimens and fecal specimens at low prevalence (Rockett et al., 2013). It should also be
noted that HPyV6, 7, and TSPyV have all been detected on human skin of healthy
subjects,  and  that  the  possibility  of  contamination  from the  skin  during  collection  of  the
respiratory and fecal samples must be considered.
The serological behaviors of cutaneous HPyVs in a general population were analyzed
with a Luminex -based immunoassay for the presence of VP1-directed IgG antibodies;
TSPyV seroreactivity levels were strongly increased after age 2 and waned later in life,
comparable to BKPyV, whereas MCPyV, HPyV6, and HPyV7 seroreactivity remained
rather stable throughout (van der Meijden et al., 2013). Another study, by applying
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comprehensive serodiagnostic methods (IgM, IgG, and IgG avidity) and PCR, has found
that primary infections with TSPyV and MCPyV are asymptomatic in childhood (Chen et
al., 2014).
Epidemiological studies looking at polyomavirus seroprevalence in humans indicate
that HPyV infections of the general population are highly prevalent and occur at an early
age, probably without clinical manifestations. Detection of serum antibodies against
TSPyV VP1 has been described in two independent studies using either a multiplex
serology method based on Glutathione-S-transferase (GST)-VP1 fusion proteins (van der
Meijden  et  al.,  2011)  or  on  VP1  VLP-based  antibody  detection  by  ELISA  (Chen  et  al.,
2011b). In both of these studies, a seroprevalence of about 70% was measured, including
respectively a total of 528 Dutch and of 371 Finnish individuals, all healthy. Furthermore,
age-distribution analysis of TSPyV VP1 seroprevalence revealed an increase from 41% in
children aged 0–9 years to 75% in adults aged 30 years and older (van der Meijden et al.,
2011).
     A higher TSPyV VP1 seroprevalence of 89% has already been shown in a renal-
transplant patient population compared with 70% in healthy individuals (van der Meijden
et al., 2011). How to interpret the putative increase in TSPyV seropositivity concomitant
with immunosuppressive treatment is not fully understood. Hypothetically, this may be
explained by an increase in humoral immunity in response to TSPyV reactivation,
possibly viremia, and this would result from iatrogenic suppression of cellular immunity
(van der Meijden et al., 2010). In short, seroepidemiological data indicate that TSPyV
infection is common and occurs primarily at a young age, with a drop in antibody levels at
later stages of life. One study suggests that TSPyV Th-cell responses correlate with
TSPyV serological responses, but can sometimes also be detected in TSPyV-seronegative
individuals (Kumar et al., 2012).
Fifty-five mucosal melanomas were analyzed by a Luminex assay for the presence of
DNA of 10 HPyVs, including TSPyV and two primate viruses (SV40 and LPyV), but
none of the analyzed HPyVs were detected, suggesting they are unlikely to play a major
role in the development of this tumor type (Ramqvist et al., 2014).
Cutaneous (449 forehead swabs) DNA prevalence and viral loads of HPyV6, HPyV7,
TSPyV, HPyV9, and HPyV10 in HIV-infected men were compared to healthy male
controls by HPyV-specific real-time PCRs. HPyV6, HPyV7, TSPyV, and HPyV10 were
found significantly more frequently on the skin of HIV-infected than of HIV-negative
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men. No HPyV9 was detectable. In contrast to HPyV6, 7, and 10, TSPyV and HPyV9 do
not seem to be a regular part of the human skin microbiome (Wieland et al., 2014).
Sample No.Samples
DNA-Positive
Lesions (%) Reference
Plucked eyebrows 69 4 (van der Meijden et al., 2010)
Plucked eyebrows 81 2 (Kazem et al., 2013b)
Forehead skin swabs 249 2 (Kazem et al., 2012)
Nasopharyngeal swabs 32 3 (Siebrasse et al., 2012a)
Fecal 32 3 (Siebrasse et al., 2012a)
Fecal 160 1 (Kazem et al., 2013b)
Fecal 38 0 (Scuda et al., 2011)
Urine 179 1 (Scuda et al., 2011)
Urine 17 0 (Kazem et al., 2013b)
Sera 88 0 (Scuda et al., 2011)
Sera 19 0 (Kazem et al., 2013b)
Various skin disorders 193 0 (Scola et al., 2012)
Pilomatricoma 10 0 (Kanitakis et al., 2011)
Table 8. TSPyV DNA  detected among non-TS materials at variable frequencies.
TSPyV disease associations
TS is a rare skin disease; worldwide, some 30 cases have been described, as a
cutaneous side effect of cyclosporin-A use, first reported by Izakovic and colleagues in
1995 (Izakovic et al., 1995). In 1999, Haycox and colleagues fully described the disease
and introduced the term “trichodysplasia spinulosa” (Haycox et  al.,  1999).  They showed
for the first time the presence of virus particles and suggested a viral etiology. Subsequent
reports confirmed the typical histological findings of hyperplastic hair bulbs and the
presence of polyomavirus or papillomavirus-like particles (Wyatt et al., 2005, Tan and
Busam, 2011). Attempts to identify the nature of this virus failed until TSPyV was
identified with the help of RCA in 2010 (van der Meijden et al., 2010).
Thus far, TS has been observed in immunosuppressed organ-transplant patients and
occasionally in chronic and acute lymphocytic leukemia patients. Despite the disparity in
TS terminology, in all cases the disease was clinically characterized by spiny follicular
papules distributed largely on the face and ears, and to a lesser extent on the extremities,
trunk, and scalp. In most patients, non-scarring alopecia of the eyebrows is evident, in
which small hyperkeratotic white-yellowish spicules start to protrude from the skin. At the
same time, these features also manifest themselves on the nose and ears (Figure 10). As
the disease progresses, the skin of eyebrows, ears, and nose thickens to cause
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disfigurement of facial appearance in combination with the conspicuous spines
(Schwieger-Briel et al., 2010, van der Meijden et al., 2010).
To  date,  the  presence  of  TSPyV  in trichodysplasia spinulosa lesions has been
confirmed in patients from western Europe, North America, and Australia (Matthews et
al., 2011, Fischer et al., 2012, Kazem et al., 2012).
Fischer and colleagues reviewed the clinical, histopathologic, ultrastructural, and
molecular findings in 25 cases of TS to date. The age range at diagnosis was 5 to 70 years,
with 13 male and 12 female patients. Clinical findings were similar across all racial and
ethnic groups represented, with all patients experiencing follicular papules of the central
face, followed in frequency by the extremities, with infrequent involvement of the scalp.
Most of the patients demonstrated spiny excrescences protruding from some of the
papules. The papules were asymptomatic in almost two-thirds of cases, whereas others
experienced mild pruritus (Fischer et al., 2012).
Figure 10: Clinical appearance of a  trichodysplasia spinulosa patient. Reproduced with permission
from van der Meijden, E., Janssens, R.W., Lauber, C., Bouwes Bavinck, J.N., Gorbalenya, A.E., Feltkamp,
M.C., 2010. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an
immunocompromized patient. PLoS pathogens 6, e1001024.
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2.9. Human polyomavirus 9 (HPyV9)
In 2011, a novel polyomavirus which closely resembled African green monkey-derived
lymphotropic polyomavirus (LPyV) was identified by use of degenerative primers
independently by two research groups one, in human serum of a kidney transplant patient,
and  one,  in  skin  surface  of  a  patient  with  a  MCC,  and  was  tentatively  called  HPyV9
(Sauvage et al., 2011, Scuda et al., 2011).
For identification of HPyV9, generic nested PCR targeting of a short  fragment of the
VP1 gene (approximately 260 bp) was performed by using two pairs of degenerate and
deoxyinosine-substituted primers. All primers were designed to bind sites within the VP1
gene identified as being conserved among a wide range of PyVs. They were derived from
the sequence of MCPyV in order to bias amplification toward sequences from PyVs
related to MCPyV. Nested specific primers were derived from the sequences amplified
with the generic PCR. They were designed tail-to-tail for the amplification and sequencing
of the remaining parts of the genomes. The genome of the virus was completely amplified
and sequenced. In phylogenetic analyses, it appeared as the closest relative to the African
green monkey-derived LPyV (Leendertz et al., 2011). Several serological studies had
already shown the presence of cross-reactive antibodies in a percentage of human sera that
recognized LPyV (Viscidi and Clayman, 2006, Kean et al., 2009), which was isolated
from an African green monkey.
In the other report, DNA isolated from healthy skin swabs was subjected to high-
throughput sequencing, which resulted in millions of reads and several contigs that
matched MCPyV, HPyV6, and HPyV7, as well as many HPVs. Some contigs showed the
highest homology with LPyV, and after filling of the contig sequence gaps by designing
additional primers, a virus genome emerged that coincided with HPyV9. It was called the
IPPyV strain of HPyV9 (Sauvage et al., 2011).
Degenerate primers are used to detect viruses, including novel viruses, from existing
sufficiently homologous virus families. Novel viruses infecting humans are detectable
with this technique (Leendertz et al., 2011, Scuda et al., 2011, Yu et al., 2012b). An
alternative PCR method, degenerate PCR, uses primers designed to anneal to highly
conserved sequence regions shared by related viruses. Because these regions are almost
never completely conserved, primers generally include some degeneracy that permits
binding to all or the most common known variants on the conserved sequence. The overall
aim is to achieve a balance between covering all possible viral variants within a family
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(i.e. primers with high degeneracy) and creating an unwieldy number of different primers.
At high levels of degeneracy, only a small  proportion of primers are able to prime DNA
synthesis, whereas a large proportion of the remaining primers will be able to anneal, but
because of sequence mismatches, will be refractory to PCR extension (Bexfield and
Kellam, 2011).
HPyV9 genome and structure
HPyV9, like other novel PyVs, shares a genome organization that is typical among
polyomaviruses (Figure 4). The early region encodes the regulatory proteins sTag and
LTag, and the late region encodes the structural proteins VP1, VP2, and VP3. These
regions are separated by an NCCR. An open reading frame encoding the agnoprotein
present in BKPyV and JCPyV (Khalili et al., 2005) was not identified in the novel PyVs.
In combined phylogenetic analysis of LTag, VP1, and VP2 proteins, HPyV9 forms a clade
with the lymphotropic polyomavirus (Figure 2) (Van Ghelue et al., 2012).
HPyV9 epidemiological aspects
HPyV9 DNA sequences were amplified from the serum of a kidney transplant patient
by use of degenerate primers against conserved regions in the PyV VP1 gene. Re-
screening of the analyzed panel of clinical specimens with specific nested PCR revealed
the presence of HPyV9 in four additional specimens (plasma and urine from kidney
transplant patients, serum from a patient with leukoencephalopathy, and whole blood from
a patient suffering from acute myeloid leukemia) (Scuda et al., 2011).
 Skin swabs from 8 patients with MCC also showed 2 with HPyV9 DNA, but only 1
among 111 non-MCC patients. An additional 92 respiratory specimens from patients with
respiratory tract disorders and 92 fecal samples from children hospitalized for
gastroenteritis were all negative for HPyV9 DNA (Sauvage et al., 2011). These findings
may indicate that HPyV9 is less common than are the other known HPyVs.
Anoher study analyzed 449 forehead swabs by HPyV-specific real-time PCRs for
cutaneous DNA prevalence of HPyV9 in HIV-infected men compared to healthy male
controls.  No HPyV9 DNA was detectable in any of the samples. This may indicate that
cutaneous re-exposure or reactivation of TSPyV and HPyV9 occurs rarely or that the skin
is not the primary site of reactivation/persistence (Wieland et al., 2014). Serum samples
from 101 kidney transplant patients in the Netherlands and seroreactivity were screened
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for HPyV9 DNA and its high prevalence in serum samples (21%) suggested that HPyV9
causes a systemic rather than a skin infection (van der Meijden et al., 2014).
Sera from immunocompetent Australian individuals from newborns to age 87
underwent analysis for the presence of VP1-directed IgG antibodies against novel PyVs,
with BKPyV as a control. Findings were that, except for HPyV9, overall seropositivity
was high for the cutanous polyomaviruses (66–81% in adults), and gradually increased
with age. This might be explained by lower circulation of HPyV9 in Queensland,
Australia, compared to Europe and the USA or by possible local serotype variation or by
differences in the manner  of exposure (van der Meijden et al., 2013).
LPyV is a primate virus isolated from a lymphoblastoid cell line of African green
monkey cells (zur Hausen and Gissmann, 1979). Recently, LPyV DNA was amplified in
blood from healthy blood donors, and about 10 to 15% of the adults tested showed
antibodies against LPyV (Viscidi and Clayman, 2006, Kean et al., 2009, Pastrana et al.,
2009, Delbue et al., 2010). However, LPyV and HPyV9 VP1 share 84.1% aa identity, so
that antibodies may cross-react, and the actual LPyV seropositivity may be lower as
underscored by the lower prevalence of LPyV and HPyV9 DNA in human specimens or in
urban sewage (Bofill-Mas et al., 2010, Sauvage et al., 2011, Scuda et al., 2011). What
remains unknown is whether LPyV causes any human disease.
HPyV9 disease association
Whether HPyV9 is a human pathogen remains to be established.
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Table 9. Detection of HPyV9 in biological specimens.
Sample type DNAprevalence (%) Patients, age (years) Country
Reference
Serum
Plasma
Whole blood
1.4
(blood samples)
Serum (n = 88)
Plasma (n = 176)
Whole blood (n = 21)
Germany (Scuda et al., 2011)
Bronchoalveolar
lavage
0  (n = 21) Germany (Scuda et al., 2011)
Urine 0.6  (n = 179) Germany (Scuda et al., 2011)
CSF 0 (n = 74) Germany (Scuda et al., 2011)
Stool 0 (n = 38) Germany (Scuda et al., 2011)
Facial skin swabs
0.9
(skin controls)
25
(MCC patients)
111 controls (19–96 years)
8 MCC (57–86 years) France
(Sauvage et al.,
2011)
Respiratory tract
samples
0 46 bronchoalveolar lavage
46 nasopharyngeal aspirates France
(Sauvage et al.,
2011)
Faeces 0 92 children with gastroenteritis France (Sauvage et al.,2011)
Plasma 4 100 pregnant (16.5–41.9 years)100 non-pregnant (18–44.3 years) Hungary
(Csoma et al.,
2012)
Urine 2.5 100 pregnant (16.5–41.9 years)100 non-pregnant (18–44.3 years) Hungary
(Csoma et al.,
2012)
Throat swabs 2 100 pregnant (16.5–41.9 years)100 non-pregnant (18–44.3 years) Hungary
(Csoma et al.,
2012)
Facial skin swabs 17 (n = 6) 5 healthy adults (32–63 years)1 patient (75 years) with previous MCC France
(Foulongne et al.,
2012)
NP swabs 0 (n= 160) , mean age 5.8 years;
 median age 3.1 years USA
(Siebrasse et al.,
2012a)
Urine 0.6 (n= 169), mean age 5.8 years;
 median age 3.1 years USA
(Siebrasse et al.,
2012a)
Feces 0 (n= 122) , mean age 5.8 years;
median age 3.1 years USA
(Siebrasse et al.,
2012a)
Plasma 0 (n= 265), mean age 5.8 years;
median age 3.1 years USA
(Siebrasse et al.,
2012a)
Blood 0 27 CLL cases (49–93 years) and 18healthy donors (27–55 years) USA
(Imajoh et al.,
2012)
Serum	 21 101 kidney transplant patients(Mean age, 47 (21–74) Netherlands
(van der Meijden et
al., 2014)
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2.10. Malawi polyomavirus (MWPyV) / human polyomavirus 10
(HPyV10) / Mexico polyomavirus (MXPyV)
The tenth HPyV, by number and name, was discovered almost simultaneously in 2012
by three different research groups and provisionally designated Malawi polyomavirus
(MWPyV) or HPyV10, or Mexico polyomavirus (MXPyV) (Buck et al., 2012, Siebrasse
et al., 2012b, Yu et al., 2012a).
The whole-genome sequence of MXPyV is nearly identical to that of the recently
described gut-associated polyomavirus MWPyV (St. Louis strain) or HPyV10, sharing a
respective 99.8% or 99.7% identity (Figure 11). Multiple sequence alignment analysis
revealed MWPyV, HPyV10, and MXPyV to be different variants of the same species (Yu
et al., 2012b).
MWPyV was identified by shotgun pyrosequencing of DNA purified from virus-like
particles (VLP) in stool of a 1-year-old healthy child from Malawi (Siebrasse et al.,
2012b). This virus was discovered by suspending a small amount of feces that
subsequently was centrifuged and filtered through 0.45 and 0.22 ?m pores. After
chloroform extraction, free DNA was removed by DNase treatment. The solution that still
contained encapsidated DNA was SDS- and proteinase-K treated, and DNA was isolated.
Finally, this DNA was subjected to RCA and pyrosequencing. Hundreds of reads were
obtained, sequenced and aligned to sequences within the GenBank database. This revealed
several  polyomavirus-like  reads,  and  with  the  use  of  a  primer  walking  strategy,  the
complete MWPyV genome was achieved. Furthermore, the Siebrasse group sequenced
two complete genomes of MWPyV, one from the index child in Malawi and one from a
child in St. Louis in the USA. A high degree of strain variation (5.3%) existed between
these two MWPyV strains (Siebrasse et al., 2012b).
In the second half of 2012, in an effort to identify previously unknown viruses, Buck et
al. purified virions from a patient with a rare genetic disorder known as “warts,
hypogammaglobulinemia, infections, and myelokathexis” (WHIM) syndrome (Buck et al.,
2012). This syndrome is marked by the patients’ relative inability to effectively control
HPV infections (Kawai and Malech, 2009). For HPyV10 identification, the warts were
minced and treated with detergents and nucleases, and out of the resulting extract, virions
were purified by ultracentrifugation. DNA was extracted from the purified virions and
subjected to random-primed RCA. Restriction fragments of the RCA product were
subjected to plasmid-based cloning. This cloning-based approach revealed the presence of
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three  viral  species:  HPV6  and  HPV124,  as  well  as  an  almost  identical  virus  to  MW
polyomavirus called HPyV10. This last one was identified in an anal wart of an
immunocompromised  patient  with  WHIM syndrome with  the  help  of  RCA (Buck et  al.,
2012).
Using random PCR and an unbiased deep sequencing approach, Mexico polyomavirus
(MXPyV) was identified, like MWPyV in stool samples from children suffering from
diarrhea in Mexico (Yu et al., 2012b), as follows: viral particles were purified from stool
samples by generating a suspension in a centrifuge, and recovering the aqueous
supernatant. Supernatants were then passed through a 0.45 mm filter and treated with a
cocktail of nucleases prior to nucleic acid extraction. Sample cDNA libraries were
prepared from extracted nucleic acid by a random PCR amplification method, were
separately barcoded, and sequenced. Raw Illumina sequences consisting of 75 bp paired-
end reads were filtered to exclude low-complexity, homopolymeric, and low-quality
sequences, and then processed through an automated pipeline for pathogen identification.
Sequences corresponding to MXPyV were identified on the basis of viral BlastX
homology as the tenth polyomavirus (Yu et al., 2012b).
In the category of sequence-independent amplification techniques among new
molecular methods, one alternative technique is known as “Random” PCR (Froussard,
1992). This method is common in amplifying and labeling probes with fluorescent dyes
for microarray analysis but has also served for identification of novel viruses. Random
PCR has no requirement for an adaptor ligation step and compared with conventional
PCR, which utilizes a pair of complementary forward and reverse primers to amplify DNA
in  both  directions,  random  PCR  utilizes  two  different  primers  and  two  separate  PCR
reactions. The single primer used in the first PCR reaction has a defined sequence at its 5?
end, followed by a degenerate hexamer or heptamer sequence at the 3? end. A second PCR
reaction is then performed with a specific primer complementary to the 5? defined region
of the first primer thus enabling amplification of products formed in the first reaction
(Bexfield and Kellam, 2011).
Random PCR has been used extensively for the detection of both DNA and RNA
viruses and is currently the molecular method most commonly used to identify unknown
viruses. Random PCR has also proved successful in detecting novel viruses infecting
humans, including a parvovirus (Allander et al., 2005, Allander et al., 2007a), a
72
coronavirus (Fouchier et al., 2004), and a bocavirus in patients with diarrhea (Kapoor et
al., 2009).
HPyV10 genome and structure
The complete genome of MWPyV is 4,927 bp, and its genome structure (Figure 11)
follows that of other polyomaviruses (Siebrasse et al., 2012b). Maximum likelihood
analysis of the VP1, VP2, and LTag proteins demonstrates MWPyV to be highly divergent
from all  other known polyomaviruses (Figure 2).  Analysis of VP1 sequences shows that
MWPyV is midway between the Wukipolyomavirus and Orthopolyomavirus genera
(Figure  2).  In  contrast,  based  on  VP2  and  LTag  sequences,  MWPyV  clusters  with  the
clade  containing;  HPyV9,  LPyV,  HaPyV,  MPyV,  TSPyV,  MCPyV,  ChPyV,  and  the
orangutan polyomaviruses. These discordant phylogenetic relationships suggest that
MWPyV may be derived from an ancestral recombination event (Siebrasse et al., 2012b).
Sequence variation between the St. Louis (WD976 strain) and Malawi (MA095) isolates
diverged by 5.3% at nucleotide level. Strain WD976 has two insertions (11 bp and 1 bp) in
the  NCCR,  which  result  in  a  genome  size  of  4,939  bp.  The  vast  majority  of  the
polymorphisms in the coding regions result in synonymous mutations. One notable
mutation changes the size of the sTag ORF. The predicted TAA stop codon identified in
the MA095 strain is mutated to AAA in WD976, resulting in a protein prediction of 206
aa, seven aa longer than the index genome’s sTag (Siebrasse et al., 2012b).
HPyV10 epidemiological aspects
The initial discovery of MWPyV was in a stool specimen collected from a healthy child
in Malawi (index case, strain MA095). Further screening by real-time PCR demonstrated
the presence of the virus in 12 stool samples collected from a cohort of patients in St.
Louis, Missouri (St. Louis case, strain WD976). These data demonstrate that MWPyV is
geographically widespread in human populations and can be found on two continents
(Siebrasse et al., 2012b).
MWPyV infection is relatively common, since a seroprevalence of 41.8% has been
observed in adulthood (Nicol et al., 2013a). MWPyV seroprevalence is similar to the
seroprevalence of 39.4% reported for HPyV9 (Nicol et al., 2013b), but lower than the
seroprevalence reported for MCPyV, HPyV6, HPyV7, and TSPyV (63.6% to 87.0%)
(Nicol et al., 2013b). The relatively low seroprevalence observed for MWPyV (39.4%)
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correlates with the detection of its DNA in only 2.3% of human stools (Siebrasse et al.,
2012b). Prevalence rates and tissue tropism for MWPyV  (strains MA095, WD976),
HPyV10, and MXPyV were tested by real-time PCR targeting a conserved region of VP1
in feces, urine, blood, respiratory swabs, and CSF both from healthy control children and
children and from adults undergoing diagnostic testing.  Results were the following: viral
DNA in 1.5% of respiratory specimens from symptomatic patients, 9.8% of respiratory
samples from healthy control children, 5.9% of fecal specimens from patients suffering
gastrointestinal illness, and in 15.3% of feces from healthy control children. The tenth
HPyV occurred only in respiratory and fecal specimens from children, the oldest being 9
years old. This findings suggests that the tenth polyomavirus can result in a subclinical
infection with persistent or intermittent shedding, particularly in young children (Rockett
et al., 2013). Another study detected DNA from HPyVs TSPyV, MWPyV, HPyV6, 7, and
9 in 55 primary mucosal melanomas, analyzed by a Luminex assay (Ramqvist et al.,
2014).
HPyV10 disease association
No disease is associated with the tenth HPyVs yet.
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Virus Sample type DNA prevalence(%) Patients, age (years)
Reference
1HPyV10
Stool 2.3 514 children (0–18 years) withdiarrhea
(Siebrasse et al.,
2012b)
Stool 3.4 834 children, with or withoutdiarrhea (Yu et al., 2012b)
Nasal washes 0.7 136 nasal washes from childrenwith pneumonia (Yu et al., 2012b)
Plasma 0 480 plasma samples (Yu et al., 2012b)
Urine 0 480 urine samples (Yu et al., 2012b)
Stool
2.2(children)
0 (adults)
1.5 (cases)
1.3(controls)
514 (USA, 0–18 y)
237 (USA, adult)
722 (Gambia (Africa) 0- 5 y)
 (cases, n = 332) and without
diarrhea (controls, n = 390)
(Lim et al., 2013)
Plasma 0 261 plasma, from adult (Lim et al., 2013)
NP swabs 0 261 NP swabs from adult (Lim et al., 2013)
Urine 0 373 urine samples from adult (Lim et al., 2013)
	
STLPyV
Stool
1.1(children)
0 (adults)
0 (cases)
0.3 (controls)
514 (USA, 0–18 y)
237 (USA, adult)
722 (Gambia (Africa) 0- 5 y)
(cases, n = 332) and without
diarrhea (controls, n = 390)
(Lim et al., 2013)
Plasma 0 261 plasma, from adult (Lim et al., 2013)
NP swabs 0 261 NP swabs from adult (Lim et al., 2013)
Urine 0.3 373 urine samples from adult (Lim et al., 2013)
	
HPyV12
Stool 1.8 56 (patients' age not reported) (Korup et al., 2013)
Plasma/serum 0 99 (patients' age not reported) (Korup et al., 2013)
Urine 0 152 (patients' age notreported) (Korup et al., 2013)
Oral fluids 0 30 (patients' age not reported) (Korup et al., 2013)
BAL 0 22 (patients' age not reported) (Korup et al., 2013)
CSF 0 25 (patients' age not reported) (Korup et al., 2013)
1HPyV10 (and its isolates MWPyV and MXPyV)
Table 10. Detection of HPy10, HPy11 (STLPyV1, HPy12, in biological specimens.
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11. Human polyomavirus 11 or STL polyomavirus (STLPyV)
The virus-hunter group of David Wang in the USA in 2013 performed shotgun 454
pyrosequencing of DNA amplified by multiple displacement amplification (MDA) from
the stool of a healthy 15-month-old child in Malawi, and the novel polyomavirus
recovered from the fecal microbiota of that child was provisionally called STL
polyomavirus (STLPyV) (Lim et al., 2013).
MDA is a recently described method of whole-genome amplification that has proven
efficient in the amplification of small amounts of DNA, including DNA from single cells.
This method is based on the annealing of random hexamers to denatured DNA, followed
by strand-displacement synthesis at a constant temperature, resulting in DNA products of
high molecular weight (up to 12 kb). For discovery of STLPyV prior to DNA extraction,
the stool was processed by CsCl ultra centrifugation to generically enrich for viral
particles. DNA was purified from the fecal sample, amplified by rolling circle
amplification and subjected to FLX Titanium pyrosequencing (Reyes et al., 2010).
The complete genomes of the STLPyV MA138 and WD972 strains were PCR
amplified in three overlapping fragments, cloned and sequenced. DNA from the samples
was initially subjected to rolling circle amplification using the Illustra GenomiPhi V2 kit
(GE Healthcare) prior to PCR amplification (Lim et al., 2013). Furtheremore, use of
random-primed RCA combined with deep sequencing has uncovered, a divergent variant
of STLPyV, STLPyV-like isolate (11ww), in a disinfected human skin wart specimen
(Pastrana et al., 2013).
STLPyV genome and structure
The STLPyV genome organization and the sizes of its open reading frames is
characteristic of known polyomaviruses (Figure 11). Further, the non-coding control
region of STLPyV (nucleotide positions 1–352) contains features typical of
polyomaviruses (Van Ghelue et al., 2012). In addition, there is a 17-nucleotide stretch of
an AT-rich region including the putative TATA box (nucleotide positions 59–75).
Complete genome comparisons of two STLPyV strains (MA138 and WD972) (Lim et al.,
2013) demonstrated that 5.2% nucleotide divergence and the complete genomic sequence
of the new STLPyV-like isolate (11ww) (Pastrana et al., 2013) shares 92% similarity with
both the original MA138 and WD972 isolates of STLPyV. STLPyV-11ww shows a
pattern of ORFs and splicing signals similar to those of MA138 (Pastrana et al., 2013).
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 Alternative splicing of the STLPyV early region yielded a unique form of T antigen,
which was called 229T, in addition to the expected LTag and sTag. STLPyV has a mosaic
genome  and  shares  an  ancestral  recombinant  origin  with  MWPyV.  The  discovery  of
STLPyV highlights a novel alternative splicing strategy and advances our understanding
of the complex evolutionary history of polyomaviruses (Lim et al., 2013).
STLPyV epidemiological aspects
STLPyV was detected in human fecal samples collected in Malawi, the United States,
and the Gambia at up to 1% frequency, demonstrating that it is geographically widespread
(Lim et al., 2013). STLPyV was undetectable in 237 fecal specimens from adult renal-
transplant patients. Screening of nasopharyngeal specimens, serum, and urine from these
patients yielded a single urine sample positive for STLPyV (Lim et al., 2013). A divergent
variant of STLPyV was isolated and reported from condylomas (anogenital warts)
surgically removed from the buttocks of a patient suffering from the WHIMS syndrome
(Pastrana et al., 2013). Observation of STLPyV in a surface-disinfected tissue specimen
strongly suggests that STLPyV productively infects humans and thus can be considered
the eleventh known HPyV.
STLPyV disease associations
Questions  remain  to  be  answered  regarding  the  potential  role  of  STLPyV  in  human
infection, but STLPyV and the recently described MWPyV are the first two
polyomaviruses to be discovered in human stool samples, which raises the question of
whether they may have a primary gastrointestinal tropism. Together with the frequent
detection of WUPyV and KIPyV in respiratory specimens (Babakir-Mina et al., 2011),
and the apparent primary tropism of HPyV6 and HPyV7 for skin (Schowalter et al., 2010),
these findings demonstrate the ubiquity of polyomaviruses in various types of human
specimens. As disease associations have been established for neurotropic polyomaviruses
(JCPyV), renal-tropic polyomaviruses (BKPyV), and skin-tropic polyomaviruses
(MCPyV, TSPyV), who can guess whether disease associations for the other novel
polyomaviruses will also emerge.
We still do not know whether either STLPyV or MWPyV causes bona fide infection in
humans. Assuming that STLPyV actually does infect humans, its lower prevalence than
that  of  JCPyV  in  adult  renal  transplant  patients  may  result  from  one  or  more  of  the
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following factors: (1) STLPyV infection may be relatively rare; (2) acute STLPyV
infection may occur primarily in children; (3) STLPyV may have a distinct tropism that is
not  reflected  by  the  samples  tested;  (4)  the  life  cycle  of  STLPyV  may  not  involve
persistence and then reactivation in the context of immunosuppression.
Figure 11. Genome map of MWPyV, MXPyV, STPyVL, and HPyV12. Indicated are the five identified
ORFs representing the putative “early” genes encoding small and large T antigen, and the putative “late”
genes encoding VP1, VP2, and VP3. The NCCR is placed on top and contains the putative ori. Nucleotide
position 1 was chosen within the NCCR in the large T binding region. Each map reproduced with
permission from its source: (Siebrasse et al., 2012b, Yu et al., 2012b, Korup et al., 2013, Lim et al., 2013).
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12. Human polyomavirus 12 (HPyV12)
The  latest  HPyV  discovered  to  date  is  HPyV12  (Korup  et  al.,  2013).  With  a  generic
polyomavirus PCR targeting the VP1 major structural protein gene, this polyomavirus was
initially identified in resected human liver tissue. HPyV12 is the first HPyV whose LTag
lacks any LxCxE motif. As this motif is essential to the retinoblastoma protein-dependent
transforming activity of other polyomaviruses, HPyV12 may exhibit reduced transforming
potential (Korup et al., 2013).
Discovery of HPyV12 was by means of extraction and purification of DNA and generic
polyomavirus PCR carried out as described previously for HPyV9 (Leendertz et al., 2011,
Scuda et al., 2011). To obtain additional sequence information on the novel polyomavirus,
a 950 bp genome fragment was amplified with nested PCR using two degenerate sense
primers targeting the VP3 gene of polyomaviruses (Scuda et al., 2011) and two virus-
specific antisense primers derived from the novel VP1 sequence. From the resulting
sequence, tail-to-tail primers were derived and used in nested long-distance (LD) PCR for
amplification and sequencing of the remaining part of the virus genome.
HPyV12 genome and structure
Analysis of the HPyV12 genome for putative open reading frames (ORFs) revealed a
genome structure typical for polyomaviruses. The genome includes an early region,
encoding regulatory proteins (sTag and LTag), and a late region, encoding structural
proteins  (VP1,  VP2  and  VP3)  that  are  separated  by  an  NCCR  (Figure  11).  The  ORF
encoding for the auxiliary agnoprotein (Gerits and Moens, 2012) was not identified.
HPyV12 LTag and sTag share 71 aa residues that are encoded at the N-terminus. This
region contains the DnaJ domain HPDKGG, which is fully conserved between all known
HPyVs  identified  so  far  (Van  Ghelue  et  al.,  2012).  However,  HPyV12  LTag  lacks  the
retinoblastoma binding motif LxCxE which is present in LTag sequences of all known
HPyVs. The NCCR contains four repeats of the putative GAGGC LTag binding site and
AT-rich palindromic sequences. The NCCR possesses potential binding sites for
numerous cellular transcription factors, but the functional importance of these sites
remains to be proven (Korup et al., 2013).
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HPyV12 epidemiological aspects
HPyV12 is a very recently discovered virus and there exists only the original report
concerning its epidemiology. Organs of the gastrointestinal tract like the liver, gall
bladder, esophagus, stomach, colon, rectum, spleen, and lymph node specimens were
tested with generic polyomavirus PCR targeting the VP1 gene, and the HPyV12 sequence
was amplified from liver specimens of four individuals (Korup et al., 2013). The 242
samples from gastrointestinal organs, spleens, and lymph nodes were re-evaluated with
diagnostic nested PCR and qPCR. The presence of HPyV12 sequences was confirmed in
the samples that were originally HPyV12-positive in the initial generic PCR. In addition,
10 liver samples tested positive that had been negative in the generic PCR. In total, of 124
liver  samples,  14  (11%)  were  HPyV12-positive.  One  positive  sample  each  was  also
identified among rectum and colon samples. Analysis of gall bladder, esophagus, stomach
(cardia), spleen and lymph nodes yielded negative results. Testing of feces revealed one
HPyV12-positive sample, but plasma, serum, urine, oral fluids, bronchoalveolar lavage,
and CSFs were negative (Table 10). In qPCR, the HPyV12-positive DNA samples
revealed genome copy numbers of up to 133/PCR reaction (equivalent to 27 copies/μl
DNA from fluid samples; 532 copies/μg DNA from tissue samples). In summary, analysis
of 636 clinical samples revealed the presence of HPyV12 only in organs of the
gastrointestinal tract and in feces.
Korup  et  al.  also  for  study  of  the  seroprevalence  of  HPyV12,  performed  ELISA  to
specifically detect VP1 antibodies against HPyV12. A pediatric population of 74 subjects
and 299 healthy adults and adolescents were tested, and the data were stratified by age.
The seroprevalence of HPyV12 was 12% in children aged 2 to 5 and rose to 26% in the
group aged 6 to 11. In young adults aged 21 to 30, the prevalence was 27%. In older
adults, the prevalence ranged between 15 and 33%. No difference existed in HPyV12
seroprevalences between male and female adults. This assay thus revealed that healthy
individuals are frequently infected with HPyV12 before the age of 20 (Korup et al., 2013).
HPyV12 disease associations
No disease has been yet associated with HPyV12.
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AIMS OF THE STUDY
Emerging HPyVs have been discovered since 2007. When this thesis project was initiated,
KIPyV and WUPyV were the only new HPyVs detected. The initial aim of the study was
therefore to
I) express and purify the structural proteins of KIPyV and WUPyV.
II)  study  the  antibody  and  DNA  prevalences  of  these  two  novel  polyomaviruses  in
young children with respiratory disease.
The subsequent discovery of eight new HPyVs included only MCPyV causing MCC, and
TSPyV causing TS, both skin diseases. Because of their novelty, some very basic
questions involving molecular and serological prevalence, transmission route, and
persistence site require answers. We planned this study to address these questions. Other
aims of the study were therefore to
I) determine the molecular and serological prevalence of KIPyV, WUPyV, MCPyV,
and TSPyV in clinical samples from patients immunocompetent or
immunocompromised or both.
II) determine the frequency of fetal infections by KIPyV, WUPyV, and MCPyV.
III) determine the occurrences and blood levels of MCPyV and TSPyV DNAs among
the elderly and any association between the prevalences of their corresponding antiviral
IgG antibodies.
IV) assess whether DNA from these four viruses is detectable in tonsillar tissue of
constitutionally healthy individuals, judged against the corresponding antiviral
seroreactivities.
V) assess whether the occurrence of these novel virus DNAs in body tissues or fluids
plays any role in disease etiology.
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MATERIALS AND METHODS
1. Materials
1.1. Patients and clinical material
Seven different patient groups (Figure 12) were surveyed in this research project
(Studies I, II, III, IV, and V). Clinical materials included in all studies were
nasopharyngeal aspirates (NPAs), sera, fecal samples, tonsillar tissue, and formalin-fixed
paraffin-embedded (FFPE) tissue samples from human fetuses.
Figure 12. Seven different patient groups  surveyed in this study.
•51 febrile children with acute lymphoblastic
leukemia
•Nasal swabs, sera and fecal samples
Group 1
(Thesis studies: I, II)
•117 wheezing children
•Nasopharyngeal aspirates (NPAs) and paired
sera
Group 2
(Thesis studies: I, II)
•229 children or adults with tonsillitis or
tonsillar hypertrophy
•Matched pairs of tonsillar tissue and sera
Group 3
(Thesis studies: I and V)
•5 children hospitalized in Germany
•Sera
Group 4
(Thesis studies: II)
•25 asymptomatic adults, mostly voluntary
staff
•Sera
Group 5
(Thesis studies: II)
•550 fetuses + 462 corresponding maternal
sera
•Placenta, heart, and liver
Group 6
(Thesis studies: III)
•394 hospitalized senior citizens
•Blood samples
Group 7
(Thesis studies: IV)
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Group 1 (Thesis Studies I, II), children with acute lymphoblastic leukemia
The clinical material comprised nasal swabs, sera, and fecal samples from 51 febrile
children with acute lymphoblastic leukemia undergoing anticancer treatment. The
patients’ information has been described elsewhere (Koskenvuo et al., 2008). Briefly,
samplings were done between April 1, 2000, and October 31, 2005, at four Finnish
university hospitals, including 51 children with acute leukemia. The majority, 42, of the
children were followed from the beginning to completion of their chemotherapy regimen.
The mean follow-up time was 1.5 years (range 0.1–2.5 years). Two children with high-risk
acute myeloid leukemia (AML) and five with high-risk acute lymphoblastic leukemia
(ALL) underwent bone marrow transplantation during the study period, with their follow-
up completed on the day of transplantation.
     During the study period, in these 42 children, 156 febrile episodes were studied.
Fever was defined as an axillary temperature ?38.0°C, and the interval between separate
febrile episodes had to be ?7 days. In 18 episodes, no virologic samples were taken; 138
fever periods were included in the study. In all these cases, a blood culture was also taken,
with findings reported separately. A febrile episode was considered to be nosocomial if
fever arose 48 hours after admission. Otherwise, the febrile episode was considered to be
community acquired. The total white blood cell count, absolute neutrophil and lymphocyte
counts, and serum C-reactive protein (CRP) levels were recorded during the first febrile
day.
Group 2 (Thesis Studies I, II), children with acute expiratory wheezing
The second group comprised 278 children aged 3 months to 15 years (mean 2.3 years,
median 1.6) who were admitted to the Department of Pediatrics of Turku University
Hospital (Turku, Finland) from 1 September 2000 through 31 May 2002 for acute
expiratory wheezing. These children were observed and described elsewhere (Jartti et al.,
2004, Allander et al., 2007b, Kantola et al., 2008).
     Briefly, at their admission to the hospital, NPAs for viral diagnosis were obtained by
a standard procedure (Jartti et al., 2004). Blood samples were collected at hospital
admission and 2 to 3 weeks after hospital  discharge,  and the paired serum samples were
stored at -20oC. Of the 259 children included in the previous virus etiology study,
comprising PCR studies of NPAs for 16 viruses (adenovirus; human bocavirus (HBoV);
coronaviruses 229E, OC43, NL63, and HKU1; enteroviruses; rhinoviruses; influenza A
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and B viruses; human metapneumovirus; parainfluenza virus 1–4; and respiratory
syncytial virus), 49 (19%) were HBoV-positive by PCR (Allander et al., 2007b). Study (I),
for DNA detection of MCPyV, WUPyV, and KIPyV, involved used nasopharyngeal
aspirates (NPAs) from 140 wheezing children and paired sera from 248. In Study (II), we
studied a total of 443 serum samples (201 paired, 41 unpaired) from 242 individuals and
192 nasopharyngeal samples from 192 patients for the presence of KIPyV and WUPyV
DNA  by  polymerase  chain  reaction  (PCR).  From  the  sera  tested  by  PCR,  120  samples
(100 unpaired, 10 paired) were selected, on the basis of age (?4 years) or NPA PCR result
(KIPyV or WUPyV DNA-positive), for immunoblotting, and 50 (?2 years) for
immunofluorescence assays (IFA).
Group 3 (Thesis Studies I and V), children or adults with tonsillitis or tonsillar
hypertrophy
The third group included matched pairs of tonsillar tissue and sera from 229 children or
adults who had been studied for HPV (Chen et al., 2005). In brief, 212 enrolled patients
were operated on in 2001 and 2002, 135 because of tonsillitis and 77 for tonsillar
hypertrophy at Helsinki University Central Hospital. After tonsillectomy, a piece of tissue
from each child was immediately frozen at ?70°C. A 100-?m cryo-section per tonsil per
patient was subjected to DNA extraction. Five-micrometer sections from both ends of the
tissue were toluidine blue-stained to verify that the tissue section consisted of at least 30%
epithelial cells. After every tenth sample, an optimal cutting-temperature compound
including no tonsillar tissue was cryo-sectioned as a negative control for the DNA
extraction; none of these sections showed positive ?-globin or HPV by PCR. Serum
samples were drawn on the day of surgery. Tonsillar exfoliated cells from 189 control
subjects (age- and sex-matched to patients) with normal tonsils were collected bilaterally
from  tonsillar  surfaces  with  a  Cytobrush  Plus  Cell  Collector  (Medscand  Medical).  The
brushed samples were stored in phosphate-buffered saline at ?70°C. Serum samples were
collected on the same day.
Group 4 (Thesis Study II), children hospitalized in Germany
The fourth group consisted of five children aged 0.7 to 5.6 years (mean 3.0 years,
median 2.8), hospitalized in Germany and shown to be WUPyV PCR-positive in NPA
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(Neske et al., 2008). The sera from three of these children were taken on the same day, for
one 4 days and for one, 5 months after the first NPA samples.
Group 5 (Thesis Study   II), asymptomatic adults
The fifth group consisted of 25 asymptomatic adults aged 20.5 to 60.7 years (mean 33.5
years, median 27.8), mostly voluntary staff, from whom only serum samples were
obtained. These adult sera were immunoblotted without PCR testing.
Group 6 (Thesis Study III), fetal autopsy samples
Formalin-fixed paraffin-embedded (FFPE) tissue samples from 550 fetuses that were
collected from July 1992 through December 1995 and from January 2003 through
December 2005 at the Helsinki University Central Hospital were retrieved (Riipinen et al.,
2008). Briefly, samples from five fetuses were ?-globin PCR-negative because of DNA
degradation or PCR inhibition and were thus excluded. In twin- or multiple-fetus
pregnancies, tissue samples were available mostly from only one fetus. Both fetuses were
available  from  10  twin  pregnancies,  and  all  were  found  to  be  parvovirus  B19  DNA-
negative. For conformity and statistical analysis, we considered each set of twins as one
(10 exclusions). Thus, a total of 535 fetuses were included in the final study population.
Samples from three organs (placenta, heart, and liver) were pooled from each fetus. The
time of fetal  death ranged from 11 to 42 gestational weeks.  Fetal  loss was defined as an
intrauterine fetal death (IUFD) when it occurred during or after gestational week 22 and as
miscarriage when it occurred earlier (according to the International Classification of
Diseases, Tenth Revision). Our study comprised 120 miscarriages and 169 IUFDs.
According to official statistical records, a total of 67,858 live births and 290 IUFDs
occurred at Helsinki University Central Hospital during the study period. Thus, 169
(58.3%) of the 290 fetuses from IUFDs in the Helsinki region were available for our
study. The proportion of miscarried fetuses included in our study, however, is unknown,
because not all miscarriages are registered. From induced abortions (performed
exclusively for medical reasons), 246 fetuses served as control fetuses.
We  furthermore  examined  for  the  presence  of  MCPyV  IgG  antibodies  all  serum
samples available from the 462 corresponding mothers. These samples had been collected
at the municipal maternity centers during antenatal screening around the ninth gestational
week (mean 9; median 9; range 2 to 36) and were stored frozen at the Finnish Maternity
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Cohort,  National  Institute  for  Health  and  Welfare,  Oulu,  Finland.  The  mothers’  ages
ranged between 18 and 45 years (mean 31, median 31).
Group 7 (Thesis Study IV), hospitalized elderly individuals with respiratory
symptoms
 From 394 hospitalized senior citizens with respiratory symptoms or suspected
pneumonia, cardiovascular, or other diseases in the city hospital of Turku, Finland, 621
blood samples were collected between July 2007 and April 2009. The criteria for sampling
were age 65 years or older, disease requiring hospitalization, and a written assignment
from the patient or trustee. Patients having a short elective operation were excluded.
Eligible patients were informed of this study at hospital entry. After signing the consent,
the patient or trustee had an interview, and hospital records were reviewed for clinical
history. Nasopharyngeal swab samples (flocked swab, 520CS01, Copan, Brescia, Italy)
and serum samples were collected at hospital entry and after 2 weeks or at discharge for
detection of acute infections. The swabs in dry tubes and serum samples were stored at -
80°C. Disposable gloves prevented contamination.
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1.2. Plasmid (I, II, III, IV, and V)
In  Studies  I  and  III,  for  use  as  positive  controls  and  to  determine  PCRs  assay
sensitivities by limiting dilution analysis, plasmids containing the VP2 gene of WUPyV
(EU693907) and KIPyV (EU358767) and the LT3 amplification product of MCPyV
(EU375803) were constructed; the amplification products of the VP2 genes were cloned
into pCR8/GW/TOPO (Invitrogen; Carlsbad, CA, USA), whereas the MCPyV LT3 region
was synthesized and cloned into pGOv4 by Gene Oracle, Inc. (San Leandro, CA, USA). In
the MCPyV PCRs assay, plasmid controls with 30 and the KIPyV/WUPyV assay, 5 copies
per reaction were reproducibly positive. Their sensitivities remained unaffected by
inclusion of genomic human DNA from cultured 293T cells at 100 ng per reaction (4
ng/l). In a non-nested format with 40 PCR cycles the LT3 primers had a sensitivity 1 log
lower than that of the nested assay both in the presence and absence of human genomic
DNA.
In Study II, for cloning of the viral protein genes, we used several primers and the
plasmids (Table 11).
In Studies IV and V, for detection of MCPyV by real-time PCR, control plasmids were
cloned from amplicons of PCR-positive tonsillar samples from Study I by means of the
CloneJET™  PCR  Cloning  Kit  (Thermo  Fisher  Scientific,  Inc.,  Waltham,  USA).  Serial
dilutions of the plasmids allowed determination of assay sensitivity. In each assay, five
copies per reaction were reproducibly positive, corresponding to 200 copies/mL of serum.
In  TSPyV  Studies  (IV  and  V), for  use  as  positive  controls  and  to  determine  assay
sensitivities  due  to  the  lack  of  known  positive  samples,  the  TSPyV  LT  and  VP  regions
were synthesized and cloned into pUC57 by GenScript (Piscataway, NJ, USA). The
detection limit of each assay was five target copies per reaction, corresponding to 200
copies/mL of serum.
Screening  for the single-copy human RNase  P gene by real-time quantitative PCR
(qPCR) was  done by use of  the plasmid containing this gene (Study V).This plasmid was
a generous gift from Dr Janet S. Butel (Baylor College of Medicine, Houston, Texas,
USA).
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2. Methods
1.2. DNA extraction (I, II, III, IV, and V)
Total nucleic acids were extracted from the sera, tonsillar tissues, nasal swabs, and
NPAs with the DNAMini kit (Qiagen, Crawley, UK), and from the fecal samples with the
QIAamp  Qiagen  DNA  Stool  kit  (Qiagen)  according  to  manufacturer’s  instructions.  In
Study V, from the serum samples, DNA was extracted by lysis buffer/proteinase K
treatment and phenol-chloroform extraction.
In Study III, the paraffin blocks were punch-biopsied, proteinase –K digested, and the
DNA was prepared by salting out, as described (Riipinen et al., 2008). Briefly, tissue
lysates were heated at 95°C for 10 min. After centrifugation at 13,200 rpm for 5 minutes
(Eppendorf; 4°C), the paraffin then appeared floating on the surface. The liquid phase was
removed to a new tube, and sodium chloride was added to achieve a final concentration of
1.2 mol/L, and the sample was mixed for 20 s and recentrifuged. The supernatant was
transferred to a new tube, carefully avoiding particles. The DNA in the supernatant was
precipitated with absolute ethanol and was redissolved in 60 μL of water. The DNA
solution diluted 1 to 10 was stored at - 20°C until use.
2.2. DNA screening (III, V)
Human beta -globin-PCR (III)
With emphasis on DNA stability and lack of appreciable PCR inhibition, the human ? -
globin-PCR was done by primers targeting the human ?-globin gene (Table 12), and all
these DNA preparations were ? -globin-PCR-positive.
Human RNase P gene PCR (V)
All samples were screened for the single-copy human RNase  P gene by establishing
real-time quantitative PCR (qPCR). The target gene for quantifying cell number is the
proven single-copy RNAse P gene.  Each  sample  was  subjected  to  Taq  Man  PCR  for  a
control gene RNase P.  Standard curves were constructed for the RNAse P gene plasmid.
Standards were made by preparing serial 10-fold dilutions of the plasmid with copy
numbers ranging from 1 to 108 copies.  PCR  amplification  reactions  were  set  up  in  a
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reaction volume of 17 μl using 10 μl TaqMan universal PCR master mix (Applied
Biosystems), 2.7 μl DNase-RNase free water, 0.9 μl of (10μM) each primers, and 0.5 μl of
probe (Table 12). Amplifications were performed with the Stratagene Mx3005p
(Stratagene, La Jolla,  CA, USA) by use of  the following cycling parameters:  10 min at
95°C, followed by 40 cycles of 15 s at 95°C and of 1 min at 60°C. Reactions were
considered positive if >10 genome copies/reaction were detectable. This strategy detected
potential PCR inhibitors in the DNA preparations, determined the human cell equivalents
in each DNA sample, and normalized TSPyV viral loads to human cell numbers.
Virus Gene PCR
Forward primers
Reverse primers
Probes
Amplicons
size (bp)
KIPyV & WUPyV VP2 Nestedouter
5-ATCTRTAGCTGGAGGAGCAGAG-3
5-CCYTGGGGATTGTATCCTGMGG-3 336
KIPyV & WUPyV VP2 Nestedinner
5-RTCAATTGCTGGWTCTGGAGCTGC-3
5-TCCACTTGSACTTCCTGTTGGG-3 277
MCPyV LT3 Nestedouter
5-TTGTCTCGCCAGCATTGTAG-3
5-ATATAGGGGCCTCGTCAACC-3 309
MCPyV LT3 Nestedinner
5-TGACGTGGGGAGAGTGTTTTTG-3
5-GAGGAAGGAAGTAGGAGTCTAGAAAAG-3 155
MCPyV LT1 Nestedinner
5-TACAAGCACTCCACCAAAGC-3
 5-TCCAATTACAGCTGGCCTCT-3 440
MCPyV LT1 Nestedouter
5-GGCATGCCTGTGAATTAGGA-3
5-TTGCAGTAATTTGTAAGGGGACT-3 179
MCPyV VP1 qPCR
5-TGCCTCCCACATCTGCAAT-3
 5-GTGTCTCTGCCAATGCTAAATGA-3
FAM-TGTCACAGGTAATATC-MGBNFQ
59
MCPyV LT1
Semi
nested
PCR
5-CTAAGTGCGCTTGTATTAGCTGTAAG-3
5-ATATAGGGGCCTCGTCAACC-3
5-GAGGAAGGAAGTAGGAGTCTAGAAAAG-3
334
229
MCPyV LT1 qPCR
5-CCACAGCCAGAGCTCTTCCT-3
5-TGGTGGTCTCCTCTCTGCTACTG-3
FAM-TCCTTCTCAGCGTCCCAGGCTTCA-TAMRA
140
TSPyV LT qPCR
5-TGTGTTTGGAAACCAGAATCATTTG-3
5-TGCTACCTTGCTATTAAATGTGGAG-3
FAM-TTCTTCTTCCTCCTCATCCTCCACCTCAAT-BHQ1
140
TSPyV VP1 qPCR
5-AGTCTAAGGACAACTATGGTTACAG-3
5-ATTACAGGTTAGGTCCTCATTCAAC-3
FAM-ACAGCAGTGACCAGGACAAGCCTACTTCTG-BHQ1
140
TSPyV VP1 PCR 5-AGTCTAAGGACAACTATGGTTACAG-35-ATTACAGGTTAGGTCCTCATTCAAC-3 140
Beta globin                                   5-ACACAACTGTGTTCACTAGC-3                                  5-GGTGAACGTGGATGAAGTTG-3 110
RNase P gene
                                  5-GAGGGAAGCTCATCAGTGGGG-3
                                  5-CTTGGGAAGGTCTGAGACTAGGG-3
FAM-AGTGCGTCCTGTCACTCCACTC-TAMRA
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Tail Sequence AACTGACTAAACTAGGTGCCACGTCGTGAAAGTCTGACAAGTGTCTCTGC 50
Table 12. PCR primers used in the studies of this thesis.
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2.3. DNA amplification
KIPyV and WUPyV detection (I, II, III)
Nested PCR
WUPyV and KIPyV detection was performed by primer set A as described (Norja et
al., 2007). Briefly, two sets of primers hybridizing to regions of sequence conservation
between the virus groups were selected. Set A comprised positions in the published
complete genome sequence of KIPyV [NC 009238] yielding amplicon lengths of 336 and
276 bp for first- and second-round amplification reactions (Table 12).
Real-time PCR assay
Nucleic acid extraction from the NPAs underwent a single-tube dual probe, real-time
PCR assay for KIPyV and WUPyV DNA as previously described (Lindau et al., 2009).
MCPyV detection (I, III, IV)
Nested PCR
For  MCPyV  detection,  nested  PCR  was  performed  using  as  outer  primers  the
previously described LT3 primers (Table 12) (Feng et al., 2008) and as inner primers a
pair hybridizing to conserved regions within the LT3 region. To increase the robustness of
fecal  PCRs,  bovine  serum  albumin  (BSA)  (New  England  Biolabs,  Ipswich,  MA,  USA)
was included at the final concentration. All samples positive for MCPyV were re-analyzed
with the LT1/M1 nested PCR primer set as described (Kassem et al., 2008) and
sequenced. Samples positive with the LT3 nested primer set but negative with the LT1/M1
primer pair were analyzed with a third (seminested) PCR. The semi-nested forward
primers and LT3 antisense primers were used for the first-round PCR, whereas the internal
reverse primers of LT3 with the same semi-nested forward primer used for the second-
round  PCR.  The  mastermix  and  cycling  conditions  were  the  same  as  for  the  other  two
PCRs.
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Real-time PCR assay
Two published primer sets targeting conserved sequences in the MCPyV genome, the
LT gene, and the VP1 gene (Table 12), we used as described (Goh et al., 2009). PCR was
done  with  the  ABI  PRISM  7700  Sequence  Detector  (Applied  Biosystems,  Foster  City,
CA, USA) thermal cycler, using the TaqMan universal PCR master mix (PE Applied
Biosystems).
As the MCPyV VP1 PCR product was too short for direct sequencing, we added a 40-
bp nonspecific nucleotide tail (Table 12)  (Binladen et al., 2007) in addition to a poly(C)
to the 5' end of the sequencing primers to accomplish a product of 110 bp. The neutral
sequence is a randomly generated sequence not matching any sequence in a BLAST
search.
TSPyV detection (IV and V)
Real-time PCR assay
For detection of TSPyV, we applied published qPCRs, with primer pairs targeting the
VP1 and LT genes (van der Meijden et al., 2010) but changed the quenching dye TAMRA
to BHQ1 on the 3' base of the probes (Table 12). Although annealing was for 15 s at 62°C,
the cycling conditions were otherwise identical to those of the MCPyV protocol.
2.4. DNA sequencing and sequence analyses (I, II, III, IV, and V)
The PCR products were purified for automated sequencing with the High Pure PCR
product purification kit (Roche, Mannheim, Germany). The resulting DNA sequences
were aligned by means of the BLAST against the MCPyV sequences in GenBank.
2.5. Statistical analysis (I and IV)
The ages of the patients with MCPyV or WUPyV DNA in their tonsils were ranked and
compared with the unequal variance t-test (I). We examined the association between
MCPyV  DNA  positivity  in  serum  and  the  clinical  characteristics  of  the  elderly  (IV).
Univariable logistic regression served to analyze the association between patient
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characteristics and virus etiology. For statistics we used the SAS Enterprise Guide 4.3
(SAS Institute Inc., Cary, NC, USA).
2.6. DNase treatment (I)
Three NPAs testing positive for MCPyV DNA were selected for DNase treatment to
determine the encapsidation status of the viral DNA. The NPAs were centrifuged at
16,000×g for 10 min, after which both the supernatants and the pellets (after resuspension
and sonication) were diluted 1:2 with molecular biology-grade water and treated with 100
units of DNase I (Roche) or mock treated with water. After 2 h at 37 ?C, the enzyme was
inactivated with 8mM EDTA and heated at 70 ?C  for  10  min.  DNA  was  isolated  with
DNA Mini kit (Qiagen).
2.7. Serological assays
Recombinant protein production (II, III, IV, and V)
In Studies III,  IV, and V, VLPs of MCPyV and TSPyV VP1 were used for serology.
VLPs were produced in insect cells as described elsewhere (Chen et al., 2011a, Chen et
al., 2011b). Briefly, recombinant baculoviruses were generated by the Bac-to-Bac system
(Invitrogen) in accordance with the manufacturer’s instructions. Spodoptera frugiperda
(Sf9) cells, infected with high titers of recombinant virus, were harvested 4 to 5 days after
infection and processed by two-step lysis. The lysate was loaded on a 25% (wt/vol)
sucrose shelf and centrifuged in a Beckman SW55Ti rotor at 103,246 g at 4 ?C for 2 hours.
The resulting pellet was resuspended in 20 mmol/L Tris (pH 7.5) and layered on top of a
1.23–1.36 g/cm3 cesium chloride gradient. After ultracentrifugation in a Beckman
SW55Ti rotor at 103,246 g at 4 ?C for 15 hours, fractions were collected, followed by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-page). The fractions
showing VLPs in EM were pooled and dialyzed (3 times) against phosphate-buffered
saline.  For  use  as  an  antigen,  the  VLPs  were  biotinylated  with  the  EZ-Link  Sulfo-NHS-
LC-Biotinylation kit (Pierce) as described (Chen et al., 2011a, Chen et al., 2011b).
     In  Study  II,   the  VP1,  VP2,  and  VP3 genes  of  the  four  HPyVs were  amplified  by
PCR using Platinum Taq DNA polymerase (Invitrogen)  from partial or full-length KIPyV
(Allander et al., 2007a), WUPyV (Gaynor et al., 2007), BKPyV, and JCPyV (Loeber and
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Dorries, 1988) clones. All 12 amplified genes were cloned into the pET SUMO vector
(Invitrogen) for protein expression in E. coli. Protein expression utilized an N-terminal
fusion tag, a Saccharomyces cerevisiae Smt3 protein (SUMO), an 11-kDa homolog of the
mammalian SUMO-1. The tertiary structure of this tag is very accurately recognized by a
SUMO protease, which cleaves it such that no aa remain between the cleavage site and the
protein of interest (Malakhov et al., 2004). The SUMO expression constructs were
transformed into E. coli BL21 (DE3) pLysS (Novagen, Gibbstown, NJ, USA), or Rosetta
2 (DE3) pLysS (Novagen) expression strains, and grown overnight in 500 mL Luria broth
(LB) with 50 mg mL–1 kanamycin (BL21 and Rosetta) and 34 mg mL–1 chloramphenicol
(Rosetta).
     At an optical density of 0.6 at 600 nm, protein expression was induced with 1mM
IPTG for 3 h (Isopropyl ?-D-1-thiogalactopyranoside is a molecular mimic of allolactose,
a lactose metabolite that triggers transcription of the lac operon, and it is therefore used to
induce protein expression where the gene is under the control of the lac operator).
Inclusion bodies from lysed cells were pelleted by centrifugation, washed twice with
phosphate-buffered saline (PBS), and resuspended in 25 mL of lysis buffer (6M GuHCl,
100mM NaH2PO4,  and  10mM  Tris  Cl;  pH  8.0).  The  rest  of  the  purification  was  done
according to the Ni-NTA matrix manufacturer’s (Qiagen Inc., Valencia, CA, USA)
instructions. The purified proteins were renatured at 48 ?C by a  4-h  dialysis  against  2M
(WUPyV and KIPyV) or 3 M urea (BKPYV and JCPYV) containing 150 mM NaCl, 5%
(v/v)  glycerol,  and  1  mM  DTT  in  20  mM  Tris/HCl,  pH  8.0.  Cleavage  of  the  SUMO
carriers from the partially unstable WUPyV, BKPYV, and JCPYV VP3 proteins was done
with 1 U of SUMO protease (Invitrogen) per 2 μg of substrate at 30 ?C for 2 h. All other
proteins were cleaved overnight at 48 ?C with  1  U of  protease  per  10  mg substrate.  The
cleaved WUPyV and KIPyV proteins were passed twice through a Ni-NTA spin column
(Ni-NTA spin kit; Qiagen) to remove the hexahistidine-tagged SUMO protein and the
SUMO protease.
The WUPyV VP1, VP2, and VP3 proteins were expressed as native without a fusion
tag  in  Sf9  insect  cells.  The  genes  were  cloned  in  the  pCR8/GW/TOPO  gateway  entry
vector and transferred to a pDest8 gateway destination vector to create recombinant
baculoviruses.
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Western blotting and immunofluorescence assay (II)
After expressing and purifying the structural proteins of KIPyV, WUPyV, JCPyV, and
BKPyV, we performed immunoblotting to compare the immunoreactivities. The purifed
proteins VP1, VP2, and VP3 were separated by 12% SDS-PAGE and immunoblotted with
human sera and horseradish peroxidase-conjugated anti-human IgG.
     NPA PCR-positive children were also tested for IgM as previously described
(Kantola et al., 2008). In immunoblotting, a sample was regarded as seropositive if it had
an unequivocal band of correct molecular size, and all samples were scored in blinded
fashion. An increase in IgG was defined as a significant elevation in band intensity
between the acute and convalescence serum samples, when both were tested identically
and simultaneously. Borderline sera were retested with a lower dilution of serum (1:30).
All samples still (considered) borderline were regarded as negative. The IgG
seroprevalences against the SUMO fusion tag, seen with the isolated carrier protein,
increased  with  age  from 8% among children  to  72% in  adults.  To  avoid  false  positivity
due to the SUMO fusion partner required both cleaved and uncleaved recombinant
proteins; those 30 subjects reactive with all three uncleaved antigens were re-examined
with the cleaved antigens. To account for the possibility that the prokaryotic origin would
affect  the antigenicity of the recombinant proteins,  all  sera from 50 children aged 3 to 4
years old were also immunoblotted with WUPyV VP1- and VP3-expressing insect cells.
To validate our immunoblot (IB) results and to further study the importance of protein
folding for the antigenicity of KIPyV and WUPyV VP1, we used an immunofluorescence
assay (IFA) (Neske et al., 2010) using baculovirus-infected SF9 insect cells to test the sera
of 54 children for WUPyV and KIPyV VP1 IgG.  Samples for the IFA assay were selected
on the basis of age (n=50, ? 2 years). Briefly, SF9 cells infected with recombinant
baculoviruses were collected by centrifugation, washed with PBS, mounted on glass
slides, and fixed with acetone. Slides with uninfected SF9 cells and SF9 cells infected
with a control baculovirus encoding glutathione S-transferase (GST) were prepared in the
same manner to control for anti-cellular and antibaculoviral antibodies. These slides were
incubated with 1:10 and 1:40 replica dilutions of each serum for 2 h at 37 ?C, washed, and
incubated with a 1:150 dilution of fluorescein isothiocyanate (FITC)-conjugated goat anti-
human-IgG (Jackson ImmunoResearch West Grove, PA, USA) for 1 h at 37 ?C. The slides
were read in blinded fashion.
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MCPyV antibody ELISA (III and IV)
MCPyV IgG antibodies were measured by ELISA based on virus protein 1 (VP1) VLPs
(Chen et al., 2011a). Briefly, the VP1-VLPs expressed in insect cells and purified by CsCl
density gradient centrifugation were biotinylated and attached (at 60 ng/well) to
streptavidin-coated microtiter plates (Thermo Scientific) and saturated with a sample
diluent (Ani Labsystems). The sera (1:200) were applied in duplicate, the bound IgG was
quantified with peroxidase-conjugated anti-human IgG (1:2000; DakoCytomation) using
H2O2 and OPD substrates (o-Phenylenediamine dihydrochloride), and the absorbances at
492 nm were read after blank subtraction. The ELISA cut-off for IgG positivity was 0.120
OD units.
TSPyV antibody ELISA (IV and V)
TSPyV IgG antibodies were measured by in-house ELISA based on VP1 virus-like
particles  (VLPs)  as  described  (Chen  et  al.,  2011b).  For  TSPyV  IgG  ELISA,  the  lower
cutoff was 0.100, and the higher cutoff was 0.240.  Samples with absorbance values
exceeding the higher cutoff were considered IgG-positive, and those with values below the
lower cutoff, IgG-negative, whereas values between the cutoffs were considered
indiscriminate (Chen et al., 2011b). The PCR-positive individuals also were tested for IgM
by μ-capture ELISA and for IgG avidity by the corresponding ELISA, as described (Chen
et al., 2014). The cutoff values for IgM were 0.194 and 0.240; and for low and high
avidity, 15% and 25%, respectively.
2.8. Ethical aspects (I, II, III, IV, and V)
The study was approved by the Coordinating Ethics Committee of the Hospital District
of  Helsinki  and  Uusimaa.  Permission  for  use  of  fetal  tissues  came  from  the  National
Supervisory Authority for Welfare and Health (Valvira).
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RESULTS AND DISCUSSION
Since 2007, new molecular and bioinformatic techniques have uncovered ten new
polyomaviruses. This has revitalized scientific debate on polyomaviruses and their
potential contributions to human disease including cancers. What these discoveries show
is that polyomaviruses represent a large family with a high degree of divergence (Van
Ghelue et al., 2012). Although all ten of the new HPyVs  are of a genomic structure and
gene organization that are similar to those of SV40, important differences in sequence
exist that may impact the life cycle and host cell tropism of the new human viruses (Van
Ghelue  et  al.,  2012).  That  the  number  of  HPyVs  continues  to  increase  means  that  vital
questions emerge as to their tropism, transmission route, latency site, and disease-causing
potential.
For  the  newly  discovered  polyomaviruses,  over  this  short  period  of  time  much  new
knowledge has become available. Similarly to BKPyV and JCPyV, infection by these viral
agents is widespread among the human population. So it is hypothesized that a benign
primary infection occurs early in childhood, probably by a respiratory or oral-fecal route.
This infection will persist in a latent state in a yet unidentified body location, and be
reactivated in a setting of immune suppression due to immunosuppressive drugs or other
underlying medical conditions.
The association has been shown between two novel polyomaviruses (MCPyV and
TSPyV) and two skin diseases (MCC and TS) (Feng et al., 2008, van der Meijden et al.,
2010).  However,  eight of the newly discovered HPyVs still  remain orphaned. Given that
polyomaviruses retain oncogenic potential, investigation of their occurrence in benign,
semimalignant and malignant tumors could uncover no occurrence of these new
polyomaviruses in any of samples tested (Dalianis and Hirsch, 2013).
KIPyV, WUPyV, MCPyV, and TSPyV have been detectable in respiratory specimens
worldwide, but the number of patients positive to any given virus is still low, and no
convincing evidence exists at this time for an etiological role of these viruses in
respiratory disease (Babakir-Mina et al., 2013, Coursaget et al., 2013, Kazem et al.,
2013b). Furthermore, because these are frequently co-detected with other known human
pathogens, and often control groups are lacking, it is difficult to establish a causal link
between these newly discovered human viruses and clinical symptoms. It may be possible
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that  KIPyV,  WUPyV,  and  MCPyV  play  a  role  in  at  least  a  subset  of  pneumonia  in
immunocompromised patients.
Infection by all HPyVs is widespread in the human population, but they show
important differences in their tissue tropism and association with disease. Despite our
understanding of many of the clinical and biological aspects, still much remains unknown
about these new viruses. In this study, we investigated some very basic questions
concerning emerging HPyVs, such as gaps in our basic understanding of their
epidemiology and occurrence in humans from birth to death. Other examples involve the
possibility of detecting these novel polyomavirues in different types of sample materials
from fetuses up to seniors, and determining whether these viruses persist in lymphoid
tissue, or if they are associated only with acute infections or cancers. Furthermore, we also
studied routes of transmission and the epidemiology of these newly discovered viruses.
In this study we performed immunoblot with purified VP1, VP2, and VP3 proteins of
KIPyV, WUPyV and human sera. We found cross-reactivity for the VP2 and VP3
proteins. However, sera with IgG for BKPyV or JCPyV were unreactive with KIPyV and
WUPyV VP2 and VP3. There was 72% aa identity for VP2, and 66% identity for VP3 of
KIPyV and WUPyV, but only 22 to 33% identity with the corresponding proteins of
BKPyV and JCPyV. Interestingly, immunoblotting resulted in >10 times lower
seropositivity for VP1 than with VP2 and VP3. However, the immunofluorescence assay
of Sf9 insect cells infected with baculovirus encoding VP1, VP2, or VP3 gave comparable
seroprevalences for the three antigens. This indicates that serodiagnostics using
immunoblotting and VP1 as a target antigen is an inadvisable method. Our results indicate
the significance of protein conformation in immunoreactivity of VP1, and show the
antigenic importance of the WUPyV and KIPyV minor proteins VP2 and VP3.
In addition, MCPyV, TSPyV, WUPyV, and KIPyV DNAs were detectable in clinical
samples of many different types: nasal swabs and nasopharyngeal aspirates, tumor-free
tonsillar tissues, and sera. The high IgG prevalence rates observed in this study for these
four viruses support the notion that these novel polyomaviruses are widespread and are
acquired early in childhood. Whereas these emerging polyomaviruses occur frequently in
tissues  of  many  different  types,  and  also  in  environmental  samples,  our  PCR  data  from
535 pregnancies suggest that none of these viruses are frequently transmitted vertically.
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1. Detection of KI, WU and MC polyomaviruses in respiratory
samples
WUPyV was detectable in 1 (0.9%) and and KIPyV in 4 (3.8%) nasal swabs (Study I)
and of the 192 NPA samples studied by PCR, 7 (3.6%) were positive for WUPyV, and 3
(1.5%) for KIPyV DNA (Study II). Of the 7 children positive for WUPyV and the 3 for
KIPyV,  4  and  1,  respectively,  had  a  high  load  of  DNA (?104 copies/mL of the original
sample); the DNA loads in the remaining samples were ?500 copies/mL. Three of the
MCPyV-positive NPAs (Study I) were treated (before DNA isolation) with DNase I. Two
were reproducibly resistant to the enzyme with no change in their levels of viral DNA.
One sample was in three repeated assays fully susceptible to DNase I, PCR-negative
versus PCR-positive, suggesting that the viral DNA occurred in nonencapsidated form.
The encapsidated form of DNA is the result of virus replication, whereas the
nonencapsidated DNAs can be integreated DNAs in the human genome, be episomal
DNAs,  or  even  result  from  contamination.  The  DNA  encapsidation  signal  of  the
polyomavirus capsid proteins for viral progeny formation, however, has not been
determined. Our study indicated that the N-terminal region of the HPyV VP1 may be
involved in viral genome encapsidation during progeny maturation (Ou et al., 2001).
Consequently, DNA encapsidation provides basic knowledge concerning how viruses
assemble into infectious particles and will eventually help to develop the biology and
pathogeneses of viral diseases.
Since the time that KIPyV and WUPyV were first identified, viral sequences have been
confirmed in respiratory specimens worldwide (Tables 3 and 4), suggesting that both
viruses are widespread among human populations. Furthermore, available data support a
model in which primary infection with KIPyV or WUPyV occurs during childhood
(Bialasiewicz et al., 2007a, Gaynor et al., 2007, Abedi Kiasari et al., 2008). Despite their
clear presence in specimens of patients with respiratory illnesses, the pathogenicity of
KIPyV and WUPyV remains speculative (Norja et al., 2007). The proposed association of
KIPyV and WUPyV with respiratory disease is tenuous because the majority of studies to
date include no specimens from asymptomatic patients. In the three studies that include
these control groups, viral sequences were detected at similar frequencies in asymptomatic
patients (Han et al., 2007, Norja et al., 2007, Abedi Kiasari et al., 2008). The link between
KIPyV and WUPyV infection and respiratory disease is further complicated by the high
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rates of co-infection with other respiratory viruses that were observed in these studies
(Allander et al., 2007a, Bialasiewicz et al., 2007b, Gaynor et al., 2007, Han et al., 2007,
Norja et al., 2007, Abedi Kiasari et al., 2008, Neske et al., 2008). Despite the lack of
evidence for KIPyV and WUPyV as causing disease, more research is necessary to
investigate this possibility, especially considering their similarities to BKPyV and JCPyV
in nucleotide sequence and potential route of infection.
Figure 13.  Patient, sample group, and PCR results in the respiratory tract.
Leukemic children (n=51)
Nasal swab (n=106)
Median age: 5.4 y
Age range: 2.3-16.3 y
MCPyV 2 (1.9%)
KIPyV 4 (3.8%)
WUPyV 1(.9%)
Wheezing children (n=248)
NPA (n=140)
Median age: 1.6 y
Age range: 0.2-15.2 y
MCPyV 3 (2.1%)
Wheezing children (n=192)
NPA (n=192)
Median age: 1.6 y
Age range: 0.2-15.2 y
KIPyV 3 (1.5%)
WUPyV 7 (3.6%)
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MCPyV DNA was detectable in 3 (2.1%) of 140 NPAs, and in 2 (1.9%) of 106 nasal
swabs (Study I). The presence of MCPyV in the respiratory tract raises questions about the
mode of transmission and respiratory pathogenicity of this newly described polyomavirus.
MCPyV DNA was detected at a variable frequency in 27 (4.25%), of 635 NPAs and in
7 (1.3%) of 526 respiratory tract samples from Australian patients with upper respiratory
symptoms  (Table  5)  (Bialasiewicz  et  al.,  2009a,  Goh  et  al.,  2009).  MCPyV  DNA  was
amplified in 15 (17.24%) of 87 lower respiratory tract samples from hospitalized Italian
patients with lower respiratory-tract symptoms (Babakir-Mina et al., 2010b). Sequence
data showed that MCPyV found in respiratory secretions is similar to the virus identified
in  Merkel  cell  carcinoma  (Babakir-Mina  et  al.,  2010b).  Of  305  samples  tested,  MCPyV
DNA was detected in 10 (3.27%) respiratory specimens collected from immunocompetent
and immunocompromised patients and they evaluated the possibility of the contribution of
this virus in respiratory disease alone, or in combination with other respiratory viruses
(Abedi Kiasari et al., 2011).
The presence of MCPyV in respiratory secretions indicates that it is shed into the
respiratory tract or is present in cells of the respiratory tract, similar to KIPyV, WUPyV,
BKPyV, and possibly JCPyV. Its presence also suggests that the respiratory tract may be a
route of transmission and become latent in other sites, such as epidermal tissue, by
systemic spread.
MCPyV, KIPyV, and WUPyV have been found worldwide in respiratory specimens
along with a high prevalence of codetected viruses, but clear evidence for a causal
association with respiratory illness has yet to be identified. These PyVs may be merely
transmitted through the respiratory route or be detected during periods of reactivation.
Similarly, JC and BK PyVs are suspected of being transmitted by inhalation and are
occasionally detectable in respiratory samples, yet patients generally remain asymptomatic
or exhibit nonspecific upper respiratory tract symptoms (Wiedinger et al., 2014).
Conclusions about their primary target organs and pathogenicity cannot be drawn without
epidemiologic support and without further investigation into different sample types.
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2. Detection of MCPyV in blood samples
In total, 840 sera from 229 tonsilectomy patients in the age-range 1.5 to 72 years, 51
leukemic children, and 248 wheezing children were PCR-negative for KIPyV, WUPyV,
and TSPyV DNA (Studies  I,  II,  and  V)  and  the  840  sera  studied  for  MCPyV.  Only  one
serum sample, from a leukemic child, was PCR-positive (Figure 14) (Study I).
Interestingly, our survey revealed no evidence of the occurrence of new HPyV DNA in
the serum or plasma of immunocompetent individuals. In contrast, several studies have
shown blood cells of immunocompetent individuals to harbor BKPyV and JCPyV DNA.
BKPyV and JCPyV DNA has also appeared in the sera or plasma of immunocompromised
patients (Dorries et al., 1994, Sundsfjord et al., 1994, Azzi et al., 1996, Ferrante et al.,
1998, Dolei et al., 2000, Drachenberg et al., 2007). Plasma samples from 62 HIV-1-
positive patients have revealed both KIPyV and WUPyV in two (3.2%) and one (1.6%)
cases (Babakir-Mina et al., 2009a). In addition, the prevalence of KIPyV in HIV-1-
positive patients was similar to that in healthy blood donors (Babakir-Mina et al., 2010a).
Figure 14.  Patient, sample groups, and PCR results in blood.
Leukemic children
(n=51)
Serum (n=115)
Median age: 5.4 y
Age range: 2.3-16.3 y
MCPyV 1(0.9%)
KIPyV (0)
WUPyV (0)
Wheezing children
(n=242)
Serum (n=443)
Median age: 1.6 y
Age range: 0.2-15.2 y
MCPyV (0)
KIPyV (0)
WUPyV (0)
Tonsiloctomy patients
(n=229)
Serum (n=229)
Median age: 21.0 y
Age range: 1.5-72 y
MCPyV (0)
KIPyV (0)
WUPyV (0)
TSPyV (0)
Elderly patients
(n=394)
Serum (n=621)
Median age: 82 y
Age range: 65-100 y
MCPyV 6(1.5%)
TSPyV (0)
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In  Study  IV,  MCPyV  DNA,  unlike  TSPyV  DNA,  occurred  in  low  copy  numbers  in
serum samples from a notable proportion of aging individuals. Of the 394 patients, 39
(9.9%) were positive once for MCPyV DNA by the LT PCR, and 33 (8.4%) by the VP1
PCR, while 6 (1.5%) were positive by both PCR assays.  In general,  the viral  DNA copy
numbers were low. In sharp contrast, no TSPyV DNA was detectable with qPCRs for the
corresponding genomic regions. Whether this reflects enhanced viral replication possibly
due to waning immune surveillance and is associated with increased MCC risk deserves
exploration. Our results show the occurrence of MCPyV DNA rather commonly in sera
from the elderly.
Interestingly, when we examined the association between MCPyV DNA positivity in
serum  and  the  clinical  characteristics  of  the  elderly  (IV),  VP1-PCR  positivity  was
significantly  and  positively  associated  with  chronic  respiratory  disease  (p  =  0.023).
Univariable logistic regression was used to analyze the association between patient
characteristics and virus etiology. Statistical significance was established at the level of P
< 0.05. No associations appeared between LT1-PCR positivity and clinical condition.
MCPyV has been detectable in inflammatory monocytes, but not in resident monocytes
of patients with MCC, leading to the hypothesis that MCPyV persists in inflammatory
monocytes and spreads along the migration routes of inflammatory monocytes (Mertz et
al., 2010). Moreover, the presence has also been noted of MCPyV in peripheral blood at
low copy numbers (Feng et al., 2008, Shuda et al., 2009). MCPyV sequences have been
detected in buffy coats from healthy blood donors (Pancaldi et al., 2011). The prevalence
of 22%, as determined in this study, is probably an underestimate, because blood samples
contain very low copies of MCPyV DNA, and data suggest that MCPyV is able to persist
at a low viral copy number in the peripheral blood mononuclear cells of immune-
competent persons (Pancaldi et al., 2011).
Investigation has reported MCPyV sequences in 27.1% of purified malignant cells from
human chronic lymphocytic leukemia (CLL) samples (Pantulu et al., 2010). Our MCPyV
DNA results in serum samples,  together with data from reported MCPyV DNA in buffy
coats (Pancaldi et al., 2011), suggest that in a fraction of healthy individuals,  MCPyV
persists or remains latent in blood cells. In the long-term, viral persistent infection may
allow MCPyV to generate mutants that can participate in the cell transformation process.
Indeed, a novel truncating MCPyV LTag deletion in CLL cells has been detected (Pantulu
et al., 2010). As suggested, this oncogenic process, together with the immune impairment
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of the host and other factors, is a well-known multistep cell transformation mechanism
used by other DNA tumor viruses such as human papilloma viruses  (Levine, 2009),
viruses which are closely related to the PyVs.
3. Detection of KIPyV in the gastrointestinal tract
In Study I, WUPyV was detectable in none, but KIPyV in 2 (2.7%) fecal samples.  The
novel KI and WU polyomaviruses have also occurred in the digestive tract of children
with  respiratory  or  gastrointestinal  symptoms  or  both  (Gaynor  et  al.,  2007,  Ren  et  al.,
2009). KIPyV and WUPyV can occur in the stool of patients with hematological
disorders, but often in combination with other viruses involved in gastrointestinal
disorders (CMV, adenovirus, BKPyV) (Babakir-Mina et al., 2009b). Because of frequent
co-infections, a clear correlation between novel polyomaviruses and clinical symptoms
could not be established. However, it was observed that diarrhea occurred frequently in
patients infected by KIPyV compared with patients not infected by this virus (Babakir-
Mina et al., 2009b). A case-control study to investigate the correlation between the first 10
HPyV species and the occurrence of gastroenteritis, despite its frequent detection of
KIPyV,  WUPyV,  MCPyV,  and  MWPyV  in  fecal  samples,  had  no  data  to  support  a
causative role for  HPyV in gastroenteritis (Li et al., 2013).
     Rockett et al. (2013) detected MWPyV in 4.4% of fecal specimens collected from
patients suffering gastroenteritis and in 12.8% of  healthy control children, which is higher
than the   rates of 2.3%, 3.3%, and 0% from children with diarrhea in St Louis, Missouri,
in California (Siebrasse et al., 2012b) and in Chile (Yu et al., 2012b). In contrast to these
findings however, Yu et al. (2012) reported a high detection rate of 12.5% in children
suffering from diarrhea in Mexico. Rockett et al. also detected HPyV6, 7, and TSPyV in
respiratory and fecal specimens, but at low prevalence (<1%), confirming very recent
reports of HPyV6, 7, 9, and TSPyV in respiratory, urine, and fecal specimens from
immunocompromised children in St Louis, Missouri. (Siebrasse et al., 2012a). HPyV9
was detected in none of the fecal samples (Rockett et al., 2013).
     STLPyV has occurred in clinical stool specimens from the USA and Gambia at an
up to 1% frequency (Lim et al., 2013). HPyV12 was initially identified in the organs of the
gastrointestinal tract (in resected human liver tissue) (Korup et al., 2013). Besides the
novel HPyV12, only MCPyV was detected in liver and other organs of the gastrointestinal
tract (Loyo et al., 2010). Although many questions are still to be answered regarding the
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potential role of these viruses in human infection, STLPyV and the recently described
MWPyV are the first two polyomaviruses to be discovered in human stool samples. This
makes one ask whether they may have a primary gastrointestinal tropism.
4. Detection of WU, MC, and TS polyomaviruses in tonsil samples
Until now, the role of the tonsils has been regarded as solely immunologic: it is
hypothesized that their position at the entrance of the respiratory and alimentary tract
facilitates their functional role in defense against pathogens (Ramos et al., 2013).
Tonsillectomy may be indicated when the patient experiences recurrent infections of acute
tonsillitis. Viral infections are the most common cause of acute tonsillitis; adenovirus is
the most common cause of nonstreptococcal tonsillitis (Chiappini et al., 2012).
In  our  first  (I)  and  last  (V)  study,  we  found  MCPyV,  WUPyV,  and  TSPyV  DNA  in
tonsillar tissue.  The Monaco group showed that,  in addition to human glial  cells,  JCPyV
can infect tonsillar lymphocytes and stromal cells in vitro and in vivo, as well (Monaco et
al., 1996, Monaco et al., 1998).
We used PCR amplification (qualitative, quantitative, and nested PCR) to determine
whether DNA from nondissected tonsillar tissue of healthy individuals contained newly
discovered polyomavirus-specific nucleotide sequences. Of 229 matched pairs of tonsillar
tissue biopsies and serum samples from asymptomatic donors; tonsils both from children
and  adults,  8  (3.5%)  tonsillar  tissues  were  positive  for  the  MCPyV,  8  (3.5%)  for  the
TSPyV, and 5 (2.2%) for the WUPyV sequences (Figure 15).
Ages  of  patients  with  MCPyV  or  WUPyV  DNA  in  their  tonsils  were  ranked  and
compared by the unequal variance t-test (I), yielding a statistically significant difference of
p < 0.001. Moreover the difference in median age of the patients with and without
MCPyV (p = 0.032) or WUPyV (p < 0.001) in the tonsils was statistically significant.
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Figure 15.  Patient, sample groups, and PCR results in tonsil samples.
HPyVs in general establish persistent infections and undergo periodic reactivations,
causing disease in susceptible hosts (Boothpur and Brennan, 2010). Evidence suggests that
the lymphoid system plays a role in polyomavirus infections and its persistence (Goudsmit
et al., 1982, Monaco et al., 1996, Monaco et al., 1998, Kato et al., 2004). The previously
identified  HPyVs BK and JC or  their  DNA have  occurred  in  tonsillar  tissue  in  children,
and JCPyV DNA also in the spleen and lymph nodes (Monaco et al., 1996, Monaco et al.,
1998, Kato et al., 2004, Meneses et al., 2005). We and others have reported PyVs DNA in
tonsillar tissue, suggesting lifelong persistence in lymphoid tissue or mucosa (Monaco et
al., 1998, Babakir-Mina et al., 2009a, Kantola et al., 2009, Astegiano et al., 2010, Sadeghi
et al., 2014).
Furthermore, we showed occurrence of MCPyV and TSPyV DNA in tonsillar tissue.
This may be a general feature of HPyVs, as tonsillar tissues can harbor other
polyomavirus  DNA,  and  tonsillar  stromal  cells  have  shown  a  susceptibility   to  JCPyV
infection (Goudsmit et al., 1982, Monaco et al., 1996, Monaco et al., 1998).
Blood cell-derived MCPyV and TSPyV positivity of the tonsils could not be
completely ruled out, because from our tonsillectomy patients, only serum samples (all of
which tested negative for MCPyV and TSPyV DNA) were obtained at the time of surgery.
However, DNA of several HPyVs (JC, BK, KI, WU, MC, and TS) has been detectable
in tonsillar tissue, a possible point of entry (Monaco et al., 1998, Babakir-Mina et al.,
2009a, Kantola et al., 2009, Astegiano et al., 2010, Sadeghi et al., 2014). The process by
which polyomaviruses gain access to and establish persistent infections in distal body
Tonsillectomy Patients
(n=229)
Madian age: 21.0 y
Age range: 1.5 - 72.0 y
MCPyV
8 (3.5%)
TSPyV
8 (3.5%)
WUPyV
5 (2.2%)
KIPyV
0 (0)
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compartments is not well established. JCPyV has been localized to tonsillar stromal cells
and to B lymphocytes, with the latter cell type implicated in circulatory dissemination to
other anatomic sites (Monaco et al., 1998). Since all viruses can be detected at increased
frequencies in blood and lymphoid tissues during host immunosuppression (Sharp et al.,
2009), it is likely that hematolymphoid cells can carry or harbor polyomaviruses.
5. Detection of newly discovered polyomaviruses in fetal autopsy
In Study (III) we attempted to clarify whether vertical transmission of KIPyV,
WUPyV, and MCPyV occurs. To the best of our knowledge, ours was the first molecular
and serological study of these virus infections of women during pregnancy.
We searched formalin-fixed, paraffin-embedded tissues (placenta, heart, and liver) of
535 fetal autopsy samples for the KI, WU, and MC polyomaviruses. We found no
genomic  DNAs  of  KIPyV  or  WUPyV  in  any  of  the  stillborn  or  deceased  fetuses.  This
suggests that during the study period, of these two newly found viruses, neither one often
caused miscarriage or IUFD. On the other hand, one pooled sample was positive for
MCPyV by PCR.  Tissue  samples  from two sites  were  available  for  further  study  of  this
fetus. On retesting of the placenta and fetal heart separately, the heart was PCR-negative,
and the placenta was PCR-positive for MCPyV.
Transplacental transmission of PyVs after the intraperitoneal inoculation of pregnant
hamsters with SV40 and pregnant mice with murine polyoma virus (MuPyV) has been
clear in animal models (Zhang et al., 2005, Patel et al., 2009), but human transplacental
JCPyV  and  BKPyV  transmission  is  less  clear.  A  study  of  300  pregnant  women  in  their
third trimester of pregnancy offered no evidence of the transplacental crossing of PyVs in
their offspring (Boldorini et al., 2008), but a study of 15 aborted fetuses found the viral
genome  in  12  placental  and  brain  samples,  and  in  9  kidney  samples  (Pietropaolo  et  al.,
1998). Of 60 samples from 7 fetuses, the BKPyV genome was detected in 22 (36.6%)
(Boldorini et al., 2010). Serological evidence of vertical transmission of BKPyV and
JCPyV has been shown by evidence of a postnatal rise in IgG level or by transient
appearance of an IgM or IgA response in newborns as evidence of infection. Among 19
newborns this has then shown BKPyV and JCPyV infections in 4 (21%) and JCPyV
infections in 3 (16%) (Boldorini et al., 2011). Our study indicates that maternal-to-fetal
107
passage of newly discovered polyomaviruses may occur in humans, although this is not a
common means of spread for these viruses.
6. DNA sequencing and sequence analyses of PCR-positive samples
We performed for DNA samples different PCRs using specific primer pairs, generating
distinct MCPyV genomic fragments called LTag, sTag, VP1, and VP2 (Table 12). We
have obtained positive PCR for fragments and have thus sequenced the fragments. PCR
product sequencing verified the specificity of the amplified products and detected possible
genomic variants. The products showed 100% identity to each other and also to those of
the previously described KIPyV, WUPyV, MCPyV, and TSPyV strain sequences with no
deletions or other mutations. In conclusion, based on the analysis of 440 bp, 336 bp, and
140 bp long fragment of MCPyV, of KIPyV and WUPyV, and of TSPyV respectively, we
demonstrated no new geographically or pathologically-related genotype. Further analyses
based on larger fragments of these viruses, will very probably help to reveal any new
genotype existence, as it has been shown for MCPyV (Martel-Jantin et al., 2014).
7. Seroepidemiology of the newly discovered human polyomaviruses
One of the most crucial PyV structural proteins is the major capsid protein VP1. VP1
forms the exterior part of the capsid and is the immunodominant protein; the estimate is
that 1 to 10 molecules of the minor capsid proteins VP2 and VP3 occupy the interior part.
These proteins are thought to be inaccessible to antibody binding in the context of mature
assembled  virions.  Assays  to  monitor  the  presence  of  BKPyV,  JCPyV,  and  SV40
antibodies or proteins include immunoblotting, hemagglutination inhibition, neutralization
assay, complement fixation, immunoelectroosmophoresis, indirect fluorescent antibody,
and ELISA (Knowles, 2006). The most common method currently is ELISA using VP1
capsomers or VP1-based virus-like particles (VLPs) as the capture antigen. The advantage
of this method is that recombinant VP1 of all HPyVs can be produced in E. coli, yeast, or
baculovirus/insect cell expression systems. Moens et al. (2013) reviewed the degree of aa
identity between the VP1 proteins of the genuine HPyVs; this is presented in (Table 13).
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Table 13. Overall amino acid identity between the VP1 proteins of the different human polyomaviruses.
The highest degree of identity is found between BKPyV and JCPyV (78%). Serological cross-reactivity
between human polyomaviruses. Reviews in Medical Virology 23(4): 250-264.
KIPyV and WUPyV expression and purification of structural proteins
The structural  proteins VP1, VP2, and VP3 of KIPyV, WUPyV, BKPyV, and JCPyV
were each expressed with the SUMO expression system in two E. coli strains. In addition
to  this  method  for  the  prokaryotic  expression,  we  also  did  purification  of  all  three
structural proteins of each of four HPyVs, including the recently discovered WUPyV and
KIPyV, with high yield and >95% purity. We used the SUMO protein as a fusion tag to
enhance expression levels. The SUMO fusion partner was efficiently cleaved from the
KIPyV and WUPyV VP1, VP2, and VP3 to yield fully tag-free recombinant proteins, and
was then depleted by second-affinity purification. Expression levels in the E.coli Rosetta
strain were, in general, higher, most notably for WUPyV VP1, which was expressed at
levels 3 to 4 times as high as with the BL21 (DE3) strain. The protein yield was high in all
cases,  with  1  L  of  culture  resulting  in  20  to  25  mg  of  purified  protein.  Due  to  low
solubility, all proteins were purified under denaturing conditions to >95% purity as
estimated  by  SDS-PAGE.  Expression  of  WUPyV VP1 and  VP3 in  SF9 cells  resulted  in
major bands in SDS-PAGE, whereas VP2 was undetectable.
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MCPyV and TSPyV expression and purification of structural proteins
The synthetic MCPyV and TSPyV VP1 gene was cloned into a recombinant
baculovirus  and  expressed  in  Sf9  cells  (Chen et  al.,  2011a,  Chen et  al.,  2011b).  After  4
days of culture, a major protein band of 46KDa was evident in SDS-PAGE of the whole
cell lysate, and as the sole constituent of the CsCl gradient-purified material. In EM, the
purified VLPs had an icosahedral shape, and a diameter of 42 to 58 nm (Figure 16).
Figure 16. EM of recombinant MCPyV (A) and TSPyV (B) VP1 virus-like particles. Scale bar = 200 nm.
Reproduced with permission from (A) Chen, T., et al. (2011). Serological evidence of Merkel cell
polyomavirus primary infections in childhood.  J Clin Virol 50(2): 125-129 and  (B) Chen, T., et al. (2011).
Seroepidemiology of the newly found trichodysplasia spinulosa-associated polyomavirus.  J Infect Dis
204(10): 1523-1526.
A B
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KIPyV and WUPyV immunoblotting and IFA
Our  immunoblot  results  showed  a  strong  increase  in  WUPyV  and  KIPyV  VP2/VP3
seroprevalence with age. In contrast, the VP1-IgG prevalence by the same method was
very low, with little difference between age-groups. Of 100 NPA PCR-negative wheezing
children aged 4 years, 31 (31%) were positive for WUPyV and 31 (31%) for KIPyV
VP2/VP3,  compared  to  only  3  (3%)  and  5  (5%)  for  VP1  of  these,  respectively.  For
comparison, the respective WUPyV and KIPyV IgG seroprevalences as determined by
immunofluorescence assay (IFA) with nondenatured VP1 were 80% and 54% among 50
NPA PCR-negative children aged ? 2 years. This difference shows the importance of
conformational VP1 antigens.
     Of the 25 adults, 52% were IgG-positive in immunoblots for VP2/VP3 of WUPyV
and and 68% for KIPyV, and 8% and 12% for VP1 of these.   Of the 192 NPA samples
studied by PCR, 7 (3.6%) were positive for WUPyV, and 3 (1.5%) were positive for
KIPyV DNA.
The apparent importance of VP1 protein conformation for antibody binding renders
immunoblotting an inadvisable method for VP1-based polyomavirus serodiagnostics, and
underlines the requirement of correctly folded VLPs or VP1 pentamers in sensitive and
virus-specific antibody detection. Indeed, conformational VP1 pentamers were recently
shown to be highly reactive in WUPyV and KIPyV ELISA (Kean et al., 2009). Therefore,
compared with VP1, it is interesting that the minor proteins VP2 and VP3 were found in
our study to be immunogenic, even in denatured form.
     Our IFA data disclosed a ubiquitous IgG prevalence, even in young children, for
conformational WUPyV and KIPyV VP1. This contrasts with the immunoblot results,  in
which the VP2/VP3 seroprevalences increased with age. It is tempting to hypothesize that
the KIPyV and WUPyV VP2/VP3 seroreactivities might evolve by repeated exposure to
these viruses, possibly including reinfections or reactivations.
MCPyV and TSPyV -IgG ELISA
We  examined  by  VLP  ELISA  in  Studies  III,  IV,  and  V  and  detected  an  IgG
seroprevalence for MCPyV of 45.9% among the pregnant women and 59.6% among the
elderly, and an IgG seroprevalence for TSPyV of 67.3% among the elderly. In addition for
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80 children and 149 adult asymptomatic donors, TSPyV IgG seroprevalence among the
children was 39% and among the adults, 70%. Each of the eight PCR-positive subjects
had antiviral IgG of high avidity but not IgM.
     For MCPyV, seroprevalences of 40 to 80% have been reported in immunocompetent
general populations (Carter et al., 2009, Kean et al., 2009, Tolstov et al., 2009, Touze et
al., 2010, Nicol et al., 2013b), and of for TSPyV 70% (Chen et al., 2011b, van der
Meijden  et  al.,  2011,  Nicol  et  al.,  2013b).  Serological  studies  also  suggest  that  first
exposure to MCPyV may occur at a young age (Kean et al., 2009, Tolstov et al., 2009,
Chen et al., 2011a). Chen et al. have shown among the northern European pediatric
populations a seroprevalence of 9% among 79 wheezing children aged 1 to 2 years, and
35% among those aged 4 to 12. These findings are consistent with other  reports on the
presence of MCPyV IgG in childhood; though lower than the 20.5% of Kean et al. at 1 to
5 years and the 43% of Tolstov et al. at 2 to 5 years.
     Seroepidemiological studies indicate that TSPyV is ubiquitous (Chen et al., 2011b,
van  der  Meijden  et  al.,  2011).  Furthermore,  we  have  observed  the  TSPyV  VP1
seroprevalence to increase from 34% to 48% at ages 6 to 10 to 70% in adulthood, and to
be 67% among the elderly (Studies IV and V). The eight subjects carrying TSPyV DNA in
their tonsils had antiviral IgG of high avidity but not IgM, indicating that tonsillar tissue
appears to be a latency site for this virus. Obviously, such data by no means exclude
respiratory transmission of this virus, a possibility that deserves exploration.
A common feature of HPyV is that the occurrence of viral associated disease in the
population is very rare, and yet antibodies to this virus can be detected in a large
percentage of people, indicating that infection is widespread. For example, most human
beings have antibodies to BKPyV and JCPyV by their second decade of life, but viremia
is rarely detectable except in patients with, respectively, PVAN and PML.
Like  JCPyV  and  BKPyV,  the  polyomaviruses  KIPyV  and  WUPyV  are  also  rarely
detected and seem to be associated with no pathology whatsoever. Seroepidemiological
studies show infection to be widespread. In adults over 21, seropositivity rate for KIPyV
is reportedly 55% and for WUPyV, 69%  (Kean et al., 2009), whereas one study of differ
age-groups reported increases in rates from ages 1 to 79 years, reaching maximum
respective rates of 70% and 80% (Nguyen et al., 2009).
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CONCLUSIONS AND FUTURE DIRECTIONS
This thesis includes studies focusing on four of the ten recently discovered HPyVs:
MCPyV, KIPyV, WUPyV, and TSPyV, with respect to determination of their molecular
and serological epidemiology, transmission route, and latency site and in finding any
association between these novel viruses and diseases.
     In the thesis, KIPyV and WUPyV structural proteins were expressed in E. coli with
SUMO protein as a fusion tag to enhance expression levels. The proteins were
immunoblotted for antibodies of wheezing young children and asymptomatic adults, and
the children’s sera and NPA were examined for KIPyV and WUPyV DNA by PCR.
     We employed for MCPyV and TSPyV molecular and serological diagnostic assays
including PCR and ELISAs for IgG, for estimation of MCPyV and TSPyV prevalence in
clinical samples from immunocompetent or immunocompromised patients.
     With the objective of exploring the possibility of transplacental infection by newly
discovered HPyVs and identifying any site or tissue prevalence of latency, we searched for
KIPyV, WUPyV, and MCPyV DNA sequences in various organs sampled from aborted
fetuses; we obtained data to rule out vertical transmission.
     We studied the occurrences and blood levels of MCPyV and TSPyV DNAs among
the elderly and our results indicate that MCPyV DNA, unlike TSPyV DNA, occurs in low
copy numbers in serum in a notable proportion of aging individuals. In addition the
serology  data  showed  the  IgG  antibodies  against  MCPyV  and  TSPyV  occurred  at  high
rates in serum samples from the elderly.
     To  answer  the  questions  regarding  the  possibility  that  human tonsils  represent  the
initial site of infection or a latency site, or both we investigated the occurrence of KIPyV,
WUPyV, MCPyV, and TSPyV DNA in tonsillar specimens and observed MCPyV and
TSPyV DNAs particularly  often  in  tonsillitis  or  hypertrophic  tonsillar  tissues,  unlike  the
status for KIPyV or WUPyV.
     Despite understanding many clinical and biological aspects, future studies may aim
at addressing additional issues such as the development of cell culture systems for the
newer HPyVs. This is important in order to advance research into their biology, for
example, the possibility of isolating and growing the infectious polyomavirus particles in
the laboratory or an experimental system.
113
The role of the new HPyVs in human cancer (if any) is an important area of future
research requiring screening of many different types of cancer. Except for MCPyV in
MCC, none of the new HPyVs has yet to be implicated in human cancer.
Diarrheal illnesses caused by pathogenic enteric bacteria and viruses remain among the
top five causes of death worldwide, especially in developing countries. Many viruses as
possible etiologic agents of many diarrheal cases remain unknown. The detection of
MWPyV, MXPyV, and STLPyV in stool samples obtained from children with diarrhea,
many of whom have no known infectious etiology, raises the possibility that these viruses
may play a role in the development of human gastroenteropathy.
Routes of transmission and epidemiology of these newly discovered viruses will need
to be determined. The HPyV6, HPyV7, and MCPyV seem to be common in the skin and
even show a high tropism for the skin. Their continuous shedding from the skin facilitates
their transmission to other individuals and may explain their high seroprevalence, at least
that of MCPyV.
Regarding  pathogenicity,  the  majority  of  the  novel  HPyVs  are  thus  far  without  a
possible associated disease. More studies are needed to identify and correlate the presence
of the novel viral sequences with specific diseases. Because of the nature of
polyomaviruses, as well as diseases caused by acute infection, these studies will probably
focus on chronic diseases and cancer. Furthermore, as some of the novel HPyV-associated
diseases are not exclusively seen in severely immunocompromised hosts,
immunocompetent subjects may become the focus of study. In general, more research is
needed to understand the role of immunosurveillance in controlling the novel HPyVs, and
the role of genetic host factors in this regard.
To study pathogenic mechanisms of the HPyVs in more detail, more knowledge is
needed concerning the tropism of each virus. Discrepancies between detection rates and
seroprevalence rates in both immunosuppressed and immunocompetent hosts suggest that
at least some of the newly identified HPyVs persistently infect the host in a niche not yet
well identified or properly sampled. Knowledge about HPyV tropism and reservoirs is
indispensable to identify what type(s) of cell is necessary in further cellular and molecular
studies. Such studies can guide us in our research strategies to further understand and cope
with these viruses.
While many of the new HPyVs have been only very recently discovered through the
development of novel molecular biological techniques, we must ask whether additional
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viruses lurk in various populations. This also has inspired new interest in previously-
identified viruses. Sick individuals’ pathogens have been the focus of most of the current
virus discovery attempts, but it is possible that viruses exist that are associated with no
disease, ones that simply persist and spread without causing clinical symptoms.
Considering the increasing incidence of polyomavirus-associated diseases, particularly
the many severe diseases in immunocompromised individuals, one must also consider
whether antiviral therapy and vaccine development is plausible. Endlessly, the medical
world may be challenged with development of efficient therapies against emerging human
viruses with emerging disease associations.
Science itself is continuously evolving, and virology is no exception. What will be the
trends in virology in the near future? Clearly, prevention of virus disease in humans is the
major  aim  of  virologists.  We  are  continually  surprised  by  the  speed  and  precision  with
which these technologies are able to tackle a variety of fundamental and fascinating
problems, particularly in allowing investigation of non-cultivable viruses and no doubt,
will feed back to aim in preparation of better preventive measures. Finally,  I would like to
ended my doctoral book with a quote from Avicenna (973-1037), the Persian physician
and philosopher, concerning the subject-matter of medicine in his book entitled The
Canon of Medicine: ‘‘Medicine deals with the states of health and disease in the human
body.  It  is  a  truism  of  philosophy  that  a  complete  knowledge  of  a  thing  can  only  be
obtained by elucidating its causes and antecedents, provided, of course, such causes exist.
In medicine it is, therefore, necessary that causes of both health and disease should be
determined.’’
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